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TNF-α   tumor necrosis factor –α 
Vz/F   volume of distribution based on the terminal phase 
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Dendrimers are synthetic, hyperbranched polymers with repeating units 
emanating from a core to form a three-dimensional structure.  With attractive 
structural properties, dendrimers emerge as a promising nanoscale material for 
biomedical applications.  However, a major challenge is how to decrease the 
inherent toxicity of dendrimers while leveraging on the beneficial properties for 
the intended applications.  The large number of functional groups available for 
surface modification provides opportunities to address the challenge.  Thus, this 
thesis aims to study the effect of dendrimer surface modification on toxicity 
reduction and improvement of functionality in drug delivery applications. 
In chapter 3, the Poly (ethylene glycol)-conjugated (PEGylated) and thiolated 
dendrimers were successfully prepared and characterized.  PEGylation and 
thiolation could reduce toxicity of polymers to biological components.  However, 
a combination of both has not been attempted on Poly(amidoamine) PAMAM 
dendrimers before.  Amine-terminated PAMAM Dendrimers generation 4.0 with 
two different PEGylation ratios, 1.8:1 and 4.0:1, were synthesized.  Thiolation 
ratio for all the PEGylated dendrimers and original dendrimer in average was 7:1.  
The physicochemical properties of all the prepared dendrimer derivatives were 
characterized including 
1
H-NMR spectra, Fourier transform infrared spectroscopy 
(FT-IR), yield, size, zeta potential, thiol group concentration and molecular 
weight.   
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In chapter 4, different types of PAMAM dendrimers were tested for their 
compatibility with major blood components, including cells, serum albumin, 
complements, clotting factors and platelets.  The unmodified amine-terminated 
dendrimer displayed generation- and concentration-dependent toxic effects on 
blood components and functions. PEGylation was shown to be an effective way to 
improve blood compatibility of cationic dendrimers in our study. Further 
modifying PEGylated dendrimers with thiolation reduced their effect on 
haemolysis, complement activation, prothrombin time (PT) and activated partial 
thromboplastin time (aPTT).  Such improved blood compatibility warrant further 
exploration of these surface modified PAMAM dendrimer for drug delivery 
applications. 
Dual functionalized PAMAM dendrimers were evaluated for their potential use in 
oral drug delivery as tight junction modulator and P-gylcoprotein (P-gp) inhibitor 
in chapter 5.  PEG(1.8)-PM-TBA(7.0) displayed low cytotoxicity in Caco-2 and 
MDCK/MDR1 cells, while significantly increased cellular accumulation and 
permeation of the P-gp substrate Rhodamine-123 (R-123) as well as reversibly 
disrupted tight junction integrity shown via transepithelial electrical resistance 
(TEER) measurement over time.  This dendrimer derivative also improved oral 
bioavailability of model drug ganciclovir (GCV) in vivo pharmacokinetic study.   
Besides surface conjugation, complexation is another way to modify dendrimers.  
Chapter 6 explored the potential application of modifying dendrimers via physical 
complexation with lipids into dendrimer-lipid hybrid nanosystems for the delivery 
of paclitaxel (PTX).  Such system was evaluated for the therapeutic effect in the 
xxii 
 
treatment of ovarian cancer.  The hybrid nanosystem of PTX significantly 
improved inhibitory effect on IGROV-1 cells.  PTX in the hybrid nanosystem 
could significantly improve the survival of tumor-bearing animals, with 50% 
increase in the median survival time, despite a 10-fold dose reduction.  Thus, this 
dendrimer-hybrid nanosystem demonstrated great advantages to deliver PTX for 
ovarian cancer treatment.   
Taken together, the findings in this thesis demonstrate that surface modification 
with multiple groups or complexation could improve dendrimer functionality in 
drug delivery applications as well as reducing its toxicity. 
 
  
1. CHAPTER 1. INTRODUCTION 
1.1 Overview of Dendrimers 
Dendrimers are synthetic, hyperbranched polymers with repeating units 
emanating from a core to form a three-dimensional structure.  They represent a 
new class of polymeric compounds which are distinguished from traditional linear 
polymers by their unusual fractal-like architecture[1]. Dendrimer is first 
discovered in the early 1980's by Donald Tomalia and co-workers [2]. The term 
dendrimer is derived from the Greek language 'dendron' and now refers to 
polymers with tree-like structure. Its structure includes three parts: a core, 
repeating branches and outer shells.  By regulating the synthesis condition of the 
dendrimer, precise control of molecular weight, chemical structure, number of 
surface groups and low polydispersity could be achieved. Dendrimer generation is 
defined as the number of repeating branch cycles that is added upon the core. 
Dendrimers with higher generations have larger sizes, molecular weighs, more 
branches and surface groups. The unique structure and properties make 
dendrimers highly attractive as emerging novel materials in various applications, 
such as drug delivery [3-5], gene therapy[6], diagnostics[7], electronics and 
photonics[8]. Some examples of commercially available dendrimers are 
Poly(propyleneimine) (PPI), Poly(ethyleneimine) (PEI) and Poly(amidoamine) 
(PAMAM). Among them, PAMAM dendrimers are the first dendrimer family to 
be synthesized, characterized and commercialized[9]. Figure 1.1 shows the 




Figure 1.1 Chemical structures of dendrimers. (A) PAMAM dendrimer G2.0. (B) 
PPI dendrimer G2.0. 
 
1.2 Dendrimer Synthesis 
There are mainly two methods to synthesize dendrimers. Two conventional ways 
are the divergent and convergent methods. These two methods are fundamentally 
different in the construction concepts. Each method has its own benefits as well as 
disadvantages. 
1.2.1 The divergent synthesis method 
The divergent method was developed by Fritz Vögtle[10]. It starts with an 
initiator core and then the monomeric modules are assembled branch upon branch 
to form dendrimers [11]. As shown in Figure 1.2 (A), the initial core reacts with 
monomer molecules, which has one reactive group and a few dormant groups. 
This step leads to the first generation dendrimer. Subsequently, the molecule 
surface groups are activated to react with more monomers to form the second 




reached. The divergent approach is good for mass production of dendrimers [12]. 
However, a major disadvantage of this method is that excess monomers are 
required and this will lead to extensive purification process. 
1.2.2 The convergent synthesis method 
The convergent method was introduced by Hawker and Frechet to solve the 
drawback of the divergent methods [13]. This method firstly prepares the 
peripheral dendritic fragment followed by progressing inward to produce 
dendrimer [13]. When the dendritic arms meet required generations, then they are 
attached to the core molecules (Figure 1.2 (B)). The convergent methods need less 
purification process and have more precise control over the structure [12]. Yet, 
the limitation with convergent synthesis method is that only low generation of 
dendrimers could be generated with this method [14].  
 
Figure 1.2. Dendrimer synthesis methods. (A) The divergent synthesis method. (B) 
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1.2.3 Poly(amidoamine) PAMAM dendrimer synthesis 
PAMAM dendrimer, also known as starburst dendrimer, is the first synthesized 
and reported dendrimer. The synthesis method is divergent method, including two 
steps: (a) alkylation with methylacrylate and (b) amidation with ethylenediamine 
(EDA) [15]. Firstly, 1,2-diaminoethane (EN), the initial core,  in methanol was 
added dropwise to methanol solution of methylacrylate (MA) under stirring and 
nitrogen environment over 2 h. Feed ratio of EN to MA is 1:5. Then the mixture 
was stirred at 0°C for 30 min and allowed to warm to room temperature. After 24 
h stirring in room temperature, the solvent was evaporated by rotary evaporator 
and vacuum. The synthesized precursor in methanol is carefully added to excess 
amount of EN in methanol at 0°C under vigorous stirring. The rate of addition is 
controlled so that the temperature won't rise above 40°C. After complete addition, 
the mixture is stirred for at least 96 h at room temperature until no ester group 
could be detected by NMR. The solvent is removed under reduced pressure with 
temperature below 40°C. The excess EN is removed by an azeotropic mixture of 
toluene and methanol (9:1). The remaining toluene was removed by azeotropic 
distillation using methanol. The final product is amine-terminated generation 0 
PAMAM dendrimer. Then the alkylation and amidation steps are repeated 
alternatively to build up the generation. After alkylation step, the ester terminal 
groups could be further turned into carboxyl groups by saponification and this 
type of dendrimer is generally referred to as 'half generation'. After amidation step, 




Scheme 1.1. PAMAM dendrimer synthesis scheme from core to PAMAM 
generatio 1.0 
1.3 Physicochemical properties of Dendrimer 
The physicochemical properties of dendrimers are largely related to their unique 
structure, generation, surface groups, molecular weight and diameter.  The 
theoretical molecular weight (MW) of dendrimer could be calculated by the 
following equation: 
                
  
   
    
        






























































































*MWc: molecular weight of core 
MWb: molecular weight of branch cells 
MWt : molecular weight of terminal groups 
Nc: multiplicities of core 
Nb: multiplicities of branch cells 
G: generation 
 
The number of surface groups can be calculated by the equation below: 
       
     
where Z is the number of surface groups. 
Table 1.1 shows the relationship between dendrimer generation and some other 
parameters. In general, as dendrimer generation increases, it has larger sizes, 
molecular weighs, more branches and surface groups. The core affects the 3D 
morphology of the dendrimer.  The type and number of interior repeating 
branches influence overall size of the macromolecule and the number of surface 
groups [16]. Lower generation dendrimers (G < 3) are highly asymmetric. While 
as generation increases, the dendrimer shows a globular structure [17]. When the 
dendrimer grow to a critical branched state, the generation cannot increase 
furthermore because the periphery are densely packed, which leaves no space for 





Table 1.1 Relationship between PAMAM dendrimer generation and parameters 
[19] 
 
G 0 1 2 3 4 5 6 7 
M.W. 517 1,430 3,256 6,909 14,215 28,826 58,048 116,493 
Nsurface 4 8 16 32 64 128 256 512 
D (nm)  N.A. N.A. 2.2 3.1 4.0 5.3 6.7 8.0 
G: generation. M.W.: molecular weight. Nsurface: number of surface groups. D: 
diameter 
 
The surface groups of dendrimer largely affect dendrimer's properties and 
applications (Figure 1.3). The nature and density of dendrimer surface groups 
strongly influence dendrimer solubility. Dendrimers with hydrophilic terminal 
groups are more soluble in polar solvent, while hydrophobic groups terminated 
dendrimers are soluble in nonpolar solvent. Dendrimer toxicity is also closely 
related to the surface groups.  Dendrimers with cationic surface groups are 
relatively more toxic than the dendrimers with anionic surface groups or bearing 
neutral groups [20]. The large number of dendrimer terminal groups can also be 
utilized for surface modification to achieve desired properties in biomedical 





Figure 1.3. PAMAM dendrimers with different surface groups. (A) PAMAM G1-
NH2, (B) PAMAM G1-OH, (C) PAMAM G1.5-COOH 
 
Dendrimer structure shows many improved physicochemical properties compared 
to traditional linear polymers. The synthesis method of dendrimer could 
specifically control dendrimer size, generation and structure. Thus, dendrimers are 
monodisperse macromolecules. However, the linear polymers are random in 
nature and have different sizes due to the traditional polymerization process [12]. 
In solution, the high density of surface groups improved solubility of dendrimer. 
In a solubility test, the solubility of dendritic polyester was remarkably higher 
than that of analogous linear polyester in tetrahydrofuran (THF) [12]. The 
morphology of dendrimer in solution is spherical shape; in contrast, linear chains 












linear polymers [21]. As molecular weight of dendrimers increase, the intrinsic 
viscosity goes to a maximum at the fourth generation and then begins to decline 
[22]. However, for linear polymers, the intrinsic viscosity increases as molecular 
weight increases. All these unique properties of dendrimer make it as an attractive 
material for biomedical applications. 
1.4 Biomedical applications of Dendrimer 
1.4.1 Dendrimer in gene delivery 
Many different types of gene delivery vectors have been developed to carry gene 
into host cells. The earliest gene delivery vector is virus, which has high 
transfection efficiency. Alipogene tiparvovec (trade name Glybera) was the first 
approved gene therapy product based on viral vector.  However, immune 
responses, safety and cost are the major concerns for application of virus viral 
vector in gene delivery. Cationic liposomes and oligopeptides are developed later 
on as non-viral vector. However, these materials are relatively more toxic and the 
transfection efficiency is not high. Thus, poly-cationic polymers are developed as 
novel alternatives for gene delivery. The electrostatic interaction between the 
negative phosphate backbones of DNA/RNA strand and the high density cationic 
surface groups of dendrimer is the main principle for dendrimer based gene 
delivery vector [23]. Scanning force microscopy data also confirmed the structure 
that DNA wraps around the dendronized polymers [24]. The gene/dendrimer 
complex is endosomally uptaken by the cells, and after lysosomal fusion and 
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subsequent endosomal escape, the genetic materials are released from the 
complex in the vicinity of nucleus [25]. 
Dendrimers have been demonstrated as efficient in vitro gene transfection agents 
in many studies. Early studies demonstrated that Starburst
TM
 PAMAM dendrimers 
showed maximal transfection of luciferase at dendrimer to DNA at charge ratio 
6:1 [26].  It is suggested by the author that the high pKa of amine groups could 
buffer pH changes in the endosome. Such property contributes to the high 
transfection efficiency of the dendrimer [26]. Later, Bielinska et al. studied twenty 
different types of polyamidoamine dendrimers for gene transfection in 
mammalian cells. It is shown that dendrimers could deliver plasmid DNA as well 
as antisense oligonucleotides [27]. The transfection efficiency was related to the 
intrinsic properties of dendrimers, including generation, size, shape, and the 
number of surface primary amine groups.  Overall, the higher generation 
dendrimers (G > 5.0) were found to be of superior efficiency in variety of cell 
types[27]. Interestingly, Tang et al. reported a dramatic enhancement (> 50-fold) 
of transfection activity by heating PAMAM dendrimers in solvolytic solvents [28]. 
Heating treatment caused dendrimer degradation, resulting in heterodisperse and 
fractured dendrimers. The enhanced transfection efficiency of such fractured 
dendrimers was considered mainly due to the increase in flexibility of 
complexation and release of DNA [28]. This PAMAM dendrimer based 
transfection agent is commercialized as Superfect
TM
 and demonstrated superior 
transfection activity among different polymeric transfection materials. However, 
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longer incubation time was required for Superfect
TM
 and the transfection activity 
varied depending on the specific cell line [29].   
Some of dendrimer based gene delivery studies proceeded to in vivo experiment 
and showed promising results.  Kukowska et al. used PAMAM G9 to form 
complex with pCF1CAT plasmid and evaluated gene expression on female 
BALB/c mice after i.v. administration [30].  pCF1CAT plasmid showed high 
level of transgene expression in the lung at 12 and 24 h after injection.  Then the 
second peak of expression appeared 3 to 5 days after administration.  In 
comparison, a minimal level of CAT protein was expressed in the lung for naked 
plasmid DNA.  It is also important to note that protein expression was not 
observed in organs other than the lung, which is the expected site for gene 
expression in this study.  These results indicate that i.v. administered PAMAM 
G9 dendrimer could be an effective vector for pulmonary gene transfer.  In 
another study, PAMAM G3 conjugated with α-cyclodextrin (α-CDE) formed 
complexes with pDNA [31].  Conjugates with three different α-CDE/PAMAM 
ratios of 1.1, 2.4, and 5.4 were prepared and evaluated in this study.  After 
intravenous administration of dendrimer/pDNA complexes in mice, dendrimer 
conjugates with α-CDE/PAMAM ratio of 2.4 showed the highest gene transfer 
efficiency in spleen, liver, and kidney after 12 h.  The diameter of the pDNA/ α-
CDE conjugated PAMAM particles have average size of ~ 500 nm, which might 
be the reason for enhanced accumulation in spleen and liver.  Similarly, Wada et 
al. surface modified PAMAM G2 with α-cyclodextrin bearing mannose (Man- α-
CDE) for gene delivery [32].  This PAMAM conjugated with Man- α-CDE 
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showed significantly higher transfer activity than dendrimer and α-CDE in kidney 
12 h after i.v. injection in mice.  In other major organs, including heart, lung, 
spleen, and liver, the transfer activities were similar for all the vectors.  Taken 
together from these results, the delivery vehicle may play an important role in the 
gene transfer location.  It might be highly related to the dendrimer generation and 
surface modification groups.   
Delivery of anticancer gene for cancer therapy is one of the most studied 
applications of dendrimers. Such approach aims to inactivate or destroy mutated 
gene in the cancer cells [33].  Dufes et al. reported PPI dendrimer based systemic 
delivery of tumor necrosis factor alpha (TNF alpha) gene.  Such TNF 
alpha/dendrimer complex significantly improved animal survival compared to 
TNF alpha alone [34]. Nakanishi et al. demonstrated that pGEH.FasL/PAMAM 
dendrimer complex significantly reduced the viability of prostate cancer cells as 
well as improved therapeutic effect of cisplatin in systemic co-administration for 
the treatment of xenograft tumor [35]. The same group reported dendrimer deliver 
of suicide gene that pSES.Tk/dendrimer significantly prolonged the survival of 
mice implanted with A573 cells [36]. Vincent et al. used 36-mer anionic 
oligomers associated dendrimer for delivery of angiostatin and tissue inhibitor of 
metalloproteinase (TIMP)-2 genes. In vivo intratumoral angiostatin/dendrimer or 
TIMP-2/dendrimer gene delivery system effectively inhibited tumor growth by 71% 
and 84%, respectively. Moreover, the combined gene transfer approach inhibited 
96% of tumor growth [37]. All of these studies demonstrated that dendrimer could 
be potent non-viral gene delivery vector for cancer therapy. Besides cancer 
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treatment, dendrimers were also reported for the treatment of other diseases, such 
as neurodegenerative diseases [38, 39], anti-HIV therapy [40, 41], ischaemic heart 
diseases [42], diabetes [43], and stroke [40]. 
1.4.2 Dendrimer as drug delivery system 
Dendrimers are studied extensively for drug delivery applications due to the 
unique structure properties. The hydrophilic nature of dendrimer is helpful to 
deliver hydrophobic drugs with poor water solubility. Drugs can be encapsulated 
into dendrimer by three different manners: (1) covalent conjugation on peripheral 
groups of dendrimers, (2) non-covalent encapsulation in the internal cavity of 
dendrimer and (3) complexation by electrostatic interaction.  Moreover, high 
density of surface groups allows for functional modification to achieve extra 
desirable properties, such as targeting, controlled release, reduced toxicity, 
prolonged circulation time. Due to these properties, dendrimers are most 
commonly studied for systemic delivery of therapeutic molecules. Besides, 
dendrimers have also been explored for various administration routes, such as oral 
delivery, ocular delivery, pulmonary delivery, and transdermal delivery.  
1.4.2.1 Dendrimer in intravenous drug delivery 
Intravenous injection provides the most rapid and highest bioavailability for 
systemic delivery of medications.  With nano-scale and water soluble properties, 
dendrimers have been studied as a drug carrier to deliver drug in systemic 
circulation.  Cancer therapy and DNA delivery are two main focuses of using 
dendrimers as carriers for intravenous administration in recent years.  Bhadra et 
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al. studied the pharmacokinetic profile of 5-Fluorouracil (5-FU) encapsulated in 
PEG5000 modified PAMAM G4 dendrimer [44].  The 5-FU in PEGylated 
PAMAM formulation showed steady and sustained release up to 12 h.  In 
comparison, 5-FU in unmodified PAMAM or free drug showed much faster drug 
release profile and could be detected up to 6 h and 1.5 h, respectively.  It is 
concluded by the author that such PEGylated system can act as long circulatory 
and sustained release system to deliver anti-cancer drug.  Malik et al. i.v. injected 
cisplatin (Pt) conjugated PAMAM G3.5-COOH to treat a palpable s.c. B16F10 
melanoma [45].  The dendrimer-Pt showed 50-fold higher drug accumulation in 
solid tumor tissue compared to Pt by the enhanced permeation and retention effect.  
The dendrimer-Pt conjugate showed antitumor activity whereas cisplatin alone 
was inactive.  This study indicates that dendrimer-drug conjugation could help to 
increase drug retention in tumor so that the therapeutic efficiency could be 
enhanced.  In another study done by Kukowska et al., PAMAM G5 dendrimer was 
surface modified with acetyl groups, folic acid, methotrexate (MTX), and 
fluorescein (FITC) to achieve targeted delivery of MTX into immunodeficient 
mice bearing human KB tumors that over express the folic acid receptor [46].  4 
days post i.v. injection, 9% of the folic acid conjugated dendrimer selectively 
accumulated in tumor tissue, meanwhile about 15% were accumulated in liver.  
The MTX conjugated with dendrimer formulation effectively delayed tumor 
growth at dose 4-fold lower than the free drug, indicating the improved 
therapeutic effect of MTX conjugated with surface modified PAMAM dendrimer.  
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1.4.2.2 Dendrimer in oral drug delivery 
Oral drug delivery is the most common route of administration of medicinal 
agents. It is convenient, relatively safe and has high patient compliance. However, 
different types of drugs often encounter variable bioavailability due to the 
complex biological barriers and chemical/physical environment in gastrointestinal 
(GI) tract. Drug molecules will experience harsh pH changes from acidic 
environment in stomach to nearly alkaline intestine. Enzymes and bacteria in the 
intestinal epithelium also cause degradation or metabolism of drugs.  Moreover, 
drug is limited by various biological barriers such as tight junction proteins and 
drug efflux pumps. One major physical barrier for oral drug delivery is tight 
junctions expressed in intestinal epithelium. The physiological function of tight 
junctions is to regulate the passage of ions, water and small molecules as well as 
block the free diffusion of large molecules between the apical and basolateral 
domains of the intestinal membrane [47]. However, the presence of tight junction 
in intestinal epithelium largely limits the paracellular pathway for drugs to diffuse 
into blood circulation.   
Sakthivel et al. was the ﬁrst to report rapid absorption of dendrimer after oral 
administration in Sprague−Dawley rats [48]. Subsequently, poly (amido amine) or 
PAMAM dendrimers were studied for transepithelial transport. Supporting lines 
of evidence demonstrated that PAMAM dendrimers can pass through GI 
epithelial barriers in a generation- and surface charge-dependent manner [49, 50].  
Charged PAMAM dendrimers are transported across Caco-2 monolayers by a 
combination of paracellular and endocytotic pathways [51].  Paracellular transport 
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is reflected by an opening of the tight junction of the epithelium, which could be 
characterized by a decrease in transepithelial electrical resistance (TEER), 
increased permeability of model compounds, and disrupted expression of tight 
junction markers such as occludin (ZO-1). PAMAM dendrimers of cationic or 
anionic surface charge have been shown to decrease TEER and increase 
14
C-
mannitol permeability [52, 53], suggesting that the ability of PAMAM dendrimers 
to modulate integrity of tight junction and promote paracellular transport. 
Expression of occludin and actin filaments in Caco-2 cell monolayers was also 
shown to be disrupted upon incubation with cationic or anionic PAMAM 
dendrimers [54].  Endocytosis inhibitors such as brefeldin A, colchicine, filipin, 
and sucrose could reduce Caco-2 uptake of amine-terminated PAMAM G4.0 
dendrimer [55].  Both clathrin- and caveolin-mediated pathways have been shown 
to be involved in the cellular uptake of PAMAM G3.5 dendrimer [56].  Studies 
have shown that PAMAM dendrimers could increase oral bioavailability of 
poorly soluble compound silybin [57] and P-gp substrate doxorubicin [58] by 
forming drug-PAMAM complexes. In addition, drugs are conjugated covalently 
with dendrimer to form a prodrug-dendrimer conjugate for oral delivery. P-gp 
substrate drug propranolol was conjugated with PAMAM dendrimer and was 
shown to be less affected by P-glycoprotein efflux effect in cellular transport 
study across Caco-2 cell monolayers [59]. In another study, anticancer drug SN-
38 was conjugated to PAMAM G3.5 and tested its potential in oral delivery. The 
conjugate showed increased transepithelial transport of SN-38 compared to the 
free drug with reduced toxicity [60]. Najlah et al. utilized PAMAM G0 to 
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enhance transepithelial permeability of hydrophobic drug naproxen [61]. Two 
different linkers lactic ester and diethylene glycol were used to conjugate drug 
with dendrimers. Both conjugates showed significant increase of naproxen 
transport. However, conjugate with lactic ester showed much slower hydrolysis in 
both plasma and liver homogenate compared to conjugate with diethylene glycol 
ester linker [61].   
1.4.2.3 Dendrimer in transdermal drug delivery 
Dendrimers were firstly reported as penetration enhancer for transdermal drug 
delivery in a polyhydroxyalkanoate (PHA)-based system [62]. Such dendrimer-
containing PHA matrix enhanced tamsulosin permeation to clinically required 
amount demonstrated in skin model. Subsequently, dendrimers have been 
explored in various studies as transport vehicles for drugs with poor water 
solubility or low permeability. PAMAM G2, G2.5, G3, G3.5 and G4 were tested 
as solubility enhancer of riboflavin (vitamin B2). The PAMAM-riboflavin 
complex was firstly prepared in methanol and then formed an o/w emulsion after 
methanol evaporation. It was shown that PAMAM G2 was the best as solubility 
enhancer as well as permeation enhancer for riboflavin in vitro transdermal model 
[63]. In another study, PAMAM G2.5, G3, G3.5, G4 were evaluated as 
transdermal delivery carrier of 8-methoxypsoralene (8-MOP), photosensitizer for 
PUVA therapy [64]. PAMAM G3 and G4 enhanced the solubility of 8-MOP as 
well as providing controlled drug release profiles indicating that the dendrimer 
might improve delivery property of 8-MOP in PUVA therapy. Dendrimers were 
also studied with non-steroidal anti-inflammatory drugs (NSAIDs) for 
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transdermal delivery. PAMAM G4-NH2, G4-OH, and G4.5 were applied to 
deliver indomethacin [65]. G4-NH2 showed the best effect to increase steady-state 
flux of the drug both in vitro and in vivo. Therapeutic effect of indomethacin was 
improved by 1.6- and 1.5-fold for G4-NH2 and G4-OH formulations, respectively, 
compared to pure drug suspension. Later, Cheng Y. et al. used PAMAM G5 to 
deliver ketoprofen and diflunisal [66]. Both in vitro and in vivo studies showed 
improved permeation of model drugs in dendrimer complex formulation. 
Moreover, the bioavailability of ketoprofen-PAMAM and diflunisal-PAMAM 
were 2.73-fold and 2.48-fold, respectively, higher than the pure drug suspensions.   
1.4.2.4 Dendrimer in ocular delivery 
The eye is an organ readily accessible for drug delivery purposes, yet the complex 
structure and physiological properties cause great challenges in clinical 
application.  Topical applications are most commonly used for treating anterior 
segment-related diseases [67].  Steroids, anti-inflammatory drugs, anti-fungal, 
antibiotics, and miotics are typically used in liquid forms via topical route [67-69].  
However, these drugs have low ocular bioavailability mainly due to the low 
permeability across an intact corneal epithelium or easily washed out by tears [70, 
71]. 
Vandamme and Brobeck explored PAMAM as ophthalmic vehicle for ocular 
delivery [72]. Various PAMAM dendrimers with different surface groups (-OH, -
COOH, --NH2) and generations (from 1.5 to 4) were tested in this study to 
understand generation and surface charge dependent effect. PAMAM G1.5-
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COOH and PAMAM G4-OH were identified as the best ones to increase ocular 
residence time among all tested. The residence time was not concentration 
dependent at dendrimer concentration ranging from 0.25-2%. All of these 
dendrimers at concentration 2.0% or lower were classified as weakly irritant 
without causing any ocular irritation. Thus, dendrimers could be further explored 
to bring benefits to ocular drug delivery.  
Yao et al. studied dendrimer-puerarin complexes in ocular drug delivery system.  
The puerarin in complexes showed slower in vitro release and prolonged ocular 
residence times in rabbits compared with puerarin eye drops [73].  The 
permeation study was performed on excised cornea of rabbits by a Valia-Chien 
diffusion apparatus.  The permeability coefficient of puerarin in the dendrimer-
puerarin complexese was enhanced by 2.48 (PAMAM G3), 1.99 (PAMAM G4), 
and 1.36 (PAMAM G5) times, respectively, indicating that PAMAM dendrimer 
could increase the corneal permeation of puerarin mainly by altering the corneal 
barrier [74].  In the pharmacokinetic studies, the puerarin samples were collected 
from rabbit’s aqueous humor by in vivo microdialysis and quantified by mass 
spectroscopy.  The AUC of puerarin complexed with dendrimer was increased by 
2.3 (PAMAM G3), 3.5 (PAMAM G4), and 2.1 (PAMAM G5) times compared to 
puerarin alone, respectively [75].  These studies showed the promise of applying 
PAMAM dendrimers in ocular drug delivery.   
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1.4.2.5 Dendrimer in pulmonary delivery 
Pulmonary delivery has several advantages in drug delivery applications, such as 
avoidance of first-pass metabolism, large surface areas for drug absorption, 
noninvasive administration, and local delivery for the treatment of respiratory or 
pulmonary diseases.  Pulmonary route has been explored to deliver small 
molecules, proteins, peptides, and genes for the treatment of diseases such as 
asthma, pulmonary hypertension, cystic fibrosis, lung cancer, and various 
infections [76-80].   
Bai et al. reported dendrimers as carrier for pulmonary delivery of enoxaparin, a 
low-molecular weight heparin [81]. PAMAM G2 and G3 could form complex 
with enoxaparin via electrostatic interactions and improved relative bioavailability 
of enoxaparin by 40%, meanwhile negatively charge PAMAM G2.5 had no effect. 
Importantly, the dendrimer-enoxaparin complex did not adversely affect the 
mucociliary transport rate or produce extensive damage to the lungs, which 
warrants further evaluation of positively charged dendrimers as promising vehicle 
for pulmonary drug delivery.  In another study of the same group, PEGylated 
dendrimer (PEG2000-PAMAM G3) was evaluated as carrier of low molecular 
weight heparin (LMWH) for pulmonary delivery [82].  The half-life of LMWH in 
PEG-dendrimer formulation was increased by 2.4-fold compared to LMWH in 
saline control formulation.  In a rodent model to demonstrate whether such 
formulation could reduce thrombus weight, the LMWH in PEG-dendrimer 
formulation administered at 48 h intervals showed similar efficacy to LMWH 
administered via subcutaneous route at 24 h intervals.  The results suggest that 
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PEG-dendrimer loaded with LMWH could potentially be used as noninvasive 
pulmonary delivery system to treat thromboembolic disorder.   
1.4.2.6 Dendrimer in targeted drug delivery 
Targeted drug delivery is desirable to increase therapeutic efficiency as well as to 
reduce adverse effects of the treatment, for example, in cancer therapy. Dendrimer 
could provide such benefits either by passive targeting or active targeting, 
depends on the formulation design. In passive targeting, the nano-scale size of 
dendrimer itself could prolong the circulation time of the formulation and increase 
accumulation in tumor tissues due to enhanced permeation and retention effect 
(EPR). In active targeting, the targeting ligands could be conjugated to the 
external surface groups of dendrimer to achieve targeted delivery of bioactives. 
Various targeting ligands have been conjugated to dendrimer to demonstrate 
targeting effect of such delivery system. Thomas et al. conjugated CD14 and 
prostate-specific membrane antigen (PSMA) antibodies to PAMAM G5 and 
showed a specific binding and internalization to the antigen-expressing cells [83]. 
Shukla et al. reported anti-HER2 mAb (monoclonal antibody) conjugated 
PAMAM G5 to target human growth facter receptor-2 (HER2), a promising target 
overexpressed in various tumors [84]. Both in vitro and in vivo models 
demonstrated targeting effect of the conjugates to HER2-epxressing tumors. Such 
results indicate the potential of dendrimer based targeting delivery. Folic acid is 
commonly applied as targeting ligand to cancer cells. Quintana et al. conjugated 
folic acid, fluorescein, and methotrexate to the surface of dendrimers to achieve 
targeting, imaging and intracellular drug delivery capabilities [85]. The result 
22 
 
showed that this system had high selectivity and improved cytotoxicity to KB 
cells compared to free drug (over 100-fold). In another study of Kukowska-
Latallo et al., folic acid conjugated PAMAM G5 was used to deliver methotrexate 
(G5-FA-MTX) [46]. Such system was highly concentrated in tumor and liver 
tissue over 4 days after administration. Prior administration of folic acid 
decreased accumulation of folate-conjugated dendrimers, indicating the 
competitive and selective binding of folate-conjugated dendrimer to folate-
receptor. G5-FA-MTX system also significantly reduced tumor volume as well as 
improved survival in SCID mice bearing KB xenografts. Therefore, dendrimer 
structure provides great advantage to conjugate multiple functional groups on its 
surface to achieve targeted drug delivery.  
1.4.3 Dendrimer in diagnosis 
Dendrimers are explored as imaging tools for various applications, such as 
contrast agents for X-ray[86] and magnetic resonance imaging (MRI) or 
molecular probes [87]. Gadolinium (Gd) is the most widely used contrast agent in 
MRI. Wiener et al. developed a PAMAM dendrimer based chelator to complex 
with Gd(III) [88]. Such dendrimer-metal chelate conjugate increased Gd loading 
as well as prolonged circulation lifetime of Gd, which makes dendrimer 
preferable over low molecular weight MRI contract agents. In another study, 
Kobayashi et al. developed PAMAM G8-Gd based contrast agent [89]. A single 
dose of 15 Gy resulted in significant image enhancement of tumor tissue. Based 
on this concept, targeting ligands can be further attached to the dendrimer to 
achieve specific targeting and imaging effect. Wiener et al. prepared folate-
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conjugated dendrimer-chelates for diagnosis of tumors cells expressing the high-
affinity folate receptors [90]. The conjugates showed selectively increased signal 
for cells with overexpression of folate receptors and such increase was inhibited 
by an excess of free folic acid.  
Similar to MRI, dendrimers were also studied to improve the effect of iodinated 
contrast agents in computer tomography (CT). Fu et al. synthesized an array of 
dendritic iodinated contrast agents with different PEG cores (3, 6, 12 kDa) and G3, 
G4, G5 poly (lysine) dendrimers (Figure 1.4) [91]. A representative compound, 
G4 poly (lysine) dendrimer with PEG12 kDa core, showed a strong and persistent 
intravascular enhancement with monoexponential blood half-life of ~35 min, 7-
fold of typical exhaustion times for small molecule CT contrast agents. It is 
proposed by the authors that these large molecular constructs could be be 
potentially used for tumor microvascular CT imaging.  Dendrimers have also been 
surface modified as molecular probe [92], fluorescent pH sensor [93], DNA probe 
[94, 95], avidin biosensor [96], and amino alcohols detector [97]. 
 




1.5 Dendrimer Toxicity 
Despite the promising findings of dendrimers for various potential biomedical 
applications, toxicity profile is still a major concern especially for intravenous 
injection, which is considered as the major route of administration for dendrimer 
based drug delivery system and targeted diagnostics. In general, the toxic effect of 
dendrimer was surface charge, concentration and generation dependent. Positively 
charged dendrimers interact with negatively charged blood components by 
electrostatic interactions. Such effect strongly affects the stability and function of 
the blood components [98-100]. In comparison, neutral or negatively charged 
dendrimers show much less effect on the blood components [98, 101]. Besides 
surface charge, dendrimer toxicity is increased as the generation increases, which 
correlate to the increase of surface groups, molecular weight, charge density and 
particle size.  
1.5.1 In vitro cytotoxicity 
In vitro cytotoxicity of dendrimer is mainly evaluated with different types of 
cancer cell lines. In early studies, Malik et al. evaluated cytotoxicity of PAMAM, 
PEI and poly(ethylene oxide) grafted carbosilane (CSi-PEO) dendrimers [100]. 
Cationic dendrimers showed generation, concentration, and cell type dependent 
toxicity. For anionic dendrimers, they were not haemolytic or cytotoxic below 1 
mg/ml for the tested cell lines. Javprasesphant et al. studied cytotoxicity of 
different generations PAMAM on Caco-2 cells [102]. For both cationic and 
anionic dendrimers, toxicity increased with size, generation and concentration. 
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Modification of cationic dendrimers surface groups with lauroyl or PEG chains 
decreased toxicity. It was also reported that increased incubation time led to 
increased cytotoxicity of dendrimer in HepG2 and COS-7 cell lines by Agashe et 
al. [103]. Similarly, PAMAM G5 dendrimers were found to disrupt membrane of 
human umbilical vein endothelial cells (HUVEC) in a time-dependent manner 
[104]. Surface modification with PEG was shown to be an effective method to 
decrease dendrimer cytotoxicity.   
1.5.2 Toxicity of dendrimer on blood components 
1.5.2.1 Effect of dendrimer on erythrocytes 
Erythrocytes deliver oxygen to body tissues through circulatory system. The 
morphology of normal erythrocytes is round and biconcave shape. Affected by 
intrinsic or extrinsic factors, erythrocytes can transform to echinocytes (crenated 
cells) or stomatocytes (cup-shaped cells) [105]. Echinocytosis is a reversible 
condition of erythrocytes that may be found in hyperlipidemia caused by liver 
dysfunction [106]. Stomatocytes might be seen as a non-specific observation in 
various conditions, such as regenerative anemias, liver disease, or lead poisoning. 
Interaction with dendrimer can change the shape of erythrocyte. The 
concentration dependent effect of PAMAM dendrimer G4.0 on erythrocyte 
morphology was reported by Domanski et al. [107]. After 1 hour incubation, 1 
nM PAMAM G4.0 caused echinocytic transformation. 10 nM concentration 
caused elongated and spindle-shaped cells. At 100 nM, drephanocyte-like forms is 
observed. In another study by Malik et al., echinocytic transformation and 
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spheroechinocytes were observed after 1 hour of incubation with PAMAM, 
poly(propyleneimine), and poly(ethylene oxide) (PEO) grafted carbosilane (CSi-
PEO) dendrimer samples [100]. Such observations could be explained by the 
bilayer couple hypothesis that cationic components may interact mainly with one 
side of the bilayer to cause an asymmetric expansion of one monolayer [108]. 
Another common effect of cationic dendrimer treated erythrocytes is aggregation 
and cluster formation [100, 109].  For neutral PEG and stearoyl chain (C18) 
derivatized hyperhranched polyglycerol (HPG) dendrimer (HPG-C18-PEG 
polymer), spherocytosis with spicules were observed for erythrocytes after 
incubation for 1 hour above 5 mg/ml, much higher concentration than the cationic 
dendrimers [110]. 
Disruption of erythrocyte morphology is also accompanied by dendrimer induced 
haemolysis. The haemolysis effect of dendrimer is largely dependent on the 
surface charge, generation, concentration and incubation time. Early study done 
by Malik et al. reported generation, concentration dependent haemolysis by 
various dendrimers [100]. Cationic PAMAM dendrimers showed clear 
generation-dependent haemolysis from generation 1 to 4. However, 
diaminobutane (DAB) and diaminoethane (DAE) dendrimers did not show 
generation dependent haemolysis. This might due to the structure similarity 
between these two types of dendrimers. Also, the different inner structure, mainly 
amide and tertiary amino groups, may also contribute to the difference of 
haemolytic effect. Anionic PAMAM, DAB and PEO-modified CSi-PEO 
dendrimers were not haemolytic up to 2mg/ml. However, carboxyl terminated 
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PAMAM triggered haemolysis above 2 mg/ml. Ziemba et al. studied the 
incubation time dependent haemolysis caused by PPI dendrimers [109]. It was 
clearly shown that prolonged incubation time induced higher level of haemolysis. 
Such effect was remarkably reduced after surface modification with maltotriose 
[110].  
The interaction between erythrocyte and dendrimer is mainly due to electrostatic 
interaction. The surface of an erythrocyte is negatively charged due to the 
presence of glycolipids and some glycated integral and peripheral proteins. The 
negatively charged surface prevents aggregation and adhesion to blood vessels 
and other blood components [111]. The cationic dendrimers could target the 
anionic lipids or proteins to disrupt the structural integrity of the cell membrane. 
Such membrane disruption effect of cationic dendrimer is enhanced as generation 
increases [101]. 
The effect of other blood components on dendrimer induced haemolysis is also 
studied previously. An interesting finding is that the haemolysis is significantly 
reduced if human serum albumin or human plasma is added into the system [109]. 
Similar result was also reported by Klajnert et al. that the haemolytic effect of 
PAMAM G5 is significantly decreased in the presence of human serum albumin 
[112]. Thus, dendrimer might have a higher affinity to albumin than erythrocyte. 
This result indicates that the blood components might help to diminish the effect 
of dendrimer to a single system. Thus, it is necessary to increase the complexity 
of experiment design to understand the effect of dendrimer on blood component 
in the presence of the whole blood system.  
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1.5.2.2 Effect of dendrimer on serum albumin 
Serum albumin is the most abundant protein in circulatory system with many 
physiological functions. The most important function of serum albumin is 
transportation of various compounds, such as metabolites, endogenous toxins, 
hormones, drugs [113, 114]. For toxic substances, binding with albumin will 
reduce the toxic effect in blood circulation.  
Thus, it is necessary to understand the interaction between dendrimer and serum 
albumin in order to further evaluate the systemic toxic effect of dendrimer in 
circulation system. 
Human serum albumin (HSA) and bovine serum albumin (BSA) are commonly 
used to study the interaction with dendrimer, mainly because HSA and BSA are 
structurally homologous. Both HSA and BSA are composed of three domains 
[115, 116].  The main difference is that HSA has only one tryptophan residue Trp-
214 but BSA has two tryptophan, Trp-212 and Trp-134, which are fluorophores 
capable of fluorescence quenching [115]. Such effect is commonly used to study 
the interaction between dendrimer and serum albumin. In general, as dendrimer 
concentration increases, the fluorescence signal will decrease, indicating more 
interaction with serum albumin. The relationship between fluorescent quenching 
and dendrimer concentration can be displayed by Stern-Volmer plot (Figure 1.5). 
The slope of the curve, known as Stern-Volmer constant (Ksv), can be obtained 




Figure 1.5. Example curves of Stern-Volmer plot. (A) Fluorescence spectra of 
BSA after incubation with dendrimer samples at various concentrations. (B) 
Stern-Volmer plot derived from the fluorescence signal at 340 nm. 
Table 1.2 shows a collection of Stern-Volmer binding constant reported for 
different dendrimers. Although the values vary in different experiment settings, 
general trends can be observed. Generation dependent binding effect was studied 
by Giri et al. [119]. For amine terminated PAMAM dendrimers, the binding 
effect is higher as generation increases from 0 to 6. Interestingly, the binding 
constant of PAMAM G8 is lower than PAMAM G6. This could be explained by 
the size-based selective binding mechanism that dendrimer has a higher binding 
affinity toward a protein with comparable molecular surface area [120]. HSA has 
a heart-shaped 3-D structure similar to an equilateral triangular prism with side of 
~8nm and height of ~3nm [121] (Figure 1.6). The length of HSA sides is similar 
to hydrodynamic diameter of PAMAM G6 (7.62nm) [119], which consistent with 
the size-based selective binding mechanism.  
 
Figure 1.6. 3D structure of human serum albumin [122].  

























) with BSA  
mPEG-PAMAM G3 5×103 [115] 
mPEG-PAMAM G4 1×104 [115] 
PAMAM G4 1.1×104 [115] 
PAMAM G4 8.38×103 [123] 
PAMAM G3.5 3.83×103 [123] 
PAMAM G4-OH 2.87×103 [123] 
PAMAM G3.5 3.5×103 [123] 
PAMAM G4 7.6×103 [123] 
Dendrimer Ksv (M
-1
) with HSA  
mPEG-PAMAM G3 1.3×103 [124] 
mPEG-PAMAM G4 2.2×104 [124] 
PAMAM G4 2.6×104 [124] 
PAMAM-SAH G4 1.3×103 [124] 
Cd2+ 2.2×103 [125] 
PAMAM G3.5 1.6×103 [125] 
“PAMAM G3.5-Cd2+” complex 1.4×103 [125] 
G4 PAMAM-pyrrolidone 1.2×105 [126] 
PAMAM G0 1.67×105 [119] 
PAMAM G1 2.83×105 [119] 
PAMAM G2 2.91×105 [119] 
PAMAM G3 3.65×105 [119] 
PAMAM G4 1.67×106 [119] 
PAMAM G5 3.10×106 [119] 
PAMAM G6 5.42×106 [119] 
PAMAM G8 3.30×106 [119] 
PAMAM G4-EDA core 1.67×106 [119] 
PAMAM G4-DAB core 8.45×105 [119] 
PAMAM G4-DAH core 9.59×105 [119] 
PAMAM G4-DAD core 8.38×105 [119] 
PAMAM G4-CYST core 1.43×106 [119] 
PAMAM G4-amine 1.67×106 [119] 
PAMAM G4-amidoethylethanolamine 1.47×106 [119] 
PAMAM G4-succinamic acid 2.52×106 [119] 
PAMAM G4-sodium carboxylate 4.62×106 [119] 
PAMAM G4-pyrrolidinone 2.46×105 [119] 
PAMAM G4-Tris 2.95×105 [119] 
PAMAM G4-amidoethanol 1.29×104 [119] 
PAMAM G4-polyethylene glycol (PEG) 1.77×104 [119] 
 
The surface charge dependent binding effect between PAMAM dendrimer and 
BSA was reported by Klajnert et al. [123]. The binding constant for PAMAM-
NH2 G4, PAMAM-COOH G3.5 and PAMAM-OH G4 is in decreasing order. 
31 
 
Since both PAMAM-NH2 G4 and PAMAM-COOH G3.5 were ionized at pH 7.4 
and have higher binding interaction than the neutral PAMAM-OH, the binding 
interaction is mainly by electrostatic interaction. At pH 7.4, overall BSA is 
negatively charged [123]; therefore, the amine-terminated dendrimers have the 
highest interaction with BSA. However, domain III of albumin is weakly 
positively charged in physiological pH [123], which explains the higher binding 
constant of anionic dendrimer compared to neutral dendrimer. In another work by 
Giri et al., similar trend is observed that PAMAM G4 dendrimers with neutral 
terminal groups have lower binding constants compared to charged dendrimers. 
The binding of neutral dendrimer is mainly by hydrogen bond between -OH 
terminal and protein amino acid residues [119]. However, the binding constant of 
anionic dendrimers is higher than the cationic dendrimers. Since HSA has five 
different binding sites for carboxylic acids consisting of hydrophobic pockets 
capped by positively charged amino residues [127], it is suggested to be the main 
reason for the high level of binding between carboxyl-terminated dendrimer and 
HSA.  
Surface modification of dendrimer could affect the binding interaction with serum 
albumin. Previous work by Mandeville et al. and Reyes et al. studied the binding 
effect of mPEG-PAMAM G3, mPEG-PAMAM G4, PAMAM G4 with BSA and 
HSA, respectively [115, 128]. The order of binding is PAMAM G4 > mPEG-
PAMAM G4 > mPEG-PAMAM G3 for both BSA and HSA. Such order of 
binding is explained by the formation of hydrogen bonding between mPEG and 
the PAMAM dendron [115], which hinders the binding interaction between 
32 
 
PAMAM and serum albumin. Sekowski et al. studied the binding interaction 
between PAMAM G3.5, Cd2
+
, and PAMAM G3.5-Cd2
+
 with HSA. After 
forming a complex with Cd2
+
, the binding constant of PAMAM G3.5-Cd2
+
 is 
lower than PAMAM G3.5 [125]. These results indicate that shielding the surface 
charge of dendrimer will help minimize the binding interaction between 
dendrimer and serum albumin.  
Some mechanisms of interactions between PAMAM dendrimers and serum 
albumins have been proposed previously. Klajanert and Bryszewska reported that 
dendrimers bind albumins mainly by electrostatic interaction [117], which 
explained the stronger binding effect of cationic dendrimers compared to anionic 
dendrimers. Subsequent studies showed that PAMAM dendrimers decreased 
protein α-helix conformation and increased β-sheet conformation [115, 129], 
which indicated that secondary structures of albumin was also altered by 
dendrimer interaction. Some other proposed mechanisms included hydrogen 
bonding between dendrimer internal groups and protein amino acid residues and 
hydrophobic interactions [119]. For carboxyl-terminated dendrimer, specific 
interactions between dendrimer carboxylic groups and protein aliphatic acid 
binding sites was also considered as important [119]. 
1.5.2.3 Effect of dendrimer on complement system 
The complement pathway is a host defence system which is activated when a 
foreign material comes into contact with blood. It initiates a series of chemical 
reactions involving several peptides and enzymes, then leads to inflammation 
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[130]. There are three separate pathways, the classical pathway, the lectin 
pathway, and the alternative pathway [131]. Among the three pathways, the 
alternative pathway is activated by nonspecific binding of C3 on the surface of 
foreign substances. Biomaterials, including dendrimers, have been shown to 
activate complement system by alternative pathway [131]. Polymers such as 
dextran, regenerated cellulose, sephadex, nylon, poly(methylmethacrylate), 
poly(propylene), poly(acrylamide), poly(hydroxyethylmethacrylate) and 
plasticized PVC are known to activate the complement system [132-134].  After 
the alternative pathway is activated, C3 will be cleaved by C3 convertase into C3a 
and C3b, which are anaphylatoxins that will further lead to activation of the 
immune system.  The concentration of C3a in plasma is commonly used as a 
measurement of the extent of complement activation [130]. 
Only a few studies have evaluated the effect of dendrimer on complement system. 
Christian et al. studied the complement activation by PAMAM G5-DNA complex. 
PAMAM G5 caused obvious complement activation as concentration increased 
from 0.1 μM to 10 μM. Such effect is reduced as PAMAM/DNA charge ratio 
decreased from 16:1 to 1:1. At 1:1 ratio, no complement activation effect was 
observed, indicating that such effect is highly dependent on the surface charge. 
Since the amine groups are considered to be potent activators of the complement 
system via alternative pathway [135], surface modification to reduce peripheral 
amine groups could help reduce complement activation. Rajesh et al. studied the 
complement activation effect of PEGylated hyerbranched cationic polymers. All 
the tested polymers, PG-PEG-Amine, PG-PEG-Amine-18, PG-PEG-Amine-44 
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and PG-PEG-Amine-100, showed very minimum C3a generation, using 
concentration of up to 10 mg/ml concentration. With limited information 
available, more studies should be done to evaluate complement activation of 
various types of dendrimers.  
1.5.2.4 Effect of dendrimer on coagulation system 
Platelets are small anucleated cells of blood coagulation system derived from 
megakaryocytes in bone marrow [136]. The diameter of platelet is 2-3 µm [137] 
and the concentration under physiological conditions is 150-450×10
9
 per liter 
circulating in the peripheral blood in 10 days [138]. The main function of platelet 
is hemostasis. Platelets are very sensitive to the microenvironment and can be 
activated by different physiological agonists such as thrombin, collagen and 
adenosine-diphosphate, as well as external components such as nanomaterials, 
drugs and microorganisms [138]. Dobrovolskaia et al. compared the effect of 
PAMAM dendrimers with different sizes and surface groups on platelets in vitro. 
It is shown that carboxyl-terminated and hydroxyl-terminated PAMAM 
dendrimers did not cause platelet aggregation, irrespective of their size and 
generation [139]. Similar result was observed in another study by Jones et al. that 
neutral (G7-OH) and anionic (G6.5-COOH) PAMAM dendrimer did not alter 
platelet function or morphology while cationic PAMAM dendrimer G7 caused 
significant changes of platelet functions [140]. For amine-terminated dendrimers, 
the effect is largely dependent on the generation and size. Higher generation 
PAMAM dendrimers (G4-G6) caused platelet aggregation as well as release of 
ATP, thrombospondin and PDGF. Although G3 did not induce platelet 
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aggregation, an increase of CD62P marker on platelet surface was observed in 
both G3 and G6 treated platelets [139]. It is also suggested that the observed 
platelet aggregation is mainly through rapid disruption of membrane integrity 
rather than signaling-mediated events [139]. In addition, PAMAM G7-NH2 is 
suggested to induce changes in the platelet cytoskeleton, resulting in release of α-
granule contents including P-selectin, RANTES, and PF4 [140]. It is also 
important to note that cationic G7 dendrimer reduced platelet-dependent thrombin 
generation. This might be due to morphological changes of platelet membrane so 
that procoagulant protein binding and prothrombinase complex formation are 
blocked, which subsequently lead to reduction of thrombin generation [140]. 
However, only a few studies have reported the effect of dendrimer on platelets. It 
is necessary to further explore the effect and mechanism of dendrimer-platelet 
interaction.  
Platelet activation usually leads to platelet-dependent thrombin generation, 
however, PAMAM G7 was reported to attenuate platelet-dependent thrombin 
generation [140]. Such observation was further supported by Junes et al. that 
PAMAM G7 inhibits thrombin generation rather than thrombin activity [141]. 
Instead of thrombin generation, PAMAM G7 directly interacts with fibrinogen to 
form dense, high-molecular-weight aggregates with minimal fibrin fibril 
formation [141]. It is proposed by the author that such effect is mainly through 
positively charged dendrimer surface and negatively charged D or E domains of 
uncleaved fibrinogen rather than classic coagulation pathway. Such mechanism 
might explain previous finding that intravenous injection of cationic dendrimers 
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caused a disseminated intravascular coagulation (DIC)-like condition 
accompanied by production of fibrinogen degradation products and rapid 
mortality [142].  
1.5.2.5 Effect of dendrimer on immune system 
Nanomaterials could trigger immune response through a complex process after 
administration. If the effect is immunostimulatory, the nanomaterials may have 
short circulation time due to rapid removal as foreign substances. However, if the 
effect is immunosuppressive, the nanomaterials may risk the whole system more 
susceptible to infections. In a study of Roberts et al. showed that amine 
terminated PAMAM G3, G5 and G7 did not cause immunogenicity both in vitro 
and in vivo [143]. Rajananthanan et al. studied the ability of amine terminated 
PAMAM G5 to amplify antigen-specific antibody responses after administration 
with a soluble protein antigen. PAMAM G5 weakly enhanced anti-ovalbumin 
immunoglobulin G and immunoglobulin M levels [144]. The inflammatory 
response of dendrimer treated mouse macrophage cells were evaluated by Naha et 
al. [145]. Amine-terminated PAMAM G4, G5 and G6 showed generation 
dependent effect. Higher generation dendrimer induced increased intracellular 
ROS and cytokine production, including macrophage inflammatory protein-2 
(MIP-2), interleukin-6 (IL-6), and tumor necrosis factor-α (TNF- α), which may 
lead to oxidative stress and inflammatory response and ultimately lead to cell 
death [145]. Based on this result and a few more studies, the mechanism model is 
proposed to be endocytosis, oxidative stress, endosomal rupture, mitochondrial 




Figure 1.7. Proposed mechanism of dendrimer cytotoxicity  
 
1.5.3 In vivo toxicity and biodistribution of dendrimers 
A major focus of the in vivo toxicity of dendrimers is to establish the maximum 
tolerated dose. Chauhan et al. injected PAMAM G4-NH2 and PAMAM G4-OH 
intraperitoneally to Swiss albino mice for 15 consecutive days and monitored 
their toxicity profiles subsequently. PAMAM G4-NH2 at 10 mg/kg did not cause 
any toxic effect. However, at 19mg/kg, declined glucose level, increased alanine 
aminotransferase and aspartate aminotransferase activities were observed. Kidney 
and liver toxicity was also observed for PAMAM G4-NH2 at high dose level (19 








result was reported by Greish et al. to evaluate acute toxicity on CD-1 mice after 
intravenous injection of PAMAM G4 and PAMAM G7 dendrimers. Amine-
terminated dendrimers were toxic at doses higher than 10 mg/kg while carboxyl- 
and hydroxyl-terminated dendrimers (G3.5-COOH, G6.5-COOH, G4-OH, and 
G7-OH) were tolerated at doses 50-fold higher [142].  Roberts et al. reported 
animal death after administration of PAMAM G7-NH2 at 45 mg/kg [143].  For 
oral administration of dendrimers, G4-NH2 was tolerated at 100 mg/kg with no 
observed toxicity effect, meanwhile G7-NH2 was found to be toxic at 50 mg/kg 
[142]. All the tested carboxyl- and hydroxyl-terminated dendrimers were tolerated 
at 300 mg/kg.  A recent study by Pryor et al. evaluated in vivo toxicity of 
dendrimers by using embryonic zebrafish model for the first time [149].  Cationic 
PAMAM dendrimers from generation 3 to 6 caused 100% mortality at 
concentration above 50 ppm after 24 h post-fertilization.  However, it is important 
to establish the correlation with other in vivo toxicity models.  
Malik et al. studied biodistribution of 
125
I-labelled PAMAM dendrimers after i.v. 
injection to Wistar rats [100]. Anionic dendrimers PAMAM G2.5-COOH G3.5-
COOH and G5.5-COOH circulated longer (20-40% recovered dose in blood at 1 h) 
than cationic dendrimer PAMAM G3-NH2 and G4-NH2 (<2% recovered dose in 
blood at 1 h). For both anionic and cationic dendrimers, majority were captured in 
liver at 1 h after administration. Sadekar studied the biodistribution of PAMAM-
OH dendrimers in orthotopic ovarian tumor-bearing mice [150]. The dendrimers 
showed different biodistribution profile for different generations. PAMAM G5-
OH mainly accumulates in kidney over 1 week. G6-OH distributed both in liver 
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and kidney. G7-OH had longer plasma circulation time, resulting in non-specific 
distribution in major organs, including heart, lung, liver, spleen, kidney as well as 
tumor. 
1.6 Surface engineering of dendrimers 
The abundant surface groups of dendrimer make it highly flexible for various 
surface engineering schemes to achieve desirable properties. A major reason for 
surface modification is to reduce potential toxicity of cationic dendrimers. Apart 
from that, dendrimer functionality could also be improved for other purposes by 
attachment of ligands. Such benefits include improved biodistribution and 
pharmacokinetic properties, targeting to specific site for action, increased 
solubility profile, higher drug encapsulation, sustained and controlled drug release 
[20]. Commonly reported surface engineering strategies are summarized below in 




Figure 1.8. Structures of reported dendrimer surface modification ligands. 
1.6.1 PEGylated dendrimers 
Modifying dendrimer surface with PEG groups is the most commonly applied 
method to reduce toxicity as well as to improve its expected functionalities [151-
154]. Jevprasesphant et al. studied the effect of surface modification with 
PEG2000 or lauroyl chains on dendrimer toxicity [102]. Decreased cellular 
toxicity was observed with increased number of attached lauroyl or PEG chains. 
Such reduction of toxicity is explained by shielding of the positive charge on the 
dendrimer surface. Another possible reason is the space between cell membrane 
and dendrimer surface group created by PEG to prevent electrostatic interactions 
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conjugated PAMAM G4 for delivery of anti-cancer drug 5-fluorouracil [44].  
Haemolytic toxicity of dendrimer was reduced for PEG modified PAMAM G4. 
Moreover, such formulation was found to have increased drug-loading capacity 
and reduced drug release rate. Kim et al. prepared PAMAM-PEG-PAMAM 
triblock copolymer as gene delivery carrier [155].  The copolymer had improved 
water solubility, little cytotoxicity and high transfection efficiency as gene 
delivery system.  Similarly, Qi et al. surface modified PAMAM G5 and G6 with 
PEG5000 for gene delivery [152].  PEGylated PAMAM significantly reduced the 
haemolysis effect and in vitro and in vivo toxicity of PAMAM.  PAMAM with 8% 
molar ratio PEGylation showed the highest transfection efficiency both in vitro 
and in vivo.  Chen et al. reported acute in vivo toxicity of PEGylated melamine 
dendrimer. No toxicity was observed for male C3H mice in a single dose up to 
2.56 g/kg i.p. or 1.28 g/kg i.v. [156].  Thus, PEGylated dendrimers greatly 
reduced toxic effect of dendrimer and enables the dendrimer to be studied in a 
wide range of biomedical applications. 
1.6.2 Carbohydrate conjugated dendrimers 
Dendrimer surface modified with carbohydrate could provide benefits such as 
reduced haemolytic toxicity, cytotoxicity and immunogenicity as well as 
controlled and targeted drug delivery [157, 158]. Agrawal et al. prepared 
galactose modified poly-L-lysine dendrimers as a delivery vehicle of chloroquine 
phosphate [157]. The galactose modified dendrimer was less toxic than 
unmodified dendrimer and could be potentially used for controlled delivery of 
chloroquine phosphate. Similarly, Bhadra et al. coated PPI dendrimer surface 
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with galactose and studied delivery of primaquine phosphate to liver organ [158].  
Surface coated PPI improved drug entrapment efficiency and prolonged drug 
release compared to unmodified PPI.  This could be explained by the increased 
steric hindrance caused by coating with galactose.  Thus, the increased numbers 
of functional groups further provide space for drug entrapment and prevent the 
drug release from the open structure.  It also showed reduced toxicity and 
effective targeting to liver. Agashe et al. studied the toxicity of PPI G5 modified 
with lactose and mannose [103]. Surface modified PPI greatly reduced 
cytotoxicity and haemolytic toxicity compared to parent dendrimer without 
modification. 
1.6.3 Acetylated dendrimers 
Acetylation is another popular method to specifically modify the surface of amine 
terminated dendrimers to reduce its toxicity. Rohit et al. modified PAMAM G2-
NH2 and G4-NH2 with acetyl groups and studied their effect on Caco-2 cell 
monolayers. For fully acetylated PAMAM G4 and G2, no toxicity on Caco-2 cells 
was observed at 1 mM concentration. Furthermore, the permeability and uptake 
profiles of acetylated dendrimers were similar to unmodified dendrimers, 
indicating reduced toxicity while remaining desirable properties of PAMAM 
dendrimers as transepithelial transport carrier [159]. Waite et al. studied 
acetylated PAMAM G5-NH2 for delivery of siRNA to U87 malignant glioma 
cells. Amine acetylation of dendrimer resulted in decreased cytotoxicity to U87 
cells, as well as enhanced dissociation of dendrimer/siRNA complexes [160]. 
However, high degree of acetylation reduced the gene silencing efficiency of the 
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dendrimer/siRNA complex, mainly due to reduced positive charge. Thus, it is 
important to find a balance in the surface modification process to maintain the 
functionality as well as reduce toxicity. Zhou et al. synthesized a series of 
poly(amide-amine) dendrimers with a core of 1,4,7,10-tetraazacyclododecane 
[161]. It was found that the water solubility of G4 and G5 dendrimers was greatly 
improved after acetylation. Such dendrimer was further conjugated with 1-
bromoacetyl-5-fluorouracil to achieve controlled release of anti-tumor drug 5-
fluorouracil.  
1.6.4 Thiolated dendrimers 
Dendrimers are surface modified with thiol groups for various research purposes.  
One main purpose is to utilize the interaction between thiol groups and metal ions.  
In an early study of Chehic and Crooks, PAMAM dendrimers functionalized with 
thiol groups were found to form stable monolayers on planar Au substrates.  They 
also prepared water-soluble nanoparticles with diameter of 1-2 nm.  Such 
thiolated dendrimer coated Au nanoparticles were stable up to 120 Au 
atoms/dendrimer [162].  This material was an attractive candidate for use in 
sensing devices and for catalysis.  In another example, thiolated Diaminobutane-
based  poly(propyleneimine) (DAB) dendrimers were studied to encapsulate CdSe 
quantum dots (QDs) [163].  The thiolated surface helped to increase the affinity 
towards QDs and enabled the dendrimer surface to act as a ligand towards soft 
metal ions.  Cd(II) and Pb(II) showed the higher enhancement and quenching 
effects respectively towards the fluorescence of such composition.  It was 
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concluded by the author that this newly developed nanosensor has potential for 
bioanalytical soft metal detection and quantification.  
Another potential application of thiolated dendrimer is to form cleavable disulfide 
linkage to deliver compounds at specific trigger condition.  Navath et al. prepared 
thiolated PAMAM dendrimer and further conjugated with N-acetyl-L-cysteine 
(NAC) [164].  Such conjugate is designed for intracellular delivery of NAC where 
the glutathione (GSH) level is high enough to cleave the disulfide bond.  The 
activity of both PAMAM G4-NH2 and PAMAM G3.5-COOH conjugates were 
confirmed as they showed significantly better nitrite inhibition both at 24 and 72 h 
compared to free NAC, indicating the protective role of dendrimer conjugation as 
well as rapid GSH responsive release of NAC.  With the same concept, PAMAM 
G4 dendrimer was conjugated to NAC in another study [165].  The conjugate can 
deliver near 60% of NAC within 1 h at intracellular GSH concentrations but no 
NAC release at plasma GSH levels.  In reactive oxygen species (ROS) assay 
tested on activated microglial cells, the dendrimer NAC conjugates showed an 
order of magnitude increase in anti-oxidant activity compared to free drug.   
Recently, thiolated dendrimer is reported as viable mucoadhesive excipient for 
controlled drug delivery [166].  PAMAM G3.5-COOH was conjugated with 
cysteamine (CYS) and used as a delivery vehicle for acyclovir.  The thiolated 
dendrimers showed sustained release profile of acyclovir and higher 
mucoadhesion effect.  The in vitro mucoadhesive activity was related to the 
PAMAM-CYS conjugation ratio.  For PAMAM-CYS conjugate at 1:60 molar 
ratio, the mucoadhesive activity was 1.53-fold higher than the PAMAM-CYS 
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conjugate at 1:30 molar ratio and 2.89-fold higher than the dendrimer alone 
formulation.  These results indicate that thiolated dendrimers could be potentially 
used as a mucoadhesive carrier in oral drug delivery.  
1.6.5 Antibody conjugated dendrimers 
Some studies have reported the conjugation of dendrimers with antibodies to 
achieve improved functionality, mainly targeting to specific receptor. An 
important aspect for antibody conjugated dendrimer is that whether such system 
will influence the immunoactivity of antibody. Wangler et al. studied the effect of 
dendrimer conjugation on the immunoreactivity of antibody [167]. Anti-EGFR 
antibody hMAb425 were conjugated with PAMAM of different sizes containing 
various number of chelating agents per conjugation site. The result showed that 
the number of derivatization sites largely influence the immunoreactivity rather 
than dendrimer size.  Shukla et al. conjugated anti-HER2 receptor monoclonal 
antibody (anti-HER2 mAb) to PAMAM G5 [168]. The antibody conjugated 
dendrimer specifically targeted cell lines overexpressing HER2 due to the anti-
HER2 mAb functional groups. Moreover, methotrexate loaded in the antibody 
modified dendrimer showed similar activity as methotrexate free drug to inhibit 
the dihidrofolate reductase with reduced cytotoxicity, indicating reduced non-
specific toxicity to normal cells without overexpression of HER2. Such reduction 
of toxicity was attributed to the slowed release of methotrexate and longer 
retention time in lysosomal pocket.  Patri et al. prepared J591 anti-PSMA 
(prostate-specific membrane antigen) monoclonal antibody conjugated PAMAM 
G5 to target prostate cancer cell line LNCaP [169].  The conjugate showed 
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selective binding to PSMA positive prostate cancer cells LNCaP over PSMA 
negative prostate cancer cells PC3.In another study, Kobayashi et al. prepared 
OST7 (a murine monoclonal IgG1) conjugated PAMAM G4 dendrimer [170]. 
Biodistribution study showed that such conjugate specifically accumulated in the 
KT005 tumor (16.1%) compared to control dendrimer without OST7 conjugation 
(5.1%)  At the same time, about 30% and 15% of the OST7 conjugated PAMAM 
dendrimers accumulated in liver and spleen, respectively.  
1.6.6 Amino acid/peptide conjugated dendrimers 
Dendrimers are also conjugated with amino acid or peptide to decrease toxicity 
and improve functionality in applications. Phenylalanine modified PPI G5 and 
PAMAM G4 dendrimers were reported to be less toxic than the original versions 
[103, 171]. Moreover, amino acid conjugate dendrimers were also reported with 
higher transfection efficiency. Kono et al. synthesized phenylalanine conjugated 
dendrimers and tested transfection efficiency on CV1 cells. Dendrimer surface 
modified with 64 phenylalanine residues achieved high transfection efficiency 
[171]. Similarly, Choi et al. prepared L-arginine conjugated PAMAM dendrimer 
and tested its transfection efficiency against L-lysine-PAMAM, PAMAM and PEI 
on 293, HepG2, Neuro 2A and primary rat vascular smooth muscle cells [172].  
Arginine-PAMAM dendrimer showed much higher transfection efficiency. Yang 
and Kao conjugated arginine-glycine-aspartate (RGD) peptides with PAMAM 
G3.5 and PAMAM G4 dendrimers.  Thomas et al. conjugated epidermal growth 
factor (EGF), a peptide containing 53 amino acids, to PAMAM G5 dendrimer. 
Such conjugate showed binding to EGFR-expressing cell lines in a receptor-
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specific fashion [173]. Thus, such EGF-dendrimer could be further conjugated 
with chemotherapeutic drug for targeted cancer treatment.  
1.7 Chapter summary 
This chapter has provided background information on dendrimer preparation, 
structure properties, biomedical applications, toxicity issues and surface 
modification methods to reduce toxicity as well as to improve functionalities. The 




2. CHAPTER 2. HYPOTHESIS AND OBJECTIVES 
2.1 Thesis rationale and hypothesis 
Dendrimer is a unique type of polymer that possesses attractive properties for 
potential biomedical applications such as drug delivery, diagnostics, and gene 
delivery. The density and type of surface groups largely affect the 
physicochemical characters of dendrimer. Amine terminated dendrimers are the 
most widely studied because the inherent cationic charge allows for interaction 
with many biological components such as DNA, cell membranes and proteins. 
However, such interaction also poses concerns for the toxicity of dendrimer in 
biomedical applications. As described in chapter 1, studies have shown that 
surface modifications are useful strategies to reduce dendrimer toxicity. Based on 
these findings, the hypothesis for this project is that surface modification with 
various functional groups or via physical complexation will improve dendrimer 
functionality in drug delivery applications as well as reduce its inherent toxicity.  
2.2 Objectives 
1. To prepare dual functionalized dendrimers with PEGylation and thiolation. 
This is described in chapter 3, where the preparation of the dendrimer 
derivatives and physicochemical characterizations were studied.  
2. To examine the compatibility of functionalized dendrimer conjugates with 
major blood components. This is described in chapter 4, where the toxic effect 
of dendrimer conjugates on various blood components was evaluated. 
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3. To investigate the potential application of dual functionalized dendrimers in 
oral drug delivery. This is described in chapter 5, where the potential 
application of dual functionalized dendrimers as epithelial penetration 
enhancer was studied in both in vitro and in vivo models.  BCS class III drug 
ganciclovir was used as model drug for in vivo evaluation. 
4. To evaluate the effect of dendrimer-lipid hybrid nanosystem on therapeutic 
efficacy of paclitaxel. This is described in chapter 6, where the dendrimers 
were physically mixed with lipids to form a hybrid nanosystem. The hybrid 




3. CHAPTER 3. SYNTHESIS AND PHYSICOCHEMICAL 
CHARACTERIZATION OF PAMAM DENDRIMER 
DERIVATIVES  
3.1 Introduction 
The systemic circulation is a complex biological milieu made up of various 
components including blood and immune cells as well as proteins that serve 
important functions such as blood coagulation and host defence.  Interactions of 
the dendrimer-based pharmaceuticals with such components could lead to rapid 
recognition and subsequent removal from systemic circulation which in turn 
dictates the in vivo fate of the dendrimer-based pharmaceuticals.   
In view of the hemotoxicity of the cationic PAMAM dendrimers, manipulation of 
the surface properties of these dendrimers would present a viable approach in 
overcoming this limitation.  PEGylation is a common method to surface-modify 
nanoscaled systems to prevent protein adsorption and cellular interactions [174, 
175] and recently, thiolation of polymers has been shown to improve the 
hemocompatibility of polymers such as poly(D,L-lactic acid/glycolic acid) 
(PLGA) and poly(ethylene terephthalate) [176, 177].  Moreover, the surface thiol 
groups have been utilized to interact with metal ions or provide mucoadhesive 
properties [163, 166].  Thus, a combination of thiolation and PEGylation might 
further improve blood compatibility of dendrimer as well as to provide additional 
properties that could be applied to improve the functionalities of dendrimer in 
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biomedical applications.  As such, in this chapter, cationic PAMAM dendrimers 
were functionalized with PEG or thiol or the combination of both. 
The synthetic scheme of PEG-PM-SH polymer is shown in Figure 3.1.  PEG 
groups were firstly attached to the amine group of PAMAM.  Subsequently, the 
PEGylated dendrimer reacted with TBA to generate free thiol groups.  The 
physicochemical properties of the dendrimer derivatives were characterized and 
discussed in this chapter. 
 
Figure 3.1. Synthetic scheme of PEG-PAMAM and PEG-PAMAM-TBA 
conjugates.  
 
3.2 Materials and Methods 
3.2.1 Materials 
PAMAM dendrimer generation 4 with ethylenediamine core was obtained from 
Dendritech, Inc. (Midland, MI, U.S.A.). Methoxy poly(ethylene glycol) 
succinimidyl carboxymethyl (mPEG-SCM) (M.W. 2000) was purchased from 
Laysan Bio, Inc. (Arab, AL, U.S.). 2-Iminothiolane hydrochloride (Traut’s 
Reagent, TBA), 5,5’-dithiobis(2-nitrobenzoic acid) (Ellman’s reagent), sodium 
borohydride (NaBH4) were obtained from Sigma-Aldrich Pte Ltd. (Singapore). 
All other chemicals used in the study were purchased from Sigma-Aldrich (St 







































3.2.2 Preparation of PEG-PM Dendrimer. 
PEG-PM conjugation was performed with modification from a method previously 
reported [178]. Briefly, 60 mg (4.2 μmol) of PAMAM-NH2 G4 was dissolved in 5 
ml of phosphate buffer (0.5 M, pH 8.0). Four (33.8 mg, 16.8 μmol) or eight (67.6 
mg, 33.6 μmol) times of mPEG-SCM (M.W. 1923 determined by GPC) was 
added to the dendrimer solution. The reaction mixture was stirred for 24 h at room 
temperature in the dark and with nitrogen protection. The product was 
subsequently dialyzed three times against distilled water for 48 h. The dialyzed 
product was lyophilized and stored at 4°C until further usage. Synthesized PEG-
PM conjugates were analyzed by 
1
H-NMR (Bruker Avance 500, Bruker AXS Pte. 
Ltd., Singapore) and Fourier transform infrared (FT-IR) spectroscopy 
(PerkinElmer Spectrum 100, PerkinElmer, Inc., MA, USA). The hydrodynamic 
diameter and zeta potential of synthesized polymers were analyzed by a Zetasizer 
Nano-ZS90 (Malvern. Instruments GmbH Herrenberg, Germany). 
3.2.3 Preparation of Thiolated PEG-PM Dendrimer (PEG-PM-SH).  
PEG-PM-SH was synthesized with modifications from a method previously 
reported [179].  Briefly, 40 mg of lyophilized PEG-PM dendrimer was dissolved 
in 5 ml of phosphate buffer (0.5 M, pH 7.2), and 21.1 mg (153.6 μM) of 2-
iminothiolane HCl was added, with the pH of the mixture adjusted to 7.0 with 
NaOH (0.1 M). The reaction mixture was stirred for 24 h at room temperature in 
the dark and with nitrogen protection. The product was dialyzed stepwise against 
(1) 5 mM HCl, (2) 5 mM HCl containing 1% NaCl twice, (3) 5 mM HCl, and (4) 
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1 mM HCl. The dialyzed product was then lyophilized and stored at −20°C until 
further usage. 
3.2.4 Molecular Weight Determination. 
Gel permeation chromatography (GPC) was used to evaluate the relative 
molecular weight of PEG-PM. Polyethylene (glycol/oxide) standards (EasiVial 
PEG/PEO, Agilent Technologies Singapore Pte. Ltd.) with molecular weights of 
106, 194, 615, 1500, 3930, 12 140, 23 520, 62 100, 116 300, 442 800, 909 500, 1 
258 000 were used to construct the calibration curve. Dendrimer molecular weight 
was also determined by matrix-assisted laser desorption ionization time-of-flight 
(MALDI-TOF) mass spectrometry (4800 Proteomics Analyzer, Applied 
Biosystems Asia Pte Ltd.). Dendrimer samples were dissolved in methanol at a 
final concentration of 0.2 mg/ml. Five milligrams per milliliter of α-cyano-4-
hydroxycinnamic acid (CHCA) in acetonitrile/water (75:25) with 0.1% 
trifluoroacetic acid was used as the matrix. Equal volumes of sample and matrix 
were mixed in a tube, and 1 μL was spotted on the sample plate. The instrument 
mode was Positive Ion mode. The operation mode was linear. Lysozyme at 100 
pmol was used as the standard. 
3.2.5 Determination of the Thiol Group Content. 
The amount of free thiol groups attached to the PAMAM dendrimer was 
determined with Ellman’s reagent (3 mg of 5,5’-dithiobis(2-nitrobenzoic acid) 
dissolved in 10 ml of 0.5 M PBS; pH 8.0). Polymer sample was dissolved in 1 ml 
of 0.5 M PBS (pH 8.0), and 100 μL sample was mixed with 500 μL Ellman’s 
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reagent. The reaction was incubated in dark at 25°C for 90 min. Afterwards, the 
absorbance was immediately measured at wavelength of 412 nm in a microtiter 
plate reader (Tecan, Infinite M2000). The amount of free thiol groups was 
calculated from a standard curve prepared using N-acetyl-cysteine. To determine 
the total amount of thiol groups, 1.5 mg of polymer was first dissolved in 500 μL 
of 0.05 M Tris buffer (pH 6.8), and 1 ml of freshly prepared 4% sodium 
borohydride (NaBH4 ) solution was added. The mixture was incubated for 60 min 
at 37°C. Thereafter, 100 μL of 10 M HCl was added to inactivate the excess 
NaBH4. The pH of the mixture was adjusted to 8.0 with 1 ml of 1 M PBS (pH 8.5). 
A sample of 100 μL was taken for Ellman’s assay as described above. 
3.3 Results 
3.3.1 Structure characterization by NMR 
Two PEG-PM conjugates with PEG: PAMAM feed ratios of 4:1 and 8:1 were 
prepared following literature method [178].  The conjugation was confirmed by 
NMR spectroscopic method (Figure 3.2). In PEG-PM samples, the appearance of 
a major peak at chemical shift at 3.4−3.6 ppm represents the protons of the repeat 
unit −CH2CH2O−of PEG. After conjugation with TBA, the signals at δ8.66 ppm 
(br, Hn) and δ1.76 ppm (br, Hq) indicate that TBA was conjugated with PAMAM 







H-NMR spectra of  a) PM G4.0, b) PEG(1.8)-PM c) PEG(4.0)-PM, d) 
PEG(1.8)-PM-TBA(7.0), e) PEG(4.0)-PM-TBA(6.7), f) PM-TBA(7.6). The 
signals for PAMAM are d 7.94 ppm (s, Hh), d 2.95-3.31 ppm (m, Ha, Hb, Hf), d 
2.65 ppm (br, Hd), d 2.43 ppm (br, He) and d 2.20 ppm (br, Hc). The signals for 
PEG-PAMAM are d 3.4-3.6 ppm (m, Hl, Hm) and d 3.24 ppm (s, Hk). The 
appearance of a major peak at chemical shift at 3.4-3.6 ppm represents the protons 
of the repeat unit -CH2CH2O- of PEG. After conjugation with TBA, the signals at 
d 8.66 ppm (br, Hn) and d 1.76 ppm (br, Hq) indicates that TBA was conjugated 




















































































































3.3.2 FTIR analysis 
In FTIR analysis, dendrimer samples were analyzed using KBr pellet method. The 
IR spectrum displayed characteristic peaks at ~3400 cm
-1
 (N-H stretch of primary 
amines); ~2916 cm
-1
 (aliphatic C-H stretch); ~1647 cm
-1
 (-C=O stretch of amide); 
~1554 cm
-1
 (N-H bending of N substituted amide); ~1455 cm
-1
 (C-H stretch of 
methylene),~1063 cm
-1
 (C-O of aliphatic ether linkage) (Figure 3.3). The IR 
spectrum peak information is listed in Table 3.1.  
 
Figure 3.3. FT-IR spectra of (1) PM G4, (2) PEG(1.8)-PM, (3) PEG(4.0)-PM, (4) 
PEG(1.8)-PM-TBA(7.0), (5) PEG(4.0)-PM-TBA(6.7), (6) PM-TBA(7.6).  
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Table 3.1. IR spectrum peak information of dendrimer samples. 
 






























































































 N-H stretch of primary amines 
b
 Aliphatic C-H stretch 
c
 –C=O stretch of amide 
d
 N-H bending of N substituted amide 
e
 C-H stretch of methylene 
f
 C-O of aliphatic ether linkage 
 
3.3.3 Yield, size, zeta potential and molecular weight determination 
All the synthesized polymers were obtained with average yields of >80%, except 
for PM-TBA(7.6), which only had a yield of ~41% (Table 3.2).  The particle size 
and zeta potential of these polymers were measured by Zetasizer Nano-ZS90. All 
the PEG or TBA conjugated dendrimers showed similar particle size and zeta 
potential as compared to unmodified PAMAM dendrimer because of low 
PEGylation ratio and introduction of imino groups to the surface while attaching 
TBA to the surface of PAMAM (Table 3.2).  The molecular weight of dendrimers 





Figure 3.4. Representative GPC chromatogram of a) PM G4.0, b) PEG(1.8)-PM c) 
PEG(4.0)-PM sample.  
(b) PEG(1.8)-PM: Mz=15,859
(c) PEG(4.0)-PM: Mz=19,492




Figure 3.5. Molecular weight of a) PM G4.0, b) PEG(1.8)-PM, c) PEG(1.8)-PM-
TBA(7.0), d) PEG(4.0)-PM, e) PEG(4.0)-PM-TBA(6.7) determined by MALDI-
TOF mass spectrometry.  
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3.3.4 Thiol group quantification 
Traut’s Reagent is very commonly used to react with primary amino groups to 
generate thiol groups [179-182]. The amount of free and total thiol groups 
conjugated on PAMAM dendrimer is shown in Table 3.2.  Two feed ratios of 
thiol to dendrimer were used (64:1 and 128:1), and the higher feed ratio of 128:1 
did not result in higher number of thiol groups per PAMAM.  The lyophilized 
thiolated dendrimers appeared as white to yellow color powder of fibrous 
structure. In order to minimize oxidation during storage, the samples were purged 
with nitrogen gas and stored at -20°C. For PEG(1.8)-PM-TBA(7.0) and 
PEG(4.0)-PM-TBA(6.7) samples, 57.4% and 60.1% of the thiol groups were 
oxidized to disulfide bond during the preparation process. In comparison, the 
degree of oxidation for PM-TBA(7.6) is 38.0%, which is less extensive in 
comparison. 
3.4 Discussion 
3.4.1 Molecular weight determination 
The molecular weights of various dendrimers were determined by GPC and 
MALDI-TOF MS. GPC is chosen as the first method as it could reflect the 
average absolute molar mass of the dendrimers [183] rather than the distribution 
of the mass fractions.  Both methods showed similar results for PEGylated 
PAMAM and unmodified version.  For PEG/dendrimer feed ratios of 4:1 and 8:1, 
the average conjugation ratio was 1.8:1 and 4:1, respectively.  However, GPC 
could not provide M.W. information for thiolated dendrimers due to the presence 
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of aggregates.  This is due to the oxidation of free thiol groups and formation of 
disulfide bonds among different dendrimer units.  Thus, it is important to 
determine the degree of oxidation after preparation, as well as the stability of free 
thiol groups at different pH conditions.  
3.4.2 Oxidation of free thiol groups after preparation 
Free thiol groups are prone to oxidation to form disulfide bond during the 
preparation process.  In order to decrease the oxidation of thiol groups, thiolation 
step took place after PEGylation.  Nitrogen gas protection and dark environment 
were carefully provided during the synthesis.  Moreover, the pH was adjusted to 
7.0 to balance between good conjugation efficiency and minimal oxidation 
condition.  Acidic environment was more favorable to protect free thiol groups 
from oxidation, yet the conjugation efficiency would be lower under acidic 
condition.  After the synthesis, dialysis was kept in acidic conditions to minimize 
oxidation.  When the final product was lyophilized in powder form, it was kept at 
acidic condition in -20°C to minimize oxidation.  Additionally, another possible 
method to reduce oxidation is to store the thiolated polymers together with 
reducing agent, for example, glutathione (GSH). 
After the processes of synthesis, dialysis and lyophilization, 57.4%, 60.1% and 
38.0% of the thiol groups were oxidized to disulfide bond for PEG(1.8)-PM-
TBA(7.0), PEG(4.0)-PM-TBA(6.7), and PM-TBA(7.6), respectively (Table 3.1).  
Although PM-TBA(7.6) dendrimer had less of the free thiol groups being 
oxidized, the total concentration of oxidized thiol groups were in a similar range: 
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233 µmol/g for PEG(1.8)-PM-TBA(7.0), 189 µmol/g for PEG(4.0)-PM-TBA(6.7) 
and 204 µmol/g for PM-TBA(7.6).  This may suggest that the preparation process 
oxidized a fixed amount of thiol groups.  
3.5 Conclusion 
In this chapter, the PEGylated and thiolated dendrimers were successfully 
prepared and characterized.  Dendrimers with two different PEGylation ratios, 
1.8:1 and 4.0:1, were synthesized.  After thiolation step, the thiol groups were 
oxidized to disulfide bond to different extents for PEG(1.8)-PM-TBA(7.0), 
PEG(4.0)-PM-TBA(6.7), and PM-TBA(7.6).  PEGylation showed weakly 
protective role against thiol groups oxidation in liquid but not in powder form.  To 
the best of our knowledge, dual functionalized PAMAM dendrimer with TBA and 
PEG were not reported by other research groups so far.  In the next chapter, the 





4. CHAPTER 4. BLOOD COMPATIBILITY OF PAMAM 
DENDRIMERS AND THEIR DERIVATIVES 
4.1 Introduction 
Thus far, studies have demonstrated the blood toxicity of unmodified cationic 
PAMAM dendrimers in vivo, whereby intravenous injection of these dendrimers 
into mice and rats with doses >10 mg/kg produced disseminated intravascular 
coagulation (DIC)-like symptoms with high mortality rates [142].  Through a 
number of in vitro assays probing blood coagulation; haemolysis; platelet 
activation, aggregation and function, cationic PAMAM dendrimers have been 
shown to be highly hemotoxic in contrast to their anionic or neutral counterparts 
[100, 139, 141].  Such hemotoxicity is thought to be a result of the electrostatic 
interaction between the cationic PAMAM dendrimers and the negatively charged 
blood proteins and platelet membranes [100, 140, 141].  Furthermore, the 
hemotoxicity was concentration- and generation-dependent. 
In the previous chapter, we have prepared dual functionalized cationic PAMAM 
dendrimer via PEGylation and thiolation.  It is hypothesized that such dual 
functionalization of PAMAM dendrimers would be an effective strategy in 
modulating the hemotoxicity profile of these dendrimers.  In this chapter, a 
number of in vitro assays have been performed to evaluate the effect of PAMAM 
dendrimers on the major blood components, including red cell morphology and 
lysis; viability of human monocytic cell line U-937; binding with bovine serum 
albumin (BSA); generation of complement C3a; blood coagulation times, and 
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platelet aggregation.  Among these in vitro assays, hemolysis, complement 
activation are considered to have good predictive correlation with in vivo 
immunotoxicity [184].  Leukocyte proliferation and thromobogenicity are 
considered to be generally predictive [184].   
4.2 Materials and Methods 
4.2.1 PAMAM dendrimers 
Amine-terminated PAMAM dendrimer generation 2.0 (PM2.0), generation 3.0 
(PM3.0), generation 4.0 (PM4.0) and carboxyl-terminated PAMAM dendrimer 
generation 3.5 (PM3.5) with ethylenediamine core were purchased from 
Dendritech, Inc (Midland, MI, U.S.A.). PM4.0 were surface modified with 
polyethylene glycol (PEG, m.w. 2,000) and 2-Iminothiolane Hydrochloride 
(Traut’s Reagent, TBA) as described in chapter 3. Physical properties of the 




Table 4.1. Physical characterization of various PAMAM dendrimers with or 
without surface functionalization. 
 
Dendrimer type M.W. 
Zeta Potential 
(mV) 
Size (nm) Nsurface groups 
PM2.0 3,256
a
 +22.0 ± 0.7 2.2 ± 0.2 16 
PM3.0 6,909
a
 +22.5 ± 0.6 3.2 ± 0.1 32 
PM4.0 13,487
b
 +30.1 ± 0.9 4.3 ± 0.4 64 
PEG(1.8)-PM4.0 16,662
b
 +26.9 ± 5.0 3.7 ± 1.4 64 
PEG(4.0)-PM 4.0 20,751
b










 +36.7±1.3 5.4±1.3 64 
PM4.0-TBA(7.6) 14,259
b
 +39.2 ± 1.8 4.4 ± 1.6 64 
PM3.5 13,061
c
 -26.5 ± 0.7 5.1 ± 1.1 64 
a
Theoretical molecular weight of PM2.0 and PM3.0.  
b
Molecular weight were reported in chapter 3 Table 3.2.  
c
Molecular weight of PM3.5 was determined by GPC. 
4.2.2 Cell cultures 
The human hematopoietic cell line U-937 was acquired from American Type 
Culture Collection (Manassas, USA). U-937 cells were maintained in RPMI 1640 
media supplemented with 10% fetal bovine serum (FBS) and were routinely 
propagated in T-75 cm
2
 flasks (Iwaki, Japan) in humidified atmosphere of 5% 
CO2 at 37°C.  
4.2.3 Cell viability assay 
The effect of PAMAM dendrimers on U-937 cell viability was evaluated by Cell 
Counting Kit-8 (CCK8, Dojindo Molecular Technologies, INC., Singapore). U-
937 cells were seeded in 96-well plates at a density of 2.5 ×10
5 
 cells/well. Cells 
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were exposed to various dendrimers and incubated at 37ºC for 72 h. Triton-X 
(0.2%) was used as positive control. After incubation, 10 µl CCK8 was added to 
each well and kept at 37 ºC for 4 h followed by measuring absorbance at 450 nm 
with Tecan SpectraFluorPlus reader. Cell viability was calculated as follows: 
Cell Viability% = (Abstest – Absbackground) / (Absvehicle – Absbackground) × 100% 
where Abstest, Absbackground, Absvehicle represent the absorbance readings from the 
dendrimer-treated well, the medium-only wells and the vehicle control wells, 
respectively. IC50 was estimated using the software Calcusyn version2.1 (Biosoft, 
Cambridge, UK). 
4.2.4 Haemolysis study 
Freshly collected rat blood was provided by NUS animal laboratory center with 
approved IACUC protocol T14/12.  The whole blood sample was centrifuged at 
1,500×g in 4°C for 10 min.  After removal of supernatant, the red blood cells 
(RBC) were washed three times with phosphate-buffered saline (PBS) and 
centrifuged at 1,500×g in 4°C for 5 min.  After washing steps, the RBCs were 
diluted in PBS to a final concentration of 4% (v/v).  The RBC samples were kept 
in 4°C prior to experiment and used within 24 h. 
Dendrimer samples (0.25 to 4 mg/ml) or 1% Triton-X were added to the freshly 
prepared rat RBC samples (4% in PBS) and incubated at 37ºC for 24 h. After 
which, the solution was centrifuged at 1500× g for 10 min. The supernatant was 
collected and absorbance was measured at 550 nm for haemoglobin. 
Haemoglobin release was calculated as follows: 
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Haemoglobin release (%) = (Abstest – Absvehicle) / (AbsTriton-X – Absvehicle) × 100% 
where Abstest,, Absvehicle, AbsTriton-X  represent the absorbance readings from the 
dendrimer, PBS only and Triton-X treated RBC, respectively. 
4.2.5 Scanning electron microscopy (SEM) of red blood cells 
4% v/v RBC were incubated with 2 mg/ml dendrimer samples at 37ºC for 4 h. 
After incubation, the cells were harvested and washed twice with ice cold PBS. 
After which the cells were fixed with 2.5% SEM grade glutaraldehyde at 4ºC for 
24 h. After washing twice with PBS, cells were placed in 1% osmium tetroxide 
for 1 h before dehydration serially in 30%, 50%, 70%, 90% and 100% ethanol. 
Then the cells were resuspended in hexamethyldisilazane (HMDS). After the 
evaporation of HMDS, cells were coated with platinum for 5 mins. SEM images 
of RBC were taken with a JEOL JSM-6701F (JEOL, Tokyo, Japan) field emission 
scanning electron microscope. 
4.2.6 Fluorescence quenching of bovine serum albumin  
Dendrimer samples at various concentrations were mixed with 0.2 mg/ml BSA 
diluted in PBS. The samples were then incubated at 25ºC for 0.5 h. Fluorescence 
emission spectra were taken with Hitachi F-7000 fluorescence spectrophotometer. 
Emission spectra were measured from wavelength 310 nm to 400 nm after 
excitation at 295 nm. Excitation and emission slits were set at 5 nm and 2.5 nm, 
respectively. The fluorescent signal appeared at 340 nm wavelength and was 




F0/F – 1 = Ksv × [Q] 
where F0 and F represent the fluorescence intensity of BSA in the absence of 
dendrimer sample and in the presence of dendrimer samples at [Q] concentration 
(µM), respectively. Ksv is the Stern-Volmer dynamic quenching constant.  
4.2.7 Complement activation 
C3a enzyme immunoassay kit (Quidel, San Diego, Ca) was used to assess 
complement component C3 activation. The formation of activation peptides, C3a 
and C3a des arg, was measured according to manufacturer’s protocol. 95 µl 
human plasma (Sigma-Aldrich, with 3.8% trisodium citrate as anticoagulant) was 
mixed with 5 µl dendrimer sample stock solution or PBS (vehicle control) and 
incubated at 37 ºC for 1 h. The samples were then diluted with the specimen 
diluent buffer and added to microtiter plate coated with murine monoclonal 
antibody specifically binding to human C3a and C3a des arg. After 1 h of 
incubation, the plates were washed and incubated with horseradish peroxidase 
(HRP)–conjugated anti-C3(C3a) polyclonal antibody for 15 min followed by 
washing and incubation with chromogenic substrate. Absorbance was measured at 
450 nm. C3a concentration of plasma samples were calculated from a standard 
curve using C3a standard provided in the kit. Relative increase in C3a generation 
(%) was calculated as follows: 
Relative increase in C3a generation% = (Abstest – Absvehicle) / Absvehicle × 100% 
where Abstest and Absvehicle represent the absorbance readings from the dendrimer 
samples or PBS treated RBC, respectively. 
70 
 
4.2.8 Determination of prothrombin time and activated partial 
thromboplastin time  
Prothrombin time (PT) and activated partial thromboplastin time (aPTT) were 
measured with Sysmex CA-500 Blood Coagulation Analyzer (Sysmex Asia 
Pacific Pte Ltd, Singapore). 50 µl dendrimer solution was mixed with 100 µl 
citrated human plasma (Ci-Trol level 1, Dade Behring Marburg GmbH, Marburg, 
Germany). For the PT determination, the extrinsic and common coagulation 
pathways were activated by incubating the sample with human thromboplastin 
containing calcium chloride (Thromborel S, Dade Behring Marburg GmbH) and 
the clotting time was measured. For the aPTT determination, the intrinsic and 
common coagulation pathways were activated by adding an activated partial 
thromboplastin reagent (Actin FSL, Dade Behring Marburg GmbH) and calcium 
chloride (25 mM) to the sample and the clotting time was measured. PBS and 
0.01% w/v heparin in PBS were used as negative and positive control, 
respectively.  
4.2.9 Platelet aggregation measurement 
Whole blood aggregation assay was tested by measuring impedance using a 
whole blood aggregometer (Chronolog Corporation, Havertown, PA) as described 
before [185]. Freshly prepared rat blood was purchased from Invivos Pte Ltd 
(Singapore) and kept at 37ºC before use. 450 µl of the blood was mixed with 450 
µl saline and allowed to equilibrate for 2 min. Subsequently, 50 µl of dendrimer 
stock solution (4 mg/ml in saline) was added to the mixture and allowed to 
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equilibrate for 2 min. In order to initiate platelet aggregation, 5 µl of collagen 
(Chrono-Log Corporation, Havertown, PA, USA) was added to the test mixture. 
Saline without dendrimer was used as control. The test was allowed to run for 10 
min. Change in collagen induced platelet aggregation was calculated as follows:  
Platelet aggregation% = Impedancetest / ImpedanceSaline × 100% 
where Impedancetest is the impedance value for the dendrimer treated blood 
sample and ImpedanceSaline is the impedance value of saline treated blood samples.  
4.2.10 Statistical analysis 
Where appropriate, results were expressed as mean ± SEM of at least three 
independent experiments. Statistical significance was determined using the 
Student t-test or one-way analysis of variance (ANOVA) Kruskal-Wallis test 
followed by Dunn’s test used for post-hoc multiple comparisons. P values of < 
0.05 were considered to be statistically significant. Statistical analyses were 
carried out using SPSS software (v 19.0; IBM, Armonk, NY). 
4.3 Results 
4.3.1 Cytotoxicity of PAMAM dendrimers on human monocytic cell line 
U937  
The cytotoxicity of PAMAM dendrimers was determined in U-937 cells which 
were exposed to a range of concentrations of the various dendrimers for 72 h 
(Figure 4.1).  U-937 cells were selected as a model human cell line to study the 
toxic effect of dendrimer on monocytes.  The half maximal inhibitory 
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concentration (IC50) was calculated by CalcuSyn (Table 4.2).  In general, the 
higher the dendrimer generation and concentration, the higher was the observed 
cytotoxicity. The IC50 values of unmodified cationic PAMAM dendrimers were in 
the order of PM4.0<PM3.0<PM2.0, with nearly a log-fold increase in IC50 value 
as the dendrimer decreased its generation by one.  This observation is in line with 
the literature that cationic PAMAM cytotoxicity is generation dependent.  
Another observation is that surface properties of the cationic PAMAM dendrimer 
could modulate its cytotoxicity.  Surface modification of PM4.0 with PEG alone 
decreased the IC50 by more than 5-fold (PM4.0 vs PEG(1.8)-PM4.0 and 
PEG(4.0)-PM4.0).  On the contrary, introduction of thiol groups onto PM4.0 did 
not offer any benefit in reducing PM4.0 cytotoxicity.  Similarly, PEGylation of 
PM4.0-TBA(7.6) did reduce the cytotoxicity of the thiolated dendrimer; however, 
such benefit could only be observed when the level of PEG engraftment was 
higher.  Modifying the PAMAM cationic surface to an anionic surface with 
carboxylic acid groups could dramatically reduce the cytotoxicity, whereby a 50-
fold higher in IC50 values could be observed when comparing PM3.5 with PM4.0 





Figure 4.1. Cell viability study measured by Cell Counting Kit-8 after 72 h 
treatment with (A) PM2.0 (▽), PM3.0 (○), PM4.0 (□), PM3.5 (△) , (B) PM4.0 
(□), PEG(1.8)-PM4.0 (◇), PEG(1.8)-PM4.0-TBA(7.0) (△), PM4.0-TBA(7.6) 
(▽), (C) PM4.0 (□), PEG(4.0)-PM 4.0 (◇), PEG(4.0)-PM4.0-TBA(6.7) (△), 
PM4.0-TBA(7.6) ( ▽ ).  Data represent mean ± SEM of 3 independent 
experiments. 
 


























































































Dendrimer type µM mg/ml 
PM2.0 1317 ± 550
*
 4.29 ± 1.79 
PM3.0 129 ± 6 0.89 ± 0.04 
PM4.0 19 ± 2 0.26 ± 0.02 
PEG(1.8)-PM4.0 108 ± 21 1.79 ± 0.35 
PEG(4.0)-PM 4.0 107 ± 15 2.21 ± 0.32 
PEG(1.8)-PM4.0-TBA(7.0) 19 ± 4 0.34 ± 0.06 
PEG(4.0)-PM4.0-TBA(6.7) 76 ± 13 1.63 ± 0.29 
PM4.0-TBA(7.6) 13 ± 4 0.19 ± 0.06 
PM3.5 1123 ± 167
*
 14.52 ± 2.16 
Data represent mean ± SEM of 3 independent experiments. * p < 0.05 compared 
to IC50 of PM4.0  
 
4.3.2 Haemolysis and RBC morphological changes induced by PAMAM 
dendrimers 
The next set of experiments involved the examination of the effects of various 
PAMAM dendrimers on RBC.  Hemoglobin release, which is indicative of RBC 
lysis, was measured 24 h after the incubation of RBC with the dendrimers (Figure 
4.2).  Similar to previous finding [186], PAMAM dendrimers with surface amine 
groups triggered hemoglobin release in a generation- and concentration-dependent 
manner.  In contrast, anionic PM3.5 induced minimum haemolysis, even when 
tested at the highest concentration of 4 mg/ml.  Thiolation of PM4.0 alone 
provided modest protection against haemolysis; yet, at the highest concentration 
of 4 mg/ml, ~30% of haemolysis was induced by PM4.0-TBA(7.6).  Modifying 
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the PAMAM dendrimers with PEG alone or a combination of PEG and thiol 
groups could effectively reduce the extent of haemolysis to < 10% even at the 
highest concentration tested.    
 
Figure 4.2. In vitro haemolysis studies of PAMAM dendrimers PM2.0 , PM3.0, 
PM4.0, PEG(1.8)-PM4.0, PEG(4.0)-PM 4.0, PEG(1.8)-PM4.0-TBA(7.0), 
PEG(4.0)-PM4.0-TBA(6.7), PM4.0-TBA(7.6), PM3.5. Data represent mean ± 
SEM of at least 3 independent experiments. Data represent mean ± SEM of 3 
independent experiments. * p < 0.05, ** p < 0.01 compared to PM 3.5. 
 
Change in RBC morphology is another important parameter for examination, as 
RBC morphology could impact on its flow properties and aggregation potential.  
The morphology of RBC was observed under SEM after exposure to various 
dendrimers at 2 mg/ml for 4 h (Figure 4.3). RBC exposed to saline displayed 
normal, round, disc-shaped and biconcave morphology (Figure 4.3), while 
morphological changes and aggregation were observed after exposure to the 







































various types of dendrimers.  Clustering of RBC and presence of echinocytes 
could be seen in samples treated with unmodified cationic PAMAM dendrimers, 
and the effect was generation-dependent.  Of note, exposure to anionic PM3.5, 
PM4.0 modified with PEG alone, or PM4.0 dual-modified with PEG and thiol 
groups also induced echinocyte formation, despite their minimal haemolytic effect.  
Modification of PM4.0 with thiol groups alone caused extensive aggregation of 
RBC that could be reduced by the introduction of sufficient PEG groups (PM4.0-
TBA vs PEG(1.8)-PM4.0-TBA(7.0) and PEG(4.0)-PM4.0-TBA(6.7) respectively).     
 
Figure 4.3. SEM images of red blood cells incubated with 2 mg/ml dendrimer 
samples for 4 h. (1) PM2.0, (2) PM3.0, (3) PM4.0, (4) PM3.5 (5) PM4.0-
TBA(7.6), (6) PEG(1.8)-PM4.0, (7) PEG(1.8)-PM4.0-TBA(7.0), (8) PEG(4.0)-
PM 4.0, (9) PEG(4.0)-PM4.0-TBA(6.7), (10) Saline. The experiments were 





























































































4.3.3 Interaction of PAMAM dendrimers with BSA  
Binding between various PAMAM dendrimers at different concentrations to BSA 
was studied by means of the tryptophan fluorophore of BSA at the emission 
wavelength of 340 nm.  The relationship between fluorescence intensity and 
dendrimer concentration was further examined according to the classical Stern-
Volmer equation which would yield the Stern-Volmer dynamic quenching 
constant (Ksv) that indicates the accessibility of the albumin fluorophore to the 
dendrimer under examination [187].  Figure 4.4 illustrate the calculation from 
fluorescence signal to Stern-Volmer dynamic quenching constant. The slope of 
the linear regression curve represents Ksv value. The Ksv values for the 
interaction of various PAMAM dendrimers with BSA were presented in Table 4.3.  
In line with previous studies [98, 117, 119], the interaction between albumin and 
unmodified, cationic PAMAM dendrimers increased as dendrimer generation 
increased from 2.0 to 4.0, whereas the anionic PM3.5 showed the lowest 
interaction with BSA among the dendrimers tested.  PEGylation of PM4.0 alone 
could significantly reduce the Ksv values by > 2 folds.  The thiolated dendrimer 
PM4.0-TBA(7.6) gave rise to precipitation in the test system, which prevented the 
inclusion of the Ksv value for comparison.  The introduction of thiol groups to 
PEG(1.8)-PM4.0 increased the Ksv value, whereas thiolation of PEG(4.0)-PM4.0 
did not affect the Ksv value, suggesting a higher level of PEG is required to 





Figure 4.4 Representative figure of Stern-Volmer constant calculation.  Each 
curve represents the fluorescent signal of BSA mixed with different concentration 
of dendrimer.  The fluorescent signal at 330 nm and dendrimer concentrations 
were converted to linear regression by Stern-Volmer equation. The slope of the 
curve represents Ksv value.   



















F0/F – 1 = Ksv× [Q]
Fluorescence spectra of BSA after 













Table 4.3. Stern-Volmer quenching constant (KSV) for the interaction of 










PM3.0 2.54±0.23 0.99±0.01 

















Coefficient of determination 
** P < 0.01, *** P < 0.005 compared to Ksv of PM4.0 (n=3) 
 
4.3.4 Activation of complement system by various PAMAM dendrimers  
The effect of PAMAM dendrimers on complement activation was studied by 
measuring C3a generation after incubating human plasma with dendrimer samples 
at 37°C for 1 h (Figure 4.5).  Unmodified cationic PAMAM dendrimers, PM2.0, 
PM3.0 and PM4.0 at 4 mg/ml, caused higher level of C3a generation as compared 
to the negative control PBS.  In contrast, a 2-fold reduction in C3a generation was 
observed when changing the cationic surface of PM4.0 to the anionic surface of 
PM3.5.  Thiolation of PM4.0 did not reduce C3a generation in comparison to 
unmodified PM4.0, whereas modification of PM4.0 with PEG alone modestly 
decreased C3a generation in comparison to unmodified PM4.0.  Of note, dual-
functionalized dendrimers, PEG(1.8)-PM4.0-TBA(7.0) and PEG(4.0)-PM4.0-
TBA(6.7) tested at 10 mg/ml, could significantly reduce C3a generation in 




Figure 4.5. Mean relative percentage increase in C3a generation by 4 mg/ml 
PM2.0 , PM3.0, PM4.0, PEG(1.8)-PM4.0, PEG(4.0)-PM 4.0, PM4.0-TBA(7.6), 
PM3.5 or 10 mg/ml PEG(1.8)-PM4.0-TBA(7.0), PEG(4.0)-PM4.0-TBA(6.7) 
compared to PBS control. Data represent mean ± SEM of 3 independent 
experiments. Data represent mean ± SEM of 3 independent experiments. * p < 
0.05, ** p < 0.01 compared to PBS control. 
 
4.4 Effect of various PAMAM dendrimers on the coagulation pathways 
and platelet aggregation  
PT and aPTT were mainly used to evaluate the extrinsic and intrinsic coagulation 
pathway, respectively.  PT values reflect the time in fibrin clot formation after the 
addition of tissue thromboplastin, and aPTT values reflect the time in fibrin clot 
formation after the addition of partial thromboplastin reagent (actin) and calcium 
chloride.  Heparin and PBS were included as controls for comparison.  The PT 






















































































































Figure 4.6 A and B.  The mean PT values for the unmodified cationic PAMAM 
dendrimers (PM2.0, 3.0 and 4.0) and PM4.0 modified with PEG were 
summarized in Figure 4.6 A, and the concentrations tested were 0.0125 and 0.25 
mg/ml.  For higher concentrations (>0.25 mg/ml), these dendrimers showed 
prolonged or no coagulation (that is, no PT value could be registered by the 
equipment).  At 0.25 mg/ml, PM2.0, PM3.0, PM4.0, and the PEGylated PM4.0 
dendrimers yielded higher PT values as compared to PBS; furthermore, the PT 
values for PM4.0 and the PEGylated PM4.0 dendrimers were significantly higher 
than that of PBS control, indicating the anti-coagulant potential of these three 
dendrimers.  PM4.0 modified with PEG alone showed shorter PT as compared to 
original PM4.0, and the effect was more obvious as PEG ratio increased.  In 
contrast, the dual-functionalized PM4.0 dendrimers and PM3.5 did not modulate 
the extrinsic coagulation pathway, as their PT values were not statistically 
different from that of PBS even when tested at 4 mg/ml.  Similar to PT 
determination, citrated human plasma treated with various dendrimers showed 
prolonged aPTT or no coagulation at concentrations that were higher than those 
reported in Figure 4.6 C.  Among the unmodified cationic PAMAM dendrimers, 
PM2.0 was the most potent in causing no coagulation of the citrated plasma.  
Modification with PEG alone did not alter the anti-coagulant potential of PM4.0.  
On the contrary, PEG(1.8)-PM4.0-TBA(7.0) and PM3.5 did not modulate the 
intrinsic coagulation pathway, as their aPTT values were not statistically different 
from that of PBS even when tested at 4 mg/ml.  In addition to PT and aPTT 
values, collagen-induced platelet aggregation was also determined, and the results 
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are summarized in Figure 4.7.  PM4.0, PM4.0 modified with TBA and PM3.5 did 
not significantly alter collagen-induced platelet aggregation; however, PEGylation 
alone or dual functionalization of PM4.0 could significantly reduce collagen-
induced platelet aggregation. 
 
Figure 4.6. Mean PT and aPTT values for different PAMAM dendrimers. (a) PT 
of PM2.0, PM3.0, PM4.0, PEG(1.8)-PM4.0 and PEG(4.0)-PM4.0 at 0.25 mg/ml 
and 0.0125 mg/ml, respectively. (b) PT of PM3.5, PEG(1.8)-PM4.0-TBA(7.0) 
and PEG(4.0)-PM4.0-TBA(6.7) at 4mg/ml and 1mg/ml, respectively. (c) aPTT of 
PEG(1.8)-PM4.0-TBA(7.0) (4 mg/ml), PEG(1.8)-PM4.0-TBA(7.0) (1 mg/ml), 
PM3.5 (4 mg/ml). Data represent mean ± SEM of 3 independent experiments. * p 
< 0.05, ** p < 0.01, *** p<0.001 compared to PBS control. 
# indicates that the aPTT was above the detection range when dendrimer 






































































































































































































































Figure 4.7. Effect of dendrimers (at 2 mg/ml) on collagen induced platelet 
aggregation.  Data represent mean ± SEM of 5 independent experiments. * p < 
0.05, to collagen control. 
 
4.5 Discussion 
The term “dendritic effect” is used to describe intrinsic physico-chemical and 
application property patterns exhibited by dendrons and dendrimers [188].  
Dendritic effect is closely related to several critical nanoscale design parameters 
(CNDPs), including: (a) size, (b) shape, (c) surface chemistry, (d) 
flexibility/rigidity, (e) architecture and (f) elemental composition.  This chapter 
mainly focused on surface chemistry dependent toxic effect of dendrimer on 
blood components [188].  Cationic PAMAM dendrimers demonstrated DIC-like 
hemotoxicity in vivo, and such hemotoxic effects would hamper the potential of 
cationic PAMAM based nanopharmaceuticals to be further translated into clinical 
applications.  While modifying PAMAM dendrimer into one bearing an anionic 






































































































well as others previously reported [186, 189],  the cationic charge plays an 
important role in the electrostatic complexation with nucleic acid materials and 
drug molecules.  As such, it is the intentions of our current study to surface 
modify the cationic PAMAM dendrimers with PEG or thiol or a combination of 
both functional groups so as to improve their hemo-compatibility.  The surface 
modified PM4.0 dendrimers in the current study displayed positive zeta potentials, 
ranging from +27 to +39 mV, which were similar to that of the unmodified PM4.0, 
and the maintenance of such cationic surface would be useful for complexation 
with the negatively charged nucleic acid materials.  The ability of the various 
modified PAMAM dendrimers to interact with blood cells and platelets as well as 
important proteins of the blood coagulation system and complement system will 
be discussed in light of the type of surface modifications in the following sections.   
4.5.1 Interactions with RBC and monocytes  
Interactions between nanopharmaceuticals and RBC could give rise to potentially 
severe acute toxicities such as haemolysis, anemia and other life-threatening 
conditions, and interactions with monocytes would give an indication to the 
immunosuppressive potential of the nanopharmaceuticals [184].  Under normal 
conditions, erythrocytes have biconcave disc shape, which can be transformed to 
echinocytes (crenated cells) or stomatocytes (cup-shaped cells) under intrinsic or 
extrinsic conditions [190] As shown in Figure 4.3, the RBCs showed irregular 
contour after incubation with dendrimers. PM3.5 induced obvious echinocytic 
transformation. In PM3.0 and PM4.0 treated samples, spheroechinocytes were 
more profound.   Although PM 3.5 did not cause obvious haemolysis, the RBCs 
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showed symptom of acanthocyte with spiked cell membrane. Similar symptoms 
were reported previously when the RBCs were treated with hyperbranched 
polyglycerol-polyethylene glycol polymers and peroxynitrite [191, 192].  The 
aggregation observed for PM4.0 treated RBCs were mainly due to the 
electrostatic interactions between positive charge of dendrimers and the 
negatively charged glycolipids and glycoproteins of RBC membranes [107].  For 
the thiolated dendrimer PM4.0-TBA(7.6) and PEG(1.8)-PM4.0-TBA(7.0), 
however, severe aggregation and clusters were formed. This might be due to the 
cross-linking of the covalent disulfide bonds among thiolated dendrimers. Such 
phenomenon raised caution to apply thiolated polymers directly into blood 
circulation as they might cause aggregation of blood component and clot.  Surface 
modification of PM4.0 with PEG alone could effectively reduce RBC lysis, and 
such results are in line with previous studies [193].  The result of dendrimer 
toxicity study on U-937 cells showed that dendrimer toxicity was concentration, 
generation and surface group dependent (Figure 4.1 and Table 4.2), agrees with 
previously reported in both mammalian and ecotoxicological studies [20, 194].  
PEGylation effectively decreased toxicity of positively charged dendrimers on U-
937 cells.  
4.5.2 Interactions with BSA 
Serum albumins are the most abundant soluble proteins in the blood circulation. 
They play crucial roles to transport various fatty acids, amino acids, hemin, 
bilirubin and drug molecules [195, 196].  It is important to evaluate the interaction 
between drug delivery vehicles and serum albumins because such interaction 
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might affect biological functions of albumin and pharmacokinetic profile of the 
nanopharmaeutical.  Some mechanisms of interactions between PAMAM 
dendrimers and serum albumins have been proposed previously. Klajanert and 
Bryszewska reported that dendrimers bind albumins mainly by electrostatic 
interaction [117], which explained the stronger binding effect of cationic 
dendrimers compared to anionic dendrimers.  As shown in Table 4.3, surface 
modified dendrimers showed fewer albumins binding effect compared to 
unmodified PM4.0. Similar observations were reported by Tajmir-Riahi et al. that 
dendrimer interaction with human serum albumin were in the order of PM4.0 > 
mPEG-PM4.0 > mPEG-PM3.0 [124]. It is also suggested that intramolecular 
hydrogen bonding between PEG and PAMAM dendrimer should result in weaker 
interaction in dendrimer/albumin complexes [124]. 
4.5.3 Interaction with the complement pathway 
The complement pathway is a host defense system which is activated when a 
foreign material comes into contact with blood. It initiates a series of biochemical 
reactions involving several peptides and enzymes, that could be potent promoters 
of inflammatory response [130], and such agents are known as anaphylatoxins 
(such as C3a, C4a and C5a).  Complement activation related pseudoallergy 
(CARPA) syndrome is a dose-limiting toxicity of certain liposomal and polymeric 
nanopharmaceuticals [197, 198].  Moreover, nanoparticle initiated complement 
activation can lead to rapid removal of the nanoparticles from systemic circulation 
by mononuclear cells via receptor-mediated phagocytosis of complement [199].  
In this study, amine-terminated PAMAM dendrimers initiated much higher level 
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of complement activation as compared to PBS control group.  Similar effect of 
positive charged PAMAM dendrimer was previously reported that PAMAM 
generation 5.0-DNA complex activated the complement system after 1h 
incubation at 37°C [200].  Thiolation alone did not offer any benefit and exhibited 
similar level of C3a activation as compared to unmodified PAMAM.  On the 
contrary, as PEGylation ratio increased, complement activation was reduced as 
compared to unmodified PM4.0.  Dual functionalization of PM4.0 improved 
complement compatibility, whereby PEG(1.8)-PM4.0-TBA(7.0), and PEG(4.0)-
PM4.0-TBA(6.7) showed equivalent level of complement activation as PM3.5 
and  PEG(4.0)-PM4.0.   
4.5.4 Interaction with coagulation pathways and platelets 
The thrombogenic potential of nanopharmaceuticals is an important criterion for 
assessment in view of the growing concern of the possibility of vascular 
thrombosis and DIC-like toxicities [184].  Assessing thrombogenicity is a 
complex process that involves multiple end-points such as platelets and 
coagulation pathways, and furthermore, careful evaluation on the hemo-
compatibility of nanomaterials is needed when they show positive reactivity even 
for one single in vitro coagulation test.  In this study, surface modification could 
help diminish the effect of dendrimer on clotting formation time.  For dual 
functionalized dendrimers, both of PEG(1.8)-PM4.0-TBA(7.0), and PEG(4.0)-
PM4.0-TBA(6.7) were tested at much higher concentrations than the unmodified 
dendrimers, and yet, PT and aPTT remained unaffected.  Thiolation has been 
employed as a strategy to reduce platelet activation of polymers and thereby 
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improving hemo-compatibility [176, 201]; however, thiolation by TBA in our 
hands is only modestly effective in reducing the toxicity of cationic PAMAM.  
This implies that the TBA functional group may not be as effective as PEG in 
providing steric hindrance or shielding the positive charge.   
4.6 Conclusion 
In this chapter, different types of PAMAM dendrimers were tested for their 
compatibility with major blood components, including cells, serum albumin, 
complements, clotting factors and platelets. The unmodified amine-terminated 
dendrimer displayed generation- and concentration-dependent toxic effects on 
blood components and functions. Modifying cationic PAMAM dendrimers via 
PEGylation and thiolation improved the compatibility with blood components, as 
reflected collectively by in vitro assays.  Such improved blood compatibility 
warrant further exploration of these surface modified PAMAM dendrimer for 
biomedical applications.  In the next chapter, these PAMAM dendrimer 
derivatives are evaluated for their potential to improve oral bioavailability of drug 




5. CHAPTER 5. EXPLORATION OF PAMAM DENDRIMER 
AND THEIR DERIVATIVES IN ORAL DRUG DELIVERY 
5.1 Introduction 
In the previous chapter, the toxic effect of dendrimer derivatives on major blood 
components is evaluated.  PEGylation and thiolation decreased the dendrimer 
toxicity to a lower extent and improved blood compatibility.  In this chapter, the 
potential use of dendrimer derivatives as intestinal penetration enhancers in oral 
drug delivery is explored.  
In oral drug delivery, a big challenge is to overcome various biological barriers so 
that drug can achieve adequate concentration in blood circulation. P-glycoprotein 
(P-gp), an important biological barrier, is a major drug efflux transporter 
expressed in intestinal epithelium as well as other tissues in human body, 
including blood-brain barrier, kidney, liver colon and stomach [202, 203].  A 
large number of drugs are P-gp substrates including calcium channel blockers 
[204], steroid hormones [205], anti-cancer drugs [206] and immunosuppressants 
[207]. Although small molecules have been developed as P-gp inhibitors, 
undesirable side effects and drug-drug interactions are major concerns that limit 
the usage of this class of P-gp inhibitors. Another potential class of P-gp 
inhibitors is polymer.  Thiomers are polymers with surface modification of thiol 
groups. Thiolated polymers are reported to exhibit inhibitory effect on P-gp efflux 
pump in many studies [179, 180, 208].  It is also reported that the combination of 
chitosan-4-thiobutylamidine (Ch-TBA) and glutathione (GSH) shows more 
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52 [209].  
Moreover, thiomers also exhibit mucoadhesive and enzyme inhibitory properties 
[210].  Therefore, thiomers as excipients to increase oral bioavailability of P-gp 
substrates is of great potential and application values. 
Another major physical barrier for oral drug delivery is tight junctions expressed 
in intestinal epithelium.  It has been reported that PAMAM dendrimer of certain 
surface groups and generations can pass through epithelial barriers in GIT, 
suggesting the possibility to apply PAMAM dendrimer as oral drug delivery 
carrier [211, 212]. The transportation of PAMAM across epithelial membrane is 
due to both paracellular and transcellular pathways [213]. El-Sayed et al. reported 
that PAMAM dendrimers from G0 to G4 with amine surface groups decreased the 
transepithelial electrical resistance (TEER) values when tested in Caco-2 cell 
monolayer. Meanwhile the permeability of mannitol, which is a known marker for 
paracellular permeation, was increased [211]. These findings suggest that cationic 
PAMAM dendrimer could modulate the tight junction and provide opportunities 
for drug molecules to cross epithelial barrier through paracellular pathway.  
However, thiolated PAMAM dendrimer has not been evaluated for its potential 
application in oral drug delivery.  Therefore, in this chapter, PAMAM dendrimer 
modified with either PEG or thiol alone or the combination of both will be 




5.2 Materials and Methods 
5.2.1 Materials 
PAMAM dendrimer generation 4 was obtained from Dendritech, Inc (Midland, 
MI, U.S.A.). Methoxy poly(ethylene glycol) succinimidyl carboxymethyl (mPEG-
SCM) (M.W. 2,000) was purchased from Laysan Bio, Inc (Arab, AL, U.S.). 
Pluronic® 85 was a gift from BASF Ltd (Singapore). Lucifer yellow was 
purchased from Invitrogen Corporation (Carlsbad, CA, U.S.). 2-Iminothiolane 
Hydrochloride (Traut’s Reagent, TBA), 5,5’-dithiobis(2-nitrobenzoic acid) 
(Ellman’s reagent), sodium borohydride (NaBH4), Rhodamine-123 (R-123), 
Rhodamine-110 (R-110) and fluorescein isothiocyanate (FITC) were obtained 
from Sigma-Aldrich Pte Ltd (Singapore). 
5.2.2 Thiol Group Stability Study at various pH conditions.  
Thiolated dendrimers were dissolved in PBS at different pH conditions (pH 7.4, 
6.5, 4.0 and 1.5) and incubated at 37°C. At 0, 1, 2, 4, and 6 h, a 100 μL sample 
was withdrawn and free thiol groups were quantified as described above. The 
results were expressed as percentages of free thiol groups compared to the sample 
at t = 0 h. 
5.2.3 Cell Culture 
The human colon adenocarcinoma cell line (Caco-2) was purchased from the 
American Type Culture Collection (Manassas, VA, USA). Madin-Darby canine 
kidney (MDCK)-multidrug resistance-1 (MDR1) cell line was a gift from Dr. Go 
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Mei Lin (National University of Singapore, Singapore). Cells were grown in T-75 
cm
2
 flasks (Iwaki, Japan) in humidified atmosphere of 5% CO2 at 37°C. Caco-2 
cell was maintained in Eagle’s minimal essential medium (EMEM) supplemented 
with 15% fetal bovine serum (FBS), 1% L-glutamine, 100 units/ml penicillin and 
100 µg/ml streptomycin. MDCK/MDR1 cell was maintained in Dulbecco's 
Modified Eagle Medium (DMEM) supplemented with 10% FBS, 100 units/ml 
penicillin and 100 µg/ml streptomycin. Upon 80-90% confluence, Caco-2 cells 
(between passage number 60-80) and MDCK-MDR1 cells (between passage 
number 10-20) were spilt using 1.0% trypsin containing 1.0 mM EDTA. Media 
were changed every 3 days. 
5.2.4 Lactose dehydrogenase (LDH) release assay 
Caco-2 cells and MDCK/MDR1 cells were seeded in 96-well plates at a density 
of 1.33 ×10
4
 cells/well for 21 days and of 1×10
5
 cells/well for 3 days, respectively, 
before experimentation. Triton-X (0.2%) was used to induce maximum LDH 
release. Cells with media only were used as the negative control. Cells were 
exposed to various dendrimers and incubated at 37°C for 24, 48 or 72 h after 
which the culture media was collected for LDH detection using Cytotox-One 
Homogenous Membrane Integrity Assay Kit (Promega Corporation, Winsicon, 
USA) following the manufacturer’s instructions.  LDH released into the culture 
medium was measured with an enzymatic assay that results in the conversion of 
resazurin into a fluorescent resorufin product, and the amount of fluorescence 
produced is proportional to the number of lysed cells.  Fluorescence was 
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measured using the Tecan SpectraFluorPlus reader (λex/λem: 560/590 nm). 
Cytotoxicity was calculated as follows: 
                         
                     
                      
      
where Ftreated, Funtreated, and Ftriton-X represent the fluorescence reading from cells 
treated with the polymer sample, the vehicle control, and 0.2% triton-X, 
respectively. 
5.2.5 R-123 and R-110 Accumulation Study in Caco-2 and MDCK/MDR1 
Cells 
Caco-2 cells were seeded in 24-well culture slides at a density of 8×10
4
 cells/well 
and incubated for 21 days before experimentation. MDCK/MDR1 cells were 
seeded in 24-well culture slides at a density of 2.5×10
5
 cells/well and incubated 
for 3 days before experimentation. Cells were exposed to 2 mg/ml of dendrimers, 
Pluronic P85 (P85), or HBSS buffer mixed either with 5 µM R-123 or 5 µM R-
110. After incubation for 90 min at 37°C, cells were washed three times with PBS 
and lysed with 1% Triton-X to release intracellular R-123 or R-110. After 
centrifuge at 13,000 rpm for 5 min to remove cell debris, fluorescence intensity of 
R-123 (λex/λem: 485/530 nm) or R110 (λex/λem: 496/520 nm) in cell lysates was 
measured using Tecan SpectraFluorPlus reader. The amount of R-123 or R-110 
accumulated was normalized to the protein content of the cells determined by the 




5.2.6 R-123 Permeability Study in Caco-2 and MDCK/MDR1 Cell 
Monolayers 
As shown in Figure 5.1, Caco-2 cells were seeded at a density of 1.2 ×10
4
 
cells/well on a 24-well collagen coated polycarbonate filter membrane transwell 
inserts obtained from BD Biocoat (Erembodegem, Belgium, UK) and incubated at 
37°C for 21 days. MDCK/MDR1 cells were seeded at a density of 5×10
4
 
cells/well on the 24-well transwell inserts for 3 days. The volumes of media were 
0.2 ml and 0.5 ml on the apical and basolateral compartments, respectively. Donor 
solutions, composed of either 2 mg/ml synthesized dendrimers or 0.1 mg/ml P85 
mixed with 5 µM R-123 dissolved in HBSS buffer, were added to either apical or 
basolateral chamber. In parallel, HBSS buffer with R-123 was investigated as 
control. The transwells were then incubated at 37°C. The permeability of R-123 
was determined by sampling the receiving chamber at regular time intervals 
(every 20 min) for 3 h. The sampled volumes were replaced with fresh HBSS 
buffer in order to maintain sink conditions. All the collected samples were 
quantified using Tecan fluorescent plate reader at λex/λem of 485/530 nm. The 
apparent permeability coefficient (Papp, cm/s) was calculated according to the 
following equation: 





    
 
where dQ/dt is the steady-state flux, A is the surface area of the filter (0.3 cm
2
) 




Figure 5.1 Diagram of a Caco-2 monolayer grown on a permeable filter [214] 
 
5.2.7 Tight junction staining with anti-ZO-1 antibody 
Caco-2 cells were seeded in 4-well Lab-tek chamber glass slides from Nalge 
Nunc Inc (Naperville, IL) at a density of 7.2 ×10
4
 cells/well and cultured for 21 
days before experiment. Cells were exposed to either PAMAM dendrimer 
samples, HBSS (vehicle control) or 0.05% Triton-X for 24 h at 37°C. After 
incubation, cells were washed three times with ice-cold PBS, and fixed with ice-
cold methanol for 10 min. Subsequently, cells were rinsed with ice-cold PBS and 
blocked with 1% BSA for 30 min. Cells were then incubated with 2 µg/ml 
primary antibody (purified mouse anti-human ZO-1, BD Transduction 
Laboratories, San Jose, CA) for 1 h. The cells were washed three times with PBS 
and incubated with 4 µg/ml secondary antibody (Alexa Fluor® 568 Goat Anti-
Mouse IgG) for 1 h. Finally, cells were washed three times with PBS and viewed 
under a Carl Zeiss fluorescence confocal microscope using 40× objective (Carl 
Zeiss, Jena, Germany).  During the acquisition of the images, the following 
settings were used: scan mode, stack; scaling of 0.22 µm × 0.22 µm × 0.95 µm; 
pixel time of 1.26 µs; wavelength of 543 nm at 30%; filters of BP 565-615 IR; 
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Pinhole of Cha 152 µm; Beam Splitters of MBS: HFT 488/543, DBS1, Mirror, 
DBS2, NFT 545, NDD MBS, none.  The experiments were repeated twice, each 
time with a minimum of three views of the same sample was captured.   
5.2.8 Transepithelial Electrical Resistance (TEER) Measurement in Caco-2 
Cells 
Caco-2 cells were seeded on 24-well, collagen-coated polycarbonate filter 
membrane transwell inserts. On day 21, the baseline TEER values were measured 
using Millicell ERS-2 Epithelial Volt-Ohm Meter to record cell monolayer 
integrity. Only inserts with values >600 Ωcm2, which indicated good monolayer 
integrity, were subjected to experimentation. Media in both sides of the chambers 
were aspirated, and the chamber was washed twice with HBSS buffer. The Caco-
2 cells in the inserts were exposed to either 2 mg/ml dendrimer samples or HBSS 
buffer for 24 h at 37°C. After taking TEER measurement, fresh media was added 
after washing cells twice with HBSS buffer. Further TEER measurements were 
recorded every 24 h for 120 h. Percentage change in TEER was calculated as 
follows: 
         
                       
                       
 
                          
                          
      
where Rtest,t, Rbackground,t, Rvehicle,t represent the TEER readings from the polymer 
sample treated wells, the no-cell control wells, and the vehicle control wells at 
time t, respectively.  (Rtest,t – Rbackground,t)/(Rtest,0 – Rbackground,0) and (Rvehicle,t – 
Rbackground,t)/(Rvehicle,0 – Rbackground,0) represents percentage change of TEER reading 
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at time t compared to time 0 of Caco-2 monolayer treated with test sample or 
HBSS, respectively.  
5.2.9 Transport of Lucifer Yellow (LY) across Caco-2 monolayer 
Similar to the conditions for TEER measurement, Caco-2 cells were grown in the 
transwell inserts for 21 days before experimentation. The cells were treated with 
HBSS buffer, 2 mg/ml dendrimers or Triton-X mixed with 60 µM LY dissolved 
in HBSS. After incubation for 2, 4 and 24 h, 200 µl of HBSS was sampled from 
the basolateral chamber and same volume of fresh HBSS was added to maintain 
sink condition. The HBSS samples were subsequently measured for LY 
fluorescence using SpectraFluorPlus reader at λex/λem of 430/540 nm.  LY 
represents a model compound that is not able to cross the normal, untreated Caco-
2 monolayer, and the percentage of LY transported to the basolateral side was 
calculated as follows: 
                   
  
        
      
where Ft, Finitial represent the cumulative fluorescence signal of LY at time t in the 
basolateral side and the fluorescence signal of LY initially added to apical side, 
respectively.  
5.2.10 Permeability of FITC-labeled dual-functionalized PAMAM 
dendrimer 
The PEG-PM dendrimer was conjugated with FITC according to a protocol 
reported in the literature [215]. Briefly, PEG-PM polymer was dissolved into 
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DMSO. FITC in DMSO solution (5 mg/ml) was added dropwise to the dendrimer 
solution at a molar ratio of 1:3 under stirring at room temperature. The mixture 
was stirred in dark for 24 h. The reaction mixture was dialyzed against Milli-Q 
water three times for 24 h followed by lyophilization. The lyophilized product 
was then conjugated with TBA as described above. Similar to the conditions for 
TEER measurement, Caco-2 cells were grown in the transwell inserts for 21 days 
before experimentation. The cells were treated with 2 mg/ml FITC-labeled dual-
functionalized dendrimers in HBSS with or without 2.4% Triton-X. At 2, 4 and 24 
h, 200 µl of HBSS was sampled from the basolateral compartment and same 
volume of fresh HBSS was added for replenishment.  Samples were then 
measured for FITC fluorescence SpectraFluorPlus reader at λex/λem of 492/518 nm. 
At 24 h, supernatant samples in the transwell inserts were collected, and the 
transwell inserts were washed three times with HBSS, with the washings pooled 
with the supernatant samples.  Cells were subsequently harvested from the 
transwell inserts and lysed with Triton-X for FITC fluorescence determination 
using SpectraFluorPlus reader at λex/λem of 492/518 nm.  Percentage of FITC-
labeled dual-functionalized dendrimers transported to the basolateral side was 
calculated as follows: 
                          
  
        
      
where Ft, Finitial represent the cumulative fluorescence signal of FITC labelled 
dendrimers at time t in basolateral side and the FITC labelled dendrimer initially 
added to apical side, respectively.  
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Percentage of FITC-labeled dual-functionalized dendrimers accumulated 
intracellularly was calculated as follows: 
                            
   
        
      
where F24  represent the fluorescence signal of FITC labelled dendrimer samples 
accumulated in cells at 24 h. 
5.2.11 Pharmacokinetic study of ganciclovir in mice 
All animal studies were completed using protocols approved by the Institutional 
Animal Care and Use Committee (IACUC) of National University of Singapore.  
BALB/C mice were divided into two groups.  The mice had no access to food 12 
h prior to the experiment.  Drug samples were freshly prepared before the 
experiment.  Ganciclovir (GCV) and PAMAM were dissolved in saline at 1 
mg/ml and 4 mg/ml, respectively.  Then GCV and PAMAM solution were mixed 
at 1:1 ratio for administration.  Control group was orally administered with GCV 
free drug (0.5 mg/ml in saline) at dose of 10 mg/kg.  The other group was 
administered with a mixture of GCV (0.5 mg/ml in saline, 10 mg/kg) and 
PEG(1.8)-PM-TBA(7.0) (2 mg/ml in saline, 40 mg/kg) (GCV/ PEG(1.8)-PM-
TBA(7.0)).  At each time points (10 min,30 min, 2 h, 4 h, 6 h and 24 h), the mice 
were euthanized with CO2 gas.  Blood were collected from animals by heart 
puncture.  Subsequently, the blood samples were centrifuged at 13,000 rpm at 4°C 
for 15 min.  The plasma samples were collected and kept at – 80°C until analysis 
by LC-MS/MS described below.   
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5.2.12 LC-MS/MS analysis of GCV 
200 µl plasma samples were mixed with 10 µl internal standard (acyclovir, 10 
µg/ml) and 600 µl methanol for protein precipitation.  After vortex mixing for 30 
s, the mixture was centrifuged at 13,000 rpm at 4°C for 15 min.  600 µl of 
supernatant was collected after centrifuge and the solvent was evaporated with 
Savant SpeedVac SC100 Centrifugal Evaporator (Savant Instruments, Inc., NY, 
USA).  Subsequently, the sample was reconstituted with 150 µl mobile phase.  
The liquid chromatography separation was carried out on Agilent 1290 Infinity 
LC System (Agilent, USA).  Sample was separated on an Acquity UPLC HSS T3 
Column (1.8 µm, 2.1 × 150 mm, Waters, MA, USA).  The mobile phase consisted 
of ACN (2%) and 10 mM Ammonium Formate in water (pH 3, 98%).  The flow 
rate was set at 0.2 ml/min.  The injection volume was 10 µl and run time was 10 
min.   
Mass spectrometric measurements were performed on Agilent 6430 Triple Quad 
LC/MS system with an electrospray ionization (ESI) source operating in positive 
ion mode.  The instrument was operated with the following parameters: gas 
temperature of 350°C, gas flow of 10 l/min, nebulizer of 25 psi, capillary of 
+6000 V, Dwell of 0.2 s, fragmentor of 70 V (GCV) and 80 V (ACV), Collision 
Energy of 7 eV (GCV) and 8 eV (ACV).  The detection ions were set as m/z 
256.2 → 152.5 for ganciclovir and m/z 226.4 → 152.5 for acyclovir (ACV).  The 
chromatogram data was analyzed with Agilent MassHunter Workstation 
Quantitative Anlysis Software (version B.03.02).  The analysis method was linear 
in the range of 31.25 -1000 ng/ml. 
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5.2.13 Statistical analysis 
Where appropriate, results were expressed as mean ± SEM of at least three 
independent experiments. Statistical significance was determined using the 
Student t-test or one-way analysis of variance (ANOVA) Kruskal-Wallis test 
followed by Dunn’s test used for post-hoc multiple comparisons. P values of < 
0.05 were considered to be statistically significant. Statistical analyses were 
carried out using SPSS software (v 19.0; IBM, Armonk, NY). 
5.3 Results 
5.3.1 Thiol Group Stability Study at various pH conditions 
Stability of the free thiol groups on the PAMAM dendrimers was evaluated under 
different pH conditions similar to those found in GI tract [216], which could 
affect the oxidation of free thiol groups (Figure 5.2). It appears that PEGylation of 
the thiol-dendrimers helped protect the thiol groups from oxidation when the 
dendrimers were subjected to low pH value (pH 1.5).  For PEG(4.0)-PM-
TBA(6.7), >80% of free thiol groups were retained at all the tested pH values. 
PEG(1.8)-PM-TBA(7.0) retained >79% of free thiol groups at pH 6.5, 4 and 1.5 
after 6 h, while 64% of free thiol groups remained at pH 7.4.  For PM-TBA(7.6), 





Figure 5.2. Effect of pH on the oxidation of free thiol groups of (a) PEG(1.8)-PM-
TBA(7.0), (b) PEG(4.0)-PM-TBA(6.7), (c) PM-TBA(7.6) at pH 1.5 (▼), 4.0 (▲), 
6.5 (), and 7.4 (●). (d) Free thiol groups% of PEG(1.8)-PM-TBA(7.0), 
PEG(4.0)-PM-TBA(6.7) and PM-TBA(7.6) after 6h incubation at pH 1.5, 4.0, 6.5 
and 7.4. Data represent mean ± SEM of 4 independent experiments. * p < 0.05, 
** p < 0.01, compared to free thiol groups% at time 0 h. 
 
5.3.2 Cytotoxicity of functionalized PAMAM dendrimers 
The cytotoxicity of the functionalized PAMAM dendrimers was determined by 
the LDH release assay in Caco-2 and MDCK/MDR1 cells tested with various 
concentrations of the dendrimers for 24 h (Figure 5.3 top panels). In general, the 
higher the dendrimer concentration, the higher was the observed cytotoxicity.  
Secondly, surface-modified PAMAM dendrimers were less cytotoxic as 
compared to unmodified PAMAM G4, with the dual-functionalized dendrimers, 

























































































































































































PEG(1.8)-PM-TBA(7.0) and PEG(4.0)-PM-TBA(6.7), showing the least 
cytotoxicity in both cell lines, with <20% LDH release at a concentration of 4 
mg/ml after 24 h exposure.  Further studies with longer exposure time of 48 and 
72 h were conducted, and the results are shown in Figure 5.3 lower panels.  
Consistent with 24 h exposure data, the dual-functionalized dendrimers showed 
significantly less cytotoxicity in both cell lines after 48 and 72 h of exposure.   
 
Figure 5.3. LDH released from (A) Caco-2 and (B) MDCK/MDR1 cell 
monolayers treated with PM G4.0, PEG(1.8)-PM, PEG(4.0)-PM, PEG(1.8)-PM-
TBA(7.0), PEG(4.0)-PM-TBA(6.7), PM-TBA(7.6) for 24 h at various 


















































































































































































































































































































































































































































A. Caco-2 B. MDCK/MDR1
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bar) and 72 h (lower panels, solid bars) were also tested with dendrimer 
concentrations of 2 mg/ml.  Data are expressed as mean ± SEM of 3 independent 
experiments. *p<0.05, **p< 0.01, ***p<0.001 compared to PM G4. 
 
5.3.3 Modulation of P-gp efflux by the dual-functionalized PAMAM 
dendrimers 
In order to further explore whether the surface-modified dendrimers could 
specifically modulate P-gp function, cellular accumulation and epithelial 
permeability of the P-gp substrate R-123 was studied with results summarized in 
Figure 5.4.  Cellular accumulation of R-123 and the non-P-gp substrate R-110 
was studied in the presence and absence of the various PAMAM dendrimers. 
Pluronic P85, a well-accepted polymeric P-gp inhibitor [217, 218], was included 
for comparison. Figure 5.4 (A), (B) show that R-123/R-110 accumulation ratio 
was significantly increased when both cell lines were treated with PEG(1.8)-PM-
TBA(7.0) and PM-TBA(7.6).  In particular, the fold increase in R-123/R-110 
accumulation ratio for PEG(1.8)-PM-TBA(7.0) and PM-TBA(7.6) in 
MDCK/MDR1 cells was higher than P85.  As for PEG(4.0)-PM-TBA(6.7), the 
fold increase in R-123/R-110 accumulation ratio was not as high as the cells 




Figure 5.4. Modulation of P-gp efflux by dual-functionalized PAMAM 
dendrimers.  R-123/R-110 cellular accumulation was studied in (A) Caco-2 and 
(B) MDCK/MDR1 cells. Cells were treated with 2 mg/ml of 1) vehicle control, 2) 
PM G4.0, 3) PEG(1.8)-PM, 4) PEG(4.0)-PM, 5) PEG(1.8)-PM-TBA(7.0), 6) 
PEG(4.0)-PM-TBA(6.7), 7) PM-TBA(7.6), and 8) P85.  (C) Epithelial 
permeability of R-123 was studied in Caco-2 and MDCK/MDR1 monolayers, 
whereby the efflux ratio represents the ratio of the secretory apparent permeability 
coefficient (Papp BL-AP) to the absorptive apparent permeability coefficient (Papp AP-
BL).  (D) Expression of P-gp in Caco-2 and MDCK/MDR1 cells, with a 
representative western blot shown out of three independent studies.  Data 
represent mean ± SEM of 3 independent experiments, with *p<0.05, **p<0.01, 















































































































































































































































































































































































































































































































Based on the results from cytotoxicity study and cellular accumulation study, 
PEG(1.8)-PM-TBA(7.0) and PEG(4.0)-PM-TBA(6.7) are selected for further 
evaluation of absorptive (apical to basolateral, AP-BL) and secretory (basolateral 
to apical, BL-AP) transport of R-123 across Caco-2 and MDCK/MDR1 cell 
monolayer. The absorptive and secretory apparent permeability coefficients (Papp) 
and efflux ratio of R-123 across Caco-2 and MDCK/MDR1 cell monolayers are 
shown in Table 5.1 and Figure 5.4 (C), respectively.  Of the two dual-
functionalized PAMAM dendrimers, PEG(1.8)-PM-TBA(7.0) was more effective 
in achieving an efflux ratio of close to 1, which was mainly due to its ability to 
increase the absorptive transport of R-123.  Furthermore, the ability of PEG(1.8)-
PM-TBA(7.0) to modulate epithelial permeability of R-123 was comparable to 
P85 in Caco-2 cells.  Of note, the difference in P-gp expression in the two cell 
lines (Figure 5.3 (D)) may account for the difference in the ability of PEG(1.8)-













































































































































































































































































































































































































































































































































5.3.4 Tight junction disruption of Caco-2 cell monolayer after exposure to 
dendrimer derivatives 
Tight junction disruption in the intestinal epithelium will open up paracellular 
route for drug transport. Therefore, ZO-1 staining, LY permeation and TEER 
measurement were conducted to examine tight junction integrity of Caco-2 cell 
monolayer after treatment with dendrimer derivatives. ZO-1 is a major protein 
expressed in the cytoplasmic plaque of the tight junction [219] and represents a 
marker of tight junction formation. After incubating Caco-2 cell monolayer with 
2mg/ml of PM G4, PEG(1.8)-PM, PEG(4.0)-PM, PEG(1.8)-PM-TBA(7.0), 
PEG(4.0)-PM-TBA(6.7), PM-TBA(7.6) for 24 h, the immunofluorescence of ZO-
1 was visualized with confocal microscopy. As seen in Figure 5.5, cells treated 
with vehicle control showed strong, uniform and integral distribution of ZO-1. In 
comparison, the Triton-X treated, positive control cells showed disrupted and 
abnormal localization of ZO-1.  Of the six dendrimers evaluated, PM G4 showed 
a decreased and disrupted distribution of ZO-1. For PEG(1.8)-PM and PEG(4.0)-
PM, the ZO-1 modulating effect was much less as compared to PM G4. After 
thiolation, PEG(1.8)-PM-TBA(7.0), PEG(4.0)-PM-TBA(6.7) and PM-TBA(7.6) 
showed stronger ZO-1 modulating effect as compared to PEGylated PAMAM 




Figure 5.5. Tight junction modulating effect of dual-functionalized PAMAM 
dendrimers observed by ZO-1 staining under fluorescence confocal microscope. 
The experiments were repeated twice, each time with a minimum of three views 



















In addition to ZO-1 immunofluorescence, LY which is a well-known, non-
radioactive molecule impermeable to the normal, untreated epithelial monolayer 
for the purpose of probing monolayer integrity[220, 221] was used to evaluate the 
effect of the dendrimers on the tight junction integrity of Caco-2 monolayers. As 
seen in Figure 5.6, minimum amount of LY was detected in the basolateral side 
after 2 and 4 h of incubation with various dendrimers.  After 24 h, the effect of 
dendrimers in promoting LY permeation was more apparent, whereby PEG(1.8)-
PM, PEG(4.0)-PM, PEG(4.0)-PM-TBA(6.7) and PM-TBA(7.6) significantly 
increased LY permeation. PM G4 and PEG(1.8)-PM-TBA(7.0) also increased LY 
permeation by 2.0-fold and 1.9-fold as compared to control, although the increase 
was not statistically significant.   
 
Figure 5.6. Permeation of LY across Caco-2 monolayer after treatment with 2 
mg/ml of various dendrimers or 0.2% Triton-X. Data represent mean ± SEM of 3 













































While results in Figure 5.5 and Figure 5.6 demonstrated the ability of the 
functionalized dendrimers to modulate tight junction transport, it is important to 
determine if such effect is reversible, as irreversible effect would represent 
potential toxicity to the intestinal epithelium and the material might not be 
suitable for oral drug delivery. Thus, time-course TEER measurement was 
performed to determine the reversibility of the tight junction modulating effect by 
the dendrimer samples. The Caco-2 monolayer was treated with the dendrimer 
samples for 24 h, after which the dendrimers were removed and fresh medium 
was added.  As shown in Figure 5.7, after 24 h treatment, the TEER values 
decreased >50% in all dendrimer-treated Caco-2 monolayers.  Of significance, 
only PEG(1.8)-PM-TBA(7.0) and PEG(4.0)-PM-TBA(6.7) treated Caco-2 
monolayers showed gradual increase of TEER values over time to ~100% of 
control.  All other dendrimer and Triton-X treated Caco-2 monolayers showed 
irreversible decrease of TEER values, suggesting irreversible disruption of tight 




Figure 5.7. Change in TEER upon treatment with dendrimers and Triton-X. The 
Caco-2 cell monolayer was exposed to dendrimer treatment during first 24 h and 
subsequent replacement with fresh medium. Data represent mean ± SEM of 3 
independent experiments. p<0.05, **p<0.01, ***p<0.001compared to Triton-X 
treated group. 
 
5.3.5 Permeability of FITC-labeled dual-functionalized dendrimers 
Since PAMAM is a non-biodegradable polymer, it is important to determine how 
much of the dual-functionalized dendrimers could pass through the intestinal 
epithelium.  Based on the biological data thus far, PEG(1.8)-PM-TBA(7.0) and 
PEG(4.0)-PM-TBA(6.7) showed low cytotoxicity to the epithelial cells yet 
showing P-gp and tight junction modulating effect.  As such, these two 




































































probe their transport through the Caco-2 monolayer.  As shown in Figure 5.8, 
minimum amount of PEG(1.8)-PM-TBA(7.0) and PEG(4.0)-PM-TBA(6.7) was 
transported through Caco-2 monolayer after 2 and 4 h of incubation. After 24 h, 
5.8% of PEG(1.8)-PM-TBA(7.0) and 17.7% of PEG(4.0)-PM-TBA(6.7) passed 
through Caco-2 monolayer.  Addition of Triton-X increased the amount of 
dendrimers in the basolateral side, indicating that the low permeability of the two 
dendrimers was not due to a defect of the Caco-2 monolayer.  In addition to 
basolateral side, the distribution of the FITC-labeled dendrimers was determined 
for the apical side and within the Caco-2 cellular compartment (Table 5.2).  Less 
than 5% of PEG(1.8)-PM-TBA(7.0) and PEG(4.0)-PM-TBA(6.7) were 
accumulated in Caco-2 cells.  Collectively, the results suggest potentially minimal 
absorption of PEG(1.8)-PM-TBA(7.0) into systemic circulation.   

































Figure 5.8. Transport of FITC-labeled PEG(1.8)-PM-TBA(7.0) , PEG(4.0)-PM-
TBA(6.7) with and without Triton-X through Caco-2 monolayer. Data represent 












PEG(1.8)-PM-TBA(7.0) 90.43 ± 1.59% 5.83 ± 0.44% 3.75 ± 1.51% 
PEG(1.8)-PM-TBA(7.0) + Triton-
X added at start of incubation 
61.14 ± 1.31% 31.38 ± 1.59% 7.48 ± 0.55% 
PEG(4.0)-PM-TBA(6.7) 79.68 ± 1.35% 17.69 ± 1.75% 2.63 ± 0.63% 
PEG(4.0)-PM-TBA(6.7) + Triton-
X added at start of incubation 
49.86 ± 2.91% 43.83 ± 3.58% 6.30 ± 1.06% 
 
5.3.6 Pharmacokinetic study of ganciclovir in mice 
Plasma pharmacokinetics of GCV free drug and GCV/ PEG(1.8)-PM-TBA(7.0) 
mixture were conducted in BALB/C mice.  The concentration of GCV in plasma 
samples were determined using LC-MS/MS based method. Figure 5.9 shows 
representative chromatograms of GCV from extracted plasma samples.  ACV was 
used as the internal standard.  The retention time for GCV and ACV were 5.7 min 
and 7.5 min, respectively.  No endogenous interferences co-eluting with GCV or 
ACV were observed in blank mice plasma as shown in Figure 5.9. Method 
validation was perfomed by analyzing inter-day precision, bias range, analytical 
recovery and absolute recovery of the lowest limit of quantification (LLOQ), 
three quality control (QC) samples against a calibration curve of 9 concentrations. 
The calibration curve was linear in the range 32.25-1000 ng/ml. The bias range 
for LLOQ and QC samples were < 20% and 15%, respectively (Table 5.3). The 





Figure 5.10. Chromatogram of (A) blank plasma extract, (B) GCV alone in 
plasma sample (C) ACV alone in plasma sample and (D) GCV and ACV in 
































32.25 29.9 ± 1.6 -18.5 ~ 15.5 13.8 92.1 ± 4.8 87.7 ± 4.6 
62.5 59.3 ± 1.8 -9.7 ~ 6.5 8.5 94.9 ± 2.9 96.8 ± 2.9 
400 406.9 ±8.5 -6.2 ~ 10.1 5.9 101.7 ± 2.1 103.0 ± 2.3 
800 826.0 ±14.7 -2.4 ~ 11.5 5.0 103.2 ± 1.8 101.7 ± 1.8 
 
The plasma GCV concentration-time profiles after oral administration are shown 
in Figure 5.10.  GCV drug concentration quickly reached peaks value within 1 h 
and decreased rapidly afterwards.  Analysis of the concentration-time profiles to 
derive various pharmacokinetic parameters was performed with WinNonlin 5.0.1 
(Pharsight Corporation, CA, USA) by using the non-compartmental analysis.  The 
pharmacokinetic parameters are listed in Table5.3.  At 30 min time point (tmax), 
the Cmax for GCV/ PEG(1.8)-PM-TBA(7.0) group (Cmax = 1004.1 ng/ml) is 56.8% 
higher than the Cmax of GCV group (Cmax = 640.2 ng/ml) (p < 0.05).  Area under 
the plasma concentration time curve (AUClast) for GCV/ PEG(1.8)-PM-TBA(7.0) 
treated group is increased by 17.2% compared to GCV group, indicating 




Figure 5.10. Plasma concentration-time curves of GCV after oral administration 
to mice at dose of 10 mg/kg. Data represent mean ± SEM of 4 independent 
experiments. * p < 0.05  



































Table 5.4 Plasma pharmacokinetic parameters of GCV after oral administration at 
dose of 10 mg/kg 











tmax (min) 30 30 
Cmax (ng/ml) 640.2 1004.1 
t1/2 (min) 142.4 100.9 














Relative increase in 
bioavailability 
-- 17.2% 
*Non-compartmental analysis was used to estimate the various pharmacokinetic 
parameters.  In the calculations, first order elimination was assumed, and uniform 
weighting was used.  Calculation and interpolation formulas are listed below: 
              
     
    
  




              
           
   
  
   
          
     
    
  





               
     
  
 
       
       
      
 
     
      
  
 
   
 
 
    
         
 
            
 
 
    





PAMAM dendrimers are originally developed by Tomalia in 1979[222, 223].  
Owing to their open internal structures and cavities for forming drug complexes, 
PAMAM dendrimers have been the most extensively studied among the class of 
hyperbranched polymers for oral delivery purposes[224].  Previous studies have 
shown that PAMAM dendrimers could modulate tight junction integrity, as well 
as increase AUC of drugs via the formation of a drug-dendrimer complex[49, 50, 
57, 58].  PAMAM dendrimers could exhibit different surface terminal groups, 
including amine-terminated, carboxyl-terminated and hydroxyl-terminated, with 
the amine-terminated PAMAM dendrimers showing the highest tight junction 
modulating effect[225].  However, these amine-terminated PAMAM dendrimers 
were relatively more toxic as compared to other terminal groups.  Based on such 
prior findings, the aim of our current work is to surface modify amine-terminated 
PAMAM dendrimers with the combination of PEGylation and thiolation so as to 
decrease their toxicities and yet improve their abilities in overcoming the barriers 
of oral drug delivery, namely, P-gp drug efflux and tight junction.  To our 
knowledge, combination of PEGylation and thiolation to surface modify PAMAM 
dendrimers is a strategy that has not been reported before.  The effect of such 
surface modifications of PAMAM dendrimers will be discussed in view of 
PAMAM cytotoxicity, cellular accumulation and permeability across the 
intestinal epithelium.   
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5.4.1 Thiol Group Stability Study at various pH conditions 
In oral delivery, one of the major challenges is the dramatic change of pH in GI 
tract. Drug and delivery excipients will experience highly acidic environment in 
the stomach (pH 1-4) followed by rapid increase to pH 6 in the duodenum. Then 
the pH will gradually increase in the small intestine from 6 to about 7.4 in the 
terminal ileum. Since the free thiol groups may be prone to oxidation and reduce 
the expected P-gp inhibitory effect, it is important to assess the stability of thiol 
groups under different pH conditions. When we subjected the dual-functionalized 
PAMAM dendrimers to different pHs using PBS buffered at pH 1.5, 4.0, 6.5 and 
7.4, we observed the trend that the PEG might prevent oxidation of the thiol 
groups, especially when the pH was low (1.5 and 4.0).  This might be attributed to 
the ability of the PEG chains on PAMAM surface to provide steric hindrance to 
reduce the interaction between the free thiol groups, when the dendrimers are 
dispersed in the aqueous PBS.  
5.4.2 Cytotoxicity of functionalized PAMAM dendrimers 
Establishing the cytotoxicity profiles of the dual-functionalized PAMAM 
dendrimers was the first question addressed in our study.  The toxicity of 
PAMAM G4 has been attributed mainly to the interaction between the positively 
charged amine groups of PAMAM and the negatively charged cell membrane[50, 
186].  As such, functionalizing the surface amines with small molecules or PEG 
chains has been attempted previously, whereby the toxicity of the PAMAM 
dendrimers was reduced by a masking effect of the amine terminals[224].  In this 
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study, increasing the number of PEG chains on the PEGylated PAMAM 
dendrimers (PEG(1.8)-PM and PEG(4.0)-PM) showed an improvement in 
PAMAM toxicity profile in Caco-2 and MDCK/MDR1 cells, which is an 
observation in line with those reported by Jevprasesphant et al. that four PEG 
chains could remarkably decrease the cytotoxicity of PAMAM[226].  In 
comparison, functionalizing the PAMAM dendrimers with TBA alone gave 
mixed results, whereby PAMAM toxicity was reduced in MDCK/MDR1 cells but 
not in Caco-2 cells.  In line with the effect of masking the surface amines of 
PAMAM, dual functionalization of PAMAM with PEG and TBA showed the 
largest reduction in PAMAM cytotoxicity, as demonstrated in Figure 5.3.  
Although the dual-functionalized PAMAM dendrimers have significantly lower 
cytotoxicity, their ability to cross the intestinal epithelium, which suggests their 
potential to be systemically absorbed, could still pose safety concern since 
PAMAM is a non-biodegradable polymer.  Minimal transport of the dual-
functionalized dendrimers through the Caco-2 cell monolayer would be desirable.  
Results in Table 5.2 showed that the dual-functionalized dendrimers generally 
exhibited low transepithelial transport and cellular accumulation, suggesting low 
systemic toxicity potential for the dual-functionalized dendrimers as modulators 
of oral drug delivery.  
5.4.3 Modulation of P-gp efflux by the dual-functionalized PAMAM 
dendrimers 
The next question that we addressed in our study was the ability of dual-
functionalized PAMAM dendrimers to overcome the two major barriers to oral 
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drug delivery, namely, P-gp efflux and tight junction.  Previously, thiolation of 
linear polymers such as polyethyleneimine (PEI)[208], chitosan[179] and 
poly(acrylic acid) (PAA)[227] has imparted these polymers with enhanced 
inhibitory effect of P-gp efflux.  Thus, thiolation of PAMAM dendrimers might 
present an approach that could be useful in improving the P-gp inhibitory effect of 
PAMAM.  Indeed, from our results, the ability of thiolated PAMAM dendrimers 
to enhance cellular accumulation of the P-gp substrate R-123 was significantly 
increased as compared to unmodified PAMAM.  PEGylation alone did not impart 
significant improvement in the ability of PAMAM to promote R-123 
accumulation.  Of note, when more PEG chains were functionalized onto the 
thiolated PAMAM dendrimers, R-123 accumulation and permeation was 
apparently reduced as we compared the P-gp inhibitory effect of PEG(1.8)-PM-
TBA(7.0) and PEG(4.0)-PM-TBA(6.7).  Such observation is in line with the steric 
hindrance effect of PEG chains that may interfere with the formation of covalent 
disulfide bonds between the thiolated dendrimers with the cysteine residues on P-
gp[227].   
5.4.4 Tight junction disruption of Caco-2 cell monolayer after exposure to 
dendrimer derivatives 
In terms of tight junction modulating effect, assessment was made based on ZO-1 
immunostaining, LY permeation and TEER measurement.  Previously, 
unmodified PM G4.0 has been reported to be able to disrupt the tight junction 
proteins of Caco-2 monolayer [49].  In this study, surface modification with either 
PEG or TBA alone or with dual functionalization could improve the ability of PM 
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G4.0 to increase LY permeation after 24 h of exposure.  This observation is in 
agreement with the studies by Jevprasesphant et al. [228] and Kolhatkar et al. 
[159] that surface modification with lauroyl groups and acetyl groups, 
respectively, could increase the permeation of mannitol in comparison to 
unmodified dendrimers.  This increase in mannitol permeation has been suggested 
to be a result of the combined effect of paracellular and transepithelial permeation 
pathways [224].  The collective data from Figures 5.5 – 5.8 and Table 5.2 seem to 
suggest that the paracellular pathway might be the dominant pathway by which 
the dual-functionalized dendrimers have acted, as cellular accumulation and 
basolateral transport of the dual-functionalized dendrimers was low.  While tight 
junction disruption was observed in the surface modified PAMAM dendrimers, 
such effect was irreversible for PAMAM dendrimers modified with PEG or TBA 
alone.  As intact tight junction is important to cell survival of the intestinal 
epithelium, irreversible disruption of the epithelial tight junction would be a sign 
of potential toxicity [229].  Such finding is also in agreement with our 
cytotoxicity study that dual-functionalized dendrimers showed much lower 
toxicity to Caco-2 cells as compared to other dendrimer samples. 
5.4.5 Effect of dual functionalized dendrimer on pharmacokinetic profile of 
ganciclovir 
With P-gp inhibitory and tight junction modulating effect demonstrated in vitro 
settings, PEG(1.8)-PM-TBA(7.0) was further selected to test whether this 
polymer could improve drug absorption in vivo.  Ganciclovir (GCV), an acyclic 
2’-deoxyguanosin analogue, was selected as the model drug.  GCV is indicated in 
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the treatment of primary and recurrent genital Herpes simplex virus (HSV) [230].  
Despite the excellent antiviral activity of GCV against the herpes family of 
viruses, GCV has low permeability across intestinal epithelial cells [231].  Oral 
bioavailability of GCV is only about 5% [232] since GCV is a P-gp substrate [233] 
and it has poor lipophilicity (logP = −1.65).  Meanwhile GCV is not metabolized 
in the intestine and liver by CYP enzymes [234].  Therefore, GCV is selected as a 
model drug in this study to evaluate the effect of dual functionalized dendrimer on 
bioavailability of compound with low permeability and suffered from P-gp efflux 
effect.   
The result in this study showed that the Cmax and AUClast of GCV/ PEG(1.8)-PM-
TBA(7.0) group increased by 56.8% and 17.2% compared to GCV group, 
respectively.  Such results indicates that PEG(1.8)-PM-TBA(7.0) improved the 
absorption of GCV.  Figure 5.10 showed the concentration-time curves of GCV 
after drug administration.  The result indicates that PEG(1.8)-PM-TBA(7.0) 
quickly increased drug absorption in the initial 30 min.  The improved drug 
absorption could be attributed to the P-gp inhibitory effect and tight junction 
modulation based on the positive findings from the in vitro studies.  Previously 
Shen et al. studied the effect of Labrasol (caprylocaproyl macrogol-8 glyceride) 
on the oral absorption of ganciclovir in rat [233].  The result showed that Labrasol 
at 0.1% (v/v) significantly enhanced absorption of GCV after oral administration 
to rats.  The Cmax increased from 3.05 to 5.29 µg/ml and the AUC increased by 
1.8-fold.  It is proposed by the authors that such improvement was due to 
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increased intestinal permeability by tight junction opening and P-gp inhibitory 
effect.   
5.5 Conclusion 
Based on a balance of acceptable cytotoxicity, cellular accumulation and 
permeability, the dual-functionalized PAMAM dendrimer, PEG(1.8)-PM-
TBA(7.0), seems to be the most promising as a modulator of intestinal epithelial 
barrier.  PEG(1.8)-PM-TBA(7.0) displayed low cytotoxicity in Caco-2 and 
MDCK/MDR1 cells, while significantly increased cellular accumulation and 
permeation of the P-gp substrate R-123 as well as reversibly disrupted tight 
junction integrity shown via TEER measurement over time.  This dual 
functionalized dendrimer also improved oral absorption of GCV as demonstrated 
by in vivo pharmacokinetic study.  Taken together, dual functionalization via 
PEGylation and thiolation represented a novel and promising approach in altering 
PAMAM dendrimer surface for potential application as oral delivery modulators.  
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6. CHAPTER 6. DENDRIMER-LIPID HYBRID NANOSYSTEM 
AS A NOVEL DELIVERY VEHICLE FOR PACLITAXEL 
6.1 Introduction 
In the previous chapter, potential application of surface modified dendrimers in 
oral drug delivery was explored. Besides surface conjugation, physical 
complexation is another commonly applied method to modify the 
physicochemical properties of dendrimers so as to achieve desirable features for 
applications in drug delivery [235-238].  
Since dendrimers, especially cationic ones, can interact with cellular membranes 
and alter the structure and integrity of the membranes, there are studies to further 
explore the mechanism of dendrimer and lipid membrane interaction.  Atomic 
force microscopy (AFM) studies of rat1 cell lines and MDCK cells showed that 
PAMAM G7 dendrimers caused hole formation with diameter of 15-40 nm in cell 
membranes [239-241].  Liposomes are also employed as tools to investigate the 
interaction between dendrimer and lipid bilayer.  After dendrimer adsorb on the 
surface of lipid layers and disrupt the bilayer structure, small vesicles were 
formed [242, 243].  Such vesicles were proposed to be composed of dendrimer 
surrounded by lipids [243].  These studies indicate that such nano-scale vesicle 
formed by dendrimer and lipids could be a novel delivery vehicle in 
pharmaceutical application. 
Kwok et al. studied peptide dendrimer/lipid hybrid system as DNA transfection 
reagents.  It was found that addition of lipid components (DOTMA/DOPE) to the 
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dendrimer-DNA complexes result in a more compact nanoparticle with size 
between 38 and 50 nm.  Moreover, the enhancement of transfection efficiency 
was increased by 30 to 50-fold compared to dendrimer/DNA complexes alone 
[244].  There are also a few studies exploring combination of dendrimer and lipids 
for drug encapsulation and delivery.  Generally, the drug encapsulation and 
release profiles are improved in the formulation containing both dendrimer and 
liposome.  Khopade et al. used PAMAM dendrimers with amine surface groups to 
increase encapsulation of methotrexate (MTX) in liposomes [245].  The drug 
loading increased as PAMAM generation increased from generation 2 to 4.  For 
the formulation with PAMAM G4, MTX release in 8 h was reduced by ~2.5-fold 
compared to liposome formulation.  In another study, Papagiannaros et al. 
studied encapsulation of doxorubicin-PAMAM dendrimer complex in liposomes 
[246].  Similarly, Gardikis et al. prepared liposomal locked-in dendrimers (LLDs) 
nanosystem as carrier of doxorubicin [247].  Both studies demonstrated improved 
drug loading and slowed drug release profile in the dendrimer-lipid vesicle 
formulations.  In summary, formulation composed of dendrimer and lipids could 
be a promising formulation to improve drug encapsulation and modified release 
properties in drug delivery applications.   
Paclitaxel (PTX), a mitotic inhibitor, is widely used in cancer chemotherapy.  A 
big challenge to delivery PTX was related to the hydrophobic nature of this 
compound.  Current commercially available i.v. formulation of PTX is composed 
of Cremophor EL (polyoxyethyleneglycerol triricinoleate 35) in 50% ethanol.  
Cremophor EL is found to induce hypersensitivity reactions and complement 
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activation in clinical application [248-250].  It is also known to be responsible for 
the nonlinear tissue distribution of PTX [251].  Thus, it is still necessary to 
develop novel formulation system for PTX so as to replace Cremophor EL.  There 
are a few studies to utilize dendrimer as drugdelivery vehicle.  Zhou et al. 
synthesized poly(butylenes oxide) (B)-poly(ethylene oxide) (E)-PAMAM G2 
linear-dedritic copolymer (BE-PAMAM) [252]. The solubility of PTX was 
increased 3700-fold by micellar encapsulation in a 2% (w/v) BE-PAMAM 
copolymer. A sustained release of 60% PTX from BE-PAMAM copolymeric 
micelle was observed after 24 h of dialysis. The same research group prepared 
lauryl chains conjugated PAMAM G3 to delivery PTX. In this study, PTX was 
covalently conjugated on PAMAM dendrimer [253]. The dendrimer conjugated 
PTX showed signicantly higher toxicity on Caco-2 and PBECs cells. The 
permeability of the drug-dendrimer conjugates across both cell monolayers were 
also improved in both directions, indicating penetration enhance effect of 
dendrimer on PTX. This chapter will explore the potential application of 
dendrimer-lipid hybrid nanosystem as a delivery vehicle of PTX and evaluate the 
therapeutic effect of such system for the treatment of ovarian cancer.   
6.2 Materials and Methods 
6.2.1 Materials 
1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) was purchased from 
Avanti-Polar-Lipids® (Alabaster, AL, USA). PAMAM G4.0-NH2 was purchased 
from Dentritech® Inc (Midland, MI, USA). Paclitaxel (PTX) was purchased from 
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the Beijing Earlybird Industry Development Co. Ltd. (Beijing, China).  3-(4,5-
dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide (MTT) and dimethyl 
sulfoxide (DMSO) were purchased from MP Biomedicals Inc (Singapore). All 
other chemicals were obtained from Sigma-Aldrich (Singapore) unless otherwise 
stated.  
6.2.2 Preparation of the Dendrimer-lipid hybrid nanosystem 
20 mg DPPC was dissolved in chloroform. 450 µl PAMAM dendrimer stock 
solution (50 mg/ml in methanol) and 554 µl Paclitaxel stock solution (5 mg/ml in 
methanol) were added to DPPC solution (molar ratio of DPPC / PAMAM / PTX 
is 86:5:9). The solvent was evaporated under a stream of nitrogen gas to obtain a 
dried thin film. The residual solvent was further removed in vacuum for 4 h. Then, 
2.43 ml of pre-warmed (55°C) Hank's balanced salt solution (HBSS) was added in 
the tube to form hybrid system. The hydrated hybrid suspension was stirred for 1 
h at 55°C followed by 2 h sonication. The unincorporated paclitaxel and DPPC 
lipid were removed by centrifugation at 3000 rpm for 3 min. Empty hybrid system 
was prepared in the same way without PTX.  
6.2.3 Size, zeta potential and morphology characterization 
The prepared hybrid nanosystem was diluted 50× in HBSS for particle size and 
zeta potential measurement. The hydrodynamic diameter and zeta potential of the 
sample were analyzed by Zetasizer Nano-ZS90 (Malvern. Instruments GmbH 
Herrenberg. Germany). Morphology of hybrid nanosystem was observed via 
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cryogenic transmission electron microscopy (Cryo-TEM) (JEOL JEM 2010F 
TEM, JOEL Ltd, Tokyo, Japan). 
6.2.4 DPPC Lipid quantification 
Lipid concentration was quantified by phophate assay as previously described 
[254]. 20 µl of diluted hybrid nanosystem or standard solution (0-2 mM 
Na2HPO4 solution) was added to 700 µl perchloric acid and heated at 190°C for 
1 h. After cooling to room temperature, 700 µl Fiske's solution and 7 ml 
ammonium molybdate solution were added to the sample and heated at 100°C for 
20 min. The solutions were cooled to room temperature and measured using UV 
spectrometry at 830 nm (Tecan Infinite™ 200, Tecan Trading AG, Switzerland). 
Lipid concentration was calculated from the standard curve of Na2HPO4 serial 
dilutions. Recovery yield% was calculated as follows: 
Recovery yield% = Cfinal / Cinitial × 100% 
where Cfinal, Cinitial represent lipid concentration from hybrid sample or initally 
added in the formulation.  
6.2.5 Paclitaxel quantification 
10 µl hybrid stock solution was diluted to 1 ml methanol. Empty hybrid stock 
solution was used as control for hybrid sample. A standard solution of PTX was 
prepared at concentration range from 0-25 µg/ml. Absorbance at 230 nm was 
measured by UV spectrometry (UV-1700, UV-visible spectrophotometer, 
Shimadzu, Pharmaspec, Kyoto, Japan). PTX concentration was calculated from 
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the standard curve of PTX serial dilutions. Recovery yield% was calculated as 
described in section 6.2.4. 
6.2.6 PAMAM dendrimer quantification 
The concentration of PAMAM dendrimer was quantified based on a previously 
described method [255].8 µl hybrid sample was diluted in 1000 µl methanol 
solution. Standard solution of PAMAM was prepared at concentration range from 
0-0.2 mg/ml. The following solutions were added to the samples sequentially, (a) 
800 µl of 200 mM sodium tetraborate buffer, pH 10, (b) 40 µl of 30 mg/ml 
phthaldiadehyde (OPA) in ethanol, (c) 40 µl of 30 mg/ml N-acetyl-d-
penicillamine in methanol. The mixture was incubated at 50°C for 3 hours to 
complete analyte derivatization. Absorbance was measured by UV spectrometry 
at 330 nm. Since PTX and DPPC lipid do not have primary amine groups in the 
structure, the presence of both compounds does not interfere with the reaction and 
analysis.  PAMAM concentration was calculated from the standard curve of 
PAMAM serial dilutions. Recovery yield% was calculated as described in section 
6.2.4.  
6.2.7 In vitro PTX release study 
The PTX hybrid nanosystem was diluted with HBSS to a PTX concentration of 
140 µg/ml.  8 ml of the sample was transferred to a Slide-A-Lyzer 3.5K dialysis 
cassette.  The cassette was placed in 1000 ml PBS at 37°C with stirring. 200 µl of 
sample was withdrawn at specific time intervals from top side of the dialysis 
cassette. During the experiment, no obvious precipitation of paclitaxel was 
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observed in the dialysis cassette.  If paclitaxel were released and aggregated in 
aqueous solution, it is likely to be released out to the container or precipitated in 
the bottom of the cassette. Since samples were withdrawn from top of the cassette, 
the measured concentration of paclitaxel should indicate the amount of paclitaxel 
remained stable inside the hybrid nanosystem.  PTX concentration was 
determined as described in previous section.  The cumulative percentage of drug 
released was calculated as follows: 
PTX release% = ( Cinitial - Ct ) / Cinitial × 100%   
where Cinitial, Ct represent the concentration of PTX at time 0 and at time t. 
Then the PTX release data were fitted into various mathematical models for drug 
release kinetics, including 0 order model, 1
st
 order model, 2
nd
 order model, 
Higuchi model, Peppas-Sahlin model, and Alfrey model.  The equations of these 
models are listed as follows: 
Ct / Cinitial = k × t   zero order 
ln [Cinitial] = -k × t + ln [Ct]  1
st
 order model 
1 / Cinitial = 1 / Ct + k × t  2
nd
 order model 
Ct / Cinitial = k × t
1/2
    Higuchi model [256] 
Ct / Cinitial = k1 × t
m
 + k2 × t
2m
  Peppas-Sahlin model [257] 
Ct / Cinitial = k1 × t + k2 × t
1/2  
Alfrey model [258] 
where Cinitial, Ct represent the concentration of PTX at time 0 and at time t. 
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Ct = Plateau + SpanFast × e
(-KFast × t)
 + SpanSlow × e




where SpanFast=(C0 - Plateau) × PercentFast × 0.01 
SpanSlow=(C0 - Plateau) × (100-PercentFast) × 0.01 
6.2.8 Cell Culture 
IGROV-1 cell line was a generous gift from Professor Larry H. Matherly (Wayne 
State University, School of Medicine, USA), and was maintained in RPMI-1640 
media supplemented with 10% FBS, 100 units/ml penicillin and 100 μg/ml 
streptomycin. Cells were grown in T-75 cm
2
 flasks in a humidified atmosphere 
containing 5% CO2 at 37°C. 
6.2.9 Cell viability assay 
Briefly, IGROV-1 cells were seeded in 96-well plates at 5000 cells/well overnight 
before exposure to treatment. Then, the cells were exposed to various fixed 
concentrations of samples for either 24 h at 37°C in the CO2 incubator. After the 
treatment, MTT was added to the cells at a final concentration of 0.2 mg/ml for 4 
h at 37°C. Then the culture medium was removed from each well and 150 μL 
DMSO was added to solubilize the purple formazan precipitate for 10 min in dark. 
Measurement of absorbance was performed at 570 nm. Cell viability was 
determined as follows: 
Cell viability% = (abstest − absblank) / (absvehicle − absblank) × 100% 
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where abstest, absblank and absvehicle represent the absorbance reading of tested cells, 
blank control and vehicle control, respectively.  
Data obtained from the MTT assay were subject to median effect analysis using 
the CalcuSyn® software (version 2, Biosoft, Cambridge, UK). The Combination 
Index (C.I.) was computed by the following equation:  
C.I. = [(D)1 / (Dx)1] + [(D)2 / (Dx)2] 
where D1 and D2 represent doses of drug 1 and drug 2, respectively, used in the 
combination to induce a defined effect (e.g. 50% cell death). (Dx)1 and (Dx)2 
represent the doses of drug 1 and drug 2, respectively, required to have the same 
effect when the two drugs were administered as single agents. C.I. < 1, ~ 1 and > 
1 represent synergistic, additive and antagonistic effects for a drug combination, 
respectively [259]. 
6.2.10 Cellular uptake study 
IGROV-1 cells were seeded in 4-well Lab-tek chamber glass slides from Nalge 
Nunc Inc (Naperville, IL) at density of 2×10
4
 cells/well and cultured for 5 days 
before experiment. Cells were exposed to hybrid nanosystem with 10% FITC 
labelled PAMAM and 5% Di-I for 4 h or 24 h at 37°C. Then, cells were washed 
with HBSS for three times and viewed under a Carl Zeiss fluorescence confocal 
microscope using 40× objective (Carl Zeiss Jena, Germany).  
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6.2.11 In vivo therapeutic efficacy study 
All animal studies were completed using protocols approved by the Institutional 
Animal Care and Use Committee (IACUC) of National University of Singapore.  
CB17/Icr-Prkdc
scid
/IcrCrl (SCID) mice were purchased from Invivos Pte Ltd 
(Singapore). Mice were acclimatized for 7 days before intraperitoneal inoculation 
of 5 × 10
6
 IGROV-1 ovarian cancer cells. After 14 days of tumor cell inoculation, 
mice were randomly divided into 4 groups, and were injected intravenously with 
(1) 0.9% saline (1/week×3 times), (2) free PTX at 2 mg/ml (20mg/kg × 1/week × 
3 times), (3) PTX loaded hybrid nanosystem at 0.2 mg/ml (2mg/kg × 1/week × 2 
times), (4) empty hybrid nanosystem (equivalent dilution as PTX loaded hybrid 
nanosystem × 1/week×2 times). Drug regimens were given on day 14, day 21 and 
day 28. General condition, body weight, and survival of the mice were monitored 
daily. Mice were euthanized if they developed any of the following symptoms: 
weight loss > 20%, scruffy coat, hunched appearance, and moribund state, and 
death was defined as the day following euthanization. The endpoint of the study 
was stipulated at 60 days post tumor cell inoculation according to the approved 
animal protocol. Mice surviving until the end of the efficacy experiment were 
termed as long term survivors (LTS) and euthanized accordingly. After 
euthanization, the tumor tissues in abdomen were collected and weighed.  
6.2.12 Statistical analysis 
All data were reported as mean ± standard error of the mean (SEM). Statistical 
differences were determined using the Student t-test or one-way ANOVA with 
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Newman-Keuls test for post-hoc multiple comparisons. Survival curves were 
plotted according to the Kaplan–Meier method, and the log-rank test was used to 
determine significant differences among groups. P values of < 0.05 were 
considered to be statistically significant. 
6.3 Results 
6.3.1 Physicochemical characterization of dendrimer-lipid hybrid 
nanosystem 
The dendrimer-lipid hybrid nanosystem was prepared by a 5-step procedure: 
physical mixing, organic solvent evaporation, hydration, sonication and 
centrifugation (Figure 6.1).  Size and zeta potential data are shown in Table 6.1.  
For PTX-PM and PTX-DPPC system, the particle size was 863 ± 121 nm and 626 
± 64 nm, much larger than the hybrid nanosystem.  PDI was also increased for 
PM only or DPPC only preparations, indicating large and non-uniform size 
distribution.  Moreover, obvious precipitations were observed for PTX-PM and 
PTX-DPPC samples, indicating instability of such preparation with dendrimer or 
lipid only.  However, if the dendrimer and lipids were put together to form the 
hybrid nanosystem, the particle size of hybrid nanosystem was much smaller (30-
40 nm).  Encapsulation of PTX did not change the particle size of the hybrid 
system. The zeta potentials of all these preparations were near neutral values.  The 
morphology of hybrid nanosystem was further observed under Cryo-TEM as 
shown in Figure 6.2. The hybrid nanosystem exhibited spherical, vesicular 
morphology with denser signal in the external areas than internal cavity.  In line 
137 
 
with the size data, the particle size was <50 nm as observed from the cryo-TEM 
images.  
 
Figure 6.1. (A) Chemical structure of DPPC and PTX. (B) Preparation process of 













Table 6.1. Size and zeta potential characterization 
 
 
Size (nm) Zeta potential (+mV) PDI 
PTX-Hybrid
a
 37.6 ± 6.9 2.5 ± 0.1 0.58 ± 0.03 
Empty-Hybrid
b
 36.8 ± 3.0 2.9 ± 0.2 0.55 ± 0.08 
PTX-PM
c
 863 ± 121 1.3 ± 0.1 0.77 ± 0.14 
PTX-DPPC
d
 626 ± 64 5.1 ± 0.9 0.84 ± 0.16 
PM (no PTX)
e
 4.3 ± 0.4 30.1 ± 0.9 0.40 ± 0.08 
a
 PTX encapsulated hybrid nanosystem 
b
 Empty hybrid nanosystem prepared without PTX encapsulation 
c
 Formulation of PTX and PAMAM dendrimer with the same preparation process 
as hybrid nanosystem 
d
 Formulation of PTX and DPPC lipid with the same preparation process as 
hybrid nanosystem 
e
 PAMAM dendrimer without loading PTX 
 
 
Figure 6.2. Representative Cryo-TEM images of (A) PTX loaded hybrid system, 
(B) Drug free hybrid system.  The experiments were repeated twice, each time 
with a minimum of three views of the same sample was captured. 
 
The recovery of PM dendrimer, DPPC lipid and PTX in each system was 
quantified and presented in Figure 6.3.  Both DPPC and PM had >80% of 







DPPC only or PM only preparation, the recovery of DPPC or PM was relatively 
lower than in hybrid nanosystem.  Importantly, PTX recovery in hybrid 
nanosystem was about 80%, significantly higher than the PTX recovery in PM 
only or DPPC only formulation. Thus, the precipitation observed in the centrifuge 
step was mainly composed of PTX. This result also indicated that combination of 
PM and DPPC could significantly increase encapsulation of PTX in the hybrid 
nanosystem than the preparation with a single excipient.  
 
Figure 6.3. Recovery yield (%) of (A) DPPC lipid, (B) PM dendrimer and (C) 
Percentage of PTX incorporated in hybrid nanosystem, PM only, or DPPC only 
formulation, respectively. Data are expressed as mean ± SEM of 3 independent 
























































































































6.3.2 In vitro PTX release study 
The in vitro PTX release profile was studied over a 24 h period at 37°C in PBS 
(Figure 6.4).  Majority of PTX (>95%) was released from hybrid nanosystem 
within 24 h. The release data was fitted to several commonly used drug release 
kinetic models as shown in figure 6.4.  PTX release from hybrid nanosystem 
fitted best in second order model with R
2
 = 0.9968. An important property of 
second order release is that half-life is related to the initial concentration: 
t1/2 = 1 / ( k × C0 ) 
where the t1/2, k, C0 represents half-life, slope of the regression curve, and initial 
concentration, respectively. 
According to the half life equation, the drug will release faster in the initial stage, 
when the drug concentration is relatively higher in the carrier.  As the drug 




Figure 6.4. PTX release profile in different release models. (A) 0 order model, (B) 
1
st
 order model, (C) 2
nd
 order model, (D) Higuchi model, (E) Peppas-Sahlin 
model, (F) Alfrey model (G) two exponential decay model. 
 















































































































































































































6.3.3 Cytotoxicity of PTX loaded hybrid nanosystem on IGROV-1 cells 
Next, the inhibitory effect of PTX on human ovarian cancer cell line IGROV-1 
cells was evaluated in vitro.  The purpose of this study was to evaluate whether 
the hybrid nanosystem would have any influence on the biological activity of 
PTX.  Cell viability after 24 h treatment with either PTX or PTX in hybrid 
nanosystem was shown in Figure 6.5.  The PTX in hybrid nanosystem showed 
improved inhibitory effect against IGROV-1 cells.  The IC50 of PTX-Hybrid was 
2.43±1.23 µg/ml, significantly lower than the IC50 of free drug PTX (88.51±15.11 
µg/ml), indicating improved therapeutic effect of PTX in the hybrid system.  The 
IC50 of empty hybrid nanosystem was more than 280 fold higher than the PTX-
Hybrid nanosystem.  In comparison, PTX was conjugated to PAMAM G4 with 
hydroxyl terminal groups. The cytotoxictiy of PTX was enhanced by 10-fold on 
A2780 human ovarian cancinoma cells. Additionally, aqueous solubility of PTX 




Figure 6.5. IGROV-1 cell viability after 24 h treatment with (A) PTX and PTX-
Hybrid, (B) PM and Empty-Hybrid nanosystem.  Data are expressed as mean ± 
SEM of at least 3 independent experiments. 
 
Since the PTX-Hybrid nanosystem release majority of PTX within 24 h, 
according to the in vitro PTX release study shown in section 6.3.2, this might be a 





























































reason for the improved cellular inhibitory effect on IGROV-1 cells.  Next, the 
possible synergistic effect of PTX and PM in the hybrid nanosystem was assessed 
based on the 24 h IC50 data.  The combination index was calculated and presented 
in Table 6.2.  Interestingly, the combination index of PTX-Hybrid versus Empty-
Hybrid alone was 0.05, indicating that PTX and PM have synergistic effect in the 
hybrid nanosystem. 




PTX-Hybrid 2.43 ± 1.23 
PTX 88.51 ± 15.11 
PM 697.27 ± 189.32 





PTX-Hybrid vs Empty-Hybrid alone 
or PTX alone 
0.05 
*
ED50: median effective dose 
6.3.4 Cellular uptake study of hybrid nanosystem 
In order to further understand the distribution of such hybrid nanosystem in 
cellular environment, cellular uptake study of hybrid nanosystem was examined 
in IGROV-1 cells.  FITC labeled PM dendrimers emitted green fluorescent signal 
and Di-I emitted red fluorescent signal under confocal fluorescent microscope.  
The imaging result after 4 h and 24 h incubation with the dye labeled hybrid 
nanosystem was shown in Figure 6.6.  The FITC-PM was mainly accumulated 
inside the cells while Di-I was mainly localized in peripheral areas.  As incubation 
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time increased from 4 h to 24 h, the increased signal indicates time dependent 
accumulation in cells.  Such observation is in line with previous reports that PM 
dendrimer was able to disrupt the cell membrane and internalize inside the cells 
[240].  Such result might explain the improved inhibitory effect of PTX-Hybrid 
system.  When the hybrid nanosystem gets contact with cell membranes, 
positively charged PM dendrimer disrupts cellular membrane and promotes hole 
formation, which makes it easier for PTX to be localized inside the cells. 
Meanwhile, dendrimer itself also internalizes inside the cells and damage the cells 
as described previously [145-147].  Thus, the PTX-Hybrid nanosystem has 
synergistic inhibitory effect. 
 
Figure 6.6. Cellular uptake of hybrid nanosystem with 10% FITC labeled PM and 
5% Di-I for 4h or 24h. The experiments were repeated twice, each time with a 
minimum of three views of the same sample was captured. 
 
6.3.5 In vivo therapeutic efficacy study on IGROV-1 ovarian tumor 
inoculated SCID mice 
The therapeutic efficacy of PTX or PTX in hybrid nanosystem was evaluated in 
the intraperitoneally grown, human IGROV-1 ovarian tumor xenograft model as 




4 h 24 h HBSS
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ovarian cancer cells intraperitoneally and kept for 14 days before the treatment. 
The inoculated mice were then randomized into four study groups: saline control, 
free PTX, empty hybrid and PTX in hybrid nanosystem.  The dose of free PTX 
was 20 mg/kg, which was the maximum tolerated dose (MTD).  PTX-Hybrid was 
given at 2 mg/kg which was the max tolerated dose.  Kaplan-Meier Survival 
analysis result was summarized in Figure 6.7 (A).  Both PTX and PTX Hybrid 
group significantly improved mice survival compared to saline control group 
(p<0.05). Although no significant difference was observed in Kaplan-Meier 
survival curves for PTX and PTX Hybrid group (p = 0.059), it is worth to note 
that PTX Hybrid was given at 10-fold lower dose than free PTX.  Moreover, PTX 
Hybrid treatment significantly prolonged both median survival time (42 d) and 
mean survival time (46.3 d) compared to all the other three groups as shown in 
Table 6.3.   
Animal body weight was monitored over the study period as an indicator of the 
general well-being of the animals during treatment.  The percentage body weight 
change was shown in Figure 6.7 (B).  The animals showed more than 10% body 
weight loss upon treatment.  Such body weight loss might be due to treatment 
related toxicity as well as tumor deterioration.  Taken together, PTX in hybrid 
nanosystem was effective in prolonging the survival of the animals at dose 10-




Figure 6.7 In vivo efficacy of PTX as free drug or in hybrid nanosystem in human 
IGROV-1 intraperitoneal ovarian tumor xenograft model.  (A) Kaplan-Meier 
survival curves for saline, empty hybrid, free PTX and PTX-Hybrid. Drug 
treatment started 14 days post tumor cell inoculation. (B) Animal body weight 

























































Table 6.3. Comparison of mean and median survival 
 
Mean survival time 
(Days) 
Median survival time 
(Days) 
Survivors 
at day 60 
Saline 24.3 ± 0.6
**
 24 ± 0.6
***
 0/6 
Empty-Hybrid 28 ± 2.3
**
 27 ± 3.3
**
 0/5 
PTX 33.6 ± 4.9
*
 28 ± 2.6
***
 0/7 
PTX Hybrid 46.3 ± 4.0 42 ± 2.6 1/7 
* P < 0.05, ** P < 0.01, *** P < 0.001 compared to PTX Hybrid  
6.4 Discussion 
6.4.1 Formation of dendrimer-lipid hybrid nanosystem 
Dendrimers are known to interact with cell membrane lipids and disrupt the 
membrane structure on a size and charge dependent basis.  Previous studies have 
investigated the interaction between dendrimer and lipid bilayers and their results 
showed that cationic dendrimers could form holes on the bilayer surface and may 
remove lipids from it [262-266].  These studies formed the basis to form such 
dendrimer-lipid hybrid nanosystem. 
Gardikis et al. examined the incorporation of PAMAM G4 and G3.5 in DPPC 
bilayers by DSC and Raman spectroscopy method. The result showed that the 
maximum 5 mol% PAMAM G4 and 3.5 mol% G3.5 can be incorporated into the 
multilamellar liposomes [267].  Thus, 5 mol% of PAMAM dendrimer was used to 
prepare hybrid nanosystem in this study. The molar percentage of PTX was tested 
from 1.5 mol% to 9 mol%. As PTX percentage increase from 1.5 mol% to 9 
mol%, the recovery of PTX was also increased. So 5 mol% PAMAM, 9 mol% 
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PTX and 86 mol% DPPC were chosen as the composition of the hybrid 
nanosystem.   In the future study, it is interesting to evaluate the effect of different 
dendrimer generations, concentrations and surface groups on the formation of 
hybrid nanosystem. 
When the PTX was encapsulated in the hybrid formulation at 9 mol%, it has 
recovery of about 80%.  However, for the same preparation procedure with PTX-
DPPC only or PTX-PM only, the recovery yield was significantly lower than 
PTX-Hybrid as shown in Figure 6.3.  PTX-PM showed relatively higher recovery 
yield than PTX-DPPC.  This might be due to the hydrophobic internal space of 
PM that can retain more PTX when they form a complex in the 
solution.  However, the recovery yield was <50% because PTX could freely 
diffuse out of the PM cavity and precipitate.  In comparison, if PM and DPPC 
were combined together to form a hybrid system, the PTX could be retained in the 
vesicle structure formed by PM and DPPC.  Thus, the recovery yield was 
significantly improved. In previous study, PTX was conjugated with polyglycerol 
dendrimers (PGDs) generation 4 and 5. The PTX solubilities in 10 wt% of PGDs 
were improved to 80 to 128 μg/ml [268].  In comparison, the concentration of 
PTX in the hybrid nanosystem was 794.7 ± 44.7μg/ml, 6 to 10 fold higher than 
the PTX-PGDs conjugates.  This is a great advantage of combining PM dendrimer 
together with DPPC lipids to encapsulate hydrophobic compounds PTX.  
The morphology of the hybrid nanosystems was observed from Cryo-TEM as 
shown in Figure 6.2.  The hybrid nanosystem were spherical, vesicular shape with 
diameter less than 50 nm, agrees with the size data measured by Zetasizer Nano-
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ZS90 (Malvern. Instruments GmbH Herrenberg. Germany).  The zeta potential of 
the hybrid system was nearly neutral while PAMAM G4 had positive charge of 
+30.1 mV.  This result indicates that dendrimer was likely embedded inside the 
hybrid nanosystem.  There are a few studies to investigate the structural 
interaction between dendrimer and lipid.  Wrobel et al. studied the influence of 
cationic phosphorus-containing dendrimers generation 3 and 4 on model DMPC 
or DPPC lipid membranes.  The measurement result of fluorescence anisotropy 
and DSC showed that dendrimers can interact both with the hydrophobic part and 
the polar head-group region of the phospholipid bilayer [269].   
Berenyi et al. studied the effect of PAMAM G5 on multilamellar DPPC vesicles.  
It was found that the terminal amino groups of dendrimers strongly interacted 
with phophate headgroups as the initial step. Then the dendrimer disrupted the 
regular multilamellar structure of DPPC and form small vesicles [242].  
Pieter et al. used solid-state NMR method to study the interaction between 
PAMAM G5, G7 with lipid bilayer.  It was found that dendrimers had stronger 
interaction with alkyl chain regions than the headgroups and restricted the motion 
of bilayer lipid tails [270]. 
Taken together, the formation of hybrid nanosystem is likely initiated from the 
interaction between the terminal amino groups of dendrimer and phophate 
headgroups of lipids.  Then, the internal hydrophobic cavity of dendrimer 
interacts strongly with alkyl chain of the lipids to form small vesicles, which helps 
to encapsulate hydrophobic compound.   
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6.4.2 Cytotoxicity of PTX-Hybrid nanosystem on IGROV-1 cells 
In the cytotoxicity study on IGROV-1 cells, PTX-Hybrid nanosystem showed 
significantly improved efficacy compared to PTX free drug after 24 h 
treatment.   The drug release profile in Figure 6.4 explained that such effect 
reached maximum at 24 h as majority of PTX was released within 24 h, which 
also explained the similar cell viability curve of PTX-Hybrid and PTX after 72 h 
treatment.  Based on 24 h cell viability result, the combination index of PTX-
Hybrid versus both PTX/PM and PTX/Empty-Hybrid were < 1, indicating 
synergistic effect of PTX and PM in hybrid nanosystem. As Figure 6.6 showed 
that PM accumulated intracellularly after 24 h of incubation, this observation 
indicated that PM might help increase cellular accumulation of PTX so as to 
improve the therapeutic effect of PTX.  At the same time, PM also induced 
cytotoxicity effect as shown in Figure 6.5.   
6.4.3 PTX-Hybrid nanosystem for the treatment of IGROV-1 ovarian 
tumor inoculated SCID mice 
Ovarian cancer ranks the most mortal of all gynecologic malignancies and the 5
th
 
leading cause of cancer related death [271].  Intravenous administration of taxane-
based chemotherapy is the most active and extensively used treatment for ovarian 
carcinoma.  Although these approaches improved survival over the past years and 
have been considered as current standard treatment, relapses and undesirable side 
effects represent the major problems for patients with advanced disease [272, 273].  
One possible solution to decrease adverse effect as well as to improve therapeutic 
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effect is to deliver the drugs via local route of administration rather than i.v. 
injection.  Theoretically, intraperitoneal injection directly delivers the drug within 
the peritoneum to achieve increased exposure of tumor to the antineoplastic 
agents [274].  In this study, the dose of PTX-Hybrid nanosystem was given at 2 
mg/kg, 10-fold lower than the MTD.  No obvious behavior change or significant 
weight loss was found for the treatment.  Meanwhile, the survival of mice bearing 
IGVOR-1 ovarian tumor significantly improved.  Also, the mean survival time 
and median survival time were significantly improved compared to the treatment 
of commercial standard drug Taxol at MTD (20 mg/kg).  Such result indicates 
that PTX-Hybrid nanosystem achieved better therapeutic effect than Taxol, 
meanwhile the PTX induced side effects might be diminished due to a reduced 
administration dose.   
6.5 Conclusion 
In this chapter, PM dendrimer was successfully surface modified with DPPC 
lipids by complexation to form hybrid nanosystem to encapsulate PTX.  This 
hybrid nanosystem was observed as spherical and uniform vesicles with diameters 
of 30-40 nm.  One major advantage of PTX-hybrid nanosystem is that the 
encapsulation of PTX at 9 mol% is nearly 80%, significantly higher than the PTX 
formulated with either DPPC or PM alone.  Moreover, the potency of PTX could 
be significantly improved by 37-fold when presented in the hybrid nanosystem, as 
reflected by the reduction in IC50 values. PTX in the hybrid nanosystem could 
significantly improve the survival of tumor-bearing animals, with 50% increase in 
the median survival time, despite a 10-fold dose reduction.  Taken together, this 
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dendrimer-hybrid nanosystem demonstrated advantages to deliver PTX for 
ovarian cancer treatment.  It could also be further explore as a novel drug delivery 
vehicle in biomedical applications.  
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7. CHAPTER 7. CONCLUSION AND FUTURE PERSPECTIVES 
The unique structural properties of dendrimers have brought a lot of interests to 
study their potential applications in the biomedical field.  Dendrimer toxicity is 
always a hurdle to be overcome so that safety aspect is warranted.  Thus, seeking 
a balance between applications and toxicities of dendrimers for drug delivery is 
the main focus of current research.  There are two common approaches to modify 
dendrimer surface to achieve desirable effects: chemical conjugation and physical 
complexation.  In this thesis, both approaches are explored to modify dendrimer 
surface to achieve improved properties in drug delivery applications.   
In the chemical conjugation approach to modify dendrimer surface, PAMAM G4 
dendrimer were successfully surface modified by PEGylation and thiolation.  
Subsequently, the compatibility of various dendrimer derivatives with major 
blood components was studied.  In general, the unmodified amine-terminated 
dendrimer displayed generation- and concentration-dependent toxic effects on 
blood components and functions.  PEGylation was an effective method to 
decrease toxicity of cationic dendrimers to blood components.  Further modifying 
PEGylated dendrimers with thiolation reduced their effect on haemolysis, 
complement activation, PT and aPTT.  These findings suggested that dual 
functionalization with PEGylation and thiolation could reduce the toxicity of 
cationic PAMAM dendrimer to certain blood components. 
With improved toxicity profile of such surface modified PAMAM dendrimers, 
these materials were further studied for their potential application in oral drug 
155 
 
delivery.  The effect of dendrimer derivatives on two major biological barriers in 
oral delivery, P-gp drug efflux pump and tight junction, were evaluated.  With 
acceptable cytotoxicity to Caco-2 cell monolayer, dual functionalized PAMAM 
dendrimers increased cellular accumulation and permeation of the P-gp substrate 
R-123 in both Caco-2 and MDCK/MDR1 cells, indicating the P-gp inhibitory 
effect of the dual functionalized dendrimers.  Meanwhile, dual functionalized 
dendrimer derivatives could reversibly disrupt the tight junction integrity over 
time.  Based on these in vitro results, the PEG(1.8)-PM-TBA(7.0) was further 
evaluated in vivo for its potential to increase the oral bioavailability of GCV, a 
BCS class III drug.  The results showed that PEG(1.8)-PM-TBA(7.0) could 
improve oral bioavailability of GCV.  To the best of our knowledge, this is the 
first study to evaluate such surface modification approaches of dendrimer for oral 
drug delivery application.  Taken together, dual functionalization via PEGylation 
and thiolation represented a novel and promising approach in altering PAMAM 
dendrimer surface for potential application such as oral drug delivery modulators.   
In the complexation approach to modify dendrimer surface, PAMAM G4 
dendrimer was modified with the lipid DPPC via the formation of a physical 
complex.  Such dendrimer-lipid hybrid nanosystem was studied as a carrier of 
PTX to treat ovarian cancer via i.p. route of administration.  PTX is not easily 
formulated due to the very hydrophobic nature of this compound.  The prepared 
dendrimer-lipid hybrid nanosystem incorporated nearly 80% of PTX, significantly 
higher than that prepared in either DPPC or PM alone formulation.  The potency 
of PTX could be significantly improved by 37-fold when presented in the hybrid 
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nanosystem, as reflected by the reduction in IC50 values.  In the survival study of 
tumor-bearing animals, PTX in the hybrid nanosystem could significantly 
improve the survival of IGROV-1 ovarian tumor inoculated SCID mice, with 50% 
increase in the median survival time, despite a 10-fold dose reduction.  Taken 
together, this dendrimer-hybrid nanosystem demonstrated great advantages to 
deliver PTX for ovarian cancer treatment.  
PAMAM dendrimer generation 4.0 with amine surface group is selected as the 
model dendrimer in this study for a few reasons.  This dendrimer shows 
promising biological effects at concentration with acceptable cytotoxic effects.  If 
the generation increases further, the cytotoxicity will be too pronounced that the 
dendrimer could only be applied at very low concentration.  Another reason for 
choosing this dendrimer is due to its popularity in the field of dendrimer research, 
which will provide more information for comparison with other studies.  However, 
PAMAM dendrimers are not biodegradable.  Thus, this class of dendrimers faces 
the challenge of long term safety concerns for clinical applications.  A potential 
solution to overcome this challenge is to explore biodegradable dendrimers in 
future studies.  Some recent examples of biodegradable dendrimers reported in the 
literature include polyester bis(methylol)propionic acid (bis-MPA) dendrimers 
[275], poly-l-lysine (PLL) dendrimers [276], or poly(glycerol succinic acid) 
(PGLSA) dendrimers [277]. 
In a broader perspective, there are a few directions to explore in the future. 
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(1)  To evaluate the absorption enhancing effect of dual functionalized dendrimer 
on a broader spectrum of drugs.  BCS class III drug GCV showed increased oral 
absorption in the presence of dual functionalized dendrimer in this study.  This is 
mainly due to the P-gp inhibition and tight junction modulation effect of the dual 
functionalized dendrimer.  The penetration enhancing effect of dual 
functionalized dendrimer might also be applicable to other drugs that suffer from 
P-gp efflux or low permeability through paracellular pathway.  Both BCS class II 
and class IV drugs have challenge of low solubility, meanwhile some drugs in 
these two classes also suffer from P-gp efflux, for example, loperamide (BCS 
class II) [278]  and digoxin (BCS class IV) [279].  In additional to the P-gp 
inhibitory and tight junction modulating benefits of dual functionalized dendrimer 
derivatives, the internal hydrophobic cavity of dendrimer might help encapsulate 
the drug so as to improve the stability of the hydrophobic drug in solution.  Thus, 
the dendrimer derivatives might be applicable to a wide range of drugs for the 
improvement of their oral bioavailability.   
(2)  To explore other surface conjugation ligands for biomedical applications.  In 
the current study, dendrimer and lipids were complexed to form a hybrid 
nanosystem.  It is also possible to conjugate the lipid groups on dendrimer surface.  
Dendrimers possess high density of hydrophilic surface groups.  After surface 
conjugation with lipid groups, the whole structure will become more hydrophobic 
in nature, which might help promote interaction with lipophilic components in 
biological environment.  One of the potential targets could be the hydrophobic 
lipopolysaccharides in bacterial cell wall and the phospholipids in bacterial 
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membranes.  Since cationic PAMAM and PPI dendrimers have been reported to 
possess antimicrobial properties [280-282], surface modification with lipid chains 
may help further improve anti-microbial activities of dendrimers.  Thus, further 
exploration of the dendrimer-lipid conjugates as anti-bacterial reagent could be a 
potentially interesting direction in the future.   
(3)  To explore drug-dendrimer conjugates for improved drug delivery application.  
By careful design of the linking chemistry, the drug-dendrimer conjugates could 
achieve desirable release under certain environment, such as change of pH, 
presence of enzyme or other intracellular component [283].  Additionally, drug-
dendrimer conjugates may also enhance stability, solubility or absorption of 
various types of therapeutic reagents [284].  The prodrug conjugates could be 
further modified with lipid ligands as discussed in point (2) so that the dendrimer 
could enhance its interaction with cellular membrane.  This might help to increase 
intracellular delivery of the drug.  Thus, it is important to explore drug-dendrimer 
conjugates for improved drug release and delivery profile in the future. 
(4) To explore in vivo pharmacokinetic profile and toxicity of PAMAM 
dendrimer as well as the dendrimer derivatives in this study.  Although PAMAM 
dendrimer is the first developed dendrimer type and also the most extensively 
studies dendrimer so far, a major concern for this class of dendrimer is 
biodegradability and toxicity issue. Since PAMAM dendrimers are not 
biodegradable in nature, it is important for us to stress PK profile as well as in 
vivo toxicity of PAMAM dendrimers in the future study. In chapter 4 of this 
thesis, the effect of dendrimer on major blood components were evaluated in vitro 
159 
 
models. However, in the future, it is necessary to address chronic toxic effect of 
dendrimers in animal models. In chapter 6, the lipid-dendrimer hybrid nanosystem 
was administrated via intraperitoneal injection. Thus, the biodistribution and toxic 
effect on major organs should be evaluated in the fture study.  
(5) To evaluate the stability of dendrimer derivatives as penetration enhancer and 
the lipid-dendrimer hybrid nanosystem. In chapter 5, the pH stability of the 
dendrimer derivatives were evaluated up to 6 h. Since the thiol groups are prone 
to oxidation process, the stability of thiol groups over long period of storage 
should be evaluated in the future. For the PTX loaded hybrid nanosystem, short-
term and long-term stability test will be carried out in the future study.  
In conclusion, the findings in this thesis demonstrate that surface modification 
with multiple groups or complexation could improve dendrimer functionality in 
drug delivery applications as well as reducing its toxicity.  In the future, it is of 
great interest and potential to explore other dendrimer surface modification 
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